Amedeo Smart

Free Medical Literature Service

 

Amedeo

Schizophrenia
  Free Subscription

Articles published in
Schizophr Res
    December 2024
  1. ZHU Z, Roy D, Feng S, Vogler B, et al
    AI-based medication adherence prediction in patients with schizophrenia and attenuated psychotic disorders.
    Schizophr Res. 2024;275:42-51.
    >> Share

  2. ODUOLA S, D'Andrea G, Smimmo D, Menchetti M, et al
    Pathways to care: Source of referral at first-episode psychosis, a cross-country comparison between Bologna and South London.
    Schizophr Res. 2024;275:35-41.
    >> Share

  3. DAZZI F, Shafer A
    Meta-analysis of the factor structure of the Scale for the Assessment of Negative Symptoms (SANS) and the Scale for the Assessment of Positive Symptoms (SAPS).
    Schizophr Res. 2024;274:464-472.
    >> Share

  4. BABADI B, Dokholyan K, DeTore NR, Tootell RBH, et al
    Arousal responses to personal space intrusions in psychotic illness: A virtual reality study.
    Schizophr Res. 2024;274:158-170.
    >> Share

    November 2024
  5. SAGER REH, North HF, Weissleder C, Clearwater MS, et al
    Divergent changes in complement pathway gene expression in schizophrenia and bipolar disorder: Links to inflammation and neurogenesis in the subependymal zone.
    Schizophr Res. 2024;275:25-34.
    >> Share

  6. CHONG YY, Chien WT, Mou H, Ip CK, et al
    Acceptance and Commitment Therapy-based Lifestyle Counselling Program for people with early psychosis on physical activity: A pilot randomized controlled trial.
    Schizophr Res. 2024;275:1-13.
    >> Share

  7. LAPPAS AS, Ioannou M, Christodoulou NG
    Histopathological evidence of cellular alterations in the dentate gyrus is associated with aberrant RB1CC1-ATG16L1 expression in the hippocampus among older adults with chronic schizophrenia: A pilot post-mortem study.
    Schizophr Res. 2024;275:14-24.
    >> Share

  8. HARDY A, Taylor KM, Grant A, Christie L, et al
    Co-designing technology to improve psychological therapy for psychosis: SloMo, a blended digital therapy for fear of harm from others.
    Schizophr Res. 2024;274:526-534.
    >> Share

  9. LI J, He J, Ren H, Li Z, et al
    Free-water imaging in subcortical gray matter in schizophrenia patients with persistent auditory verbal hallucinations.
    Schizophr Res. 2024;274:517-525.
    >> Share

  10. KESHAVAN MS, Seif P, Tandon R
    Muscarinic deficits - part of a cholinergic-dopaminergic- glutamatergic imbalance in schizophrenia?
    Schizophr Res. 2024;274:508-510.
    >> Share

  11. CAI H, Shen B, Long JX, Huang XL, et al
    Network analysis of psychotic symptoms in schizophrenia.
    Schizophr Res. 2024;274:501-507.
    >> Share

  12. POKORNY VJ, Sponheim SR, Olman CA
    Orientation-dependent contextual modulation of contrast in schizophrenia.
    Schizophr Res. 2024;274:492-500.
    >> Share

  13. JIMENEZ AM, Green MF
    Self-disturbance in schizophrenia: Updating the research and bridging the gaps.
    Schizophr Res. 2024;274:489-491.
    >> Share

  14. DENIS D, Baran B, Mylonas D, Spitzer C, et al
    Sleep oscillations and their relations with sleep-dependent memory consolidation in early course psychosis and first-degree relatives.
    Schizophr Res. 2024;274:473-485.
    >> Share

  15. SUN X, Li M, Qiu Y, Su Q, et al
    Plasma NGAL, not IFN-gamma, predicts early treatment response in drug-naive Chinese Han schizophrenia patients.
    Schizophr Res. 2024;274:457-463.
    >> Share

  16. LUCKHOFF HK, Del Re EC, Smit R, Kilian S, et al
    Sex versus gender associations with depressive symptom trajectories over 24 months in first-episode schizophrenia spectrum disorders.
    Schizophr Res. 2024;274:450-456.
    >> Share

  17. GEBREEGZIABHERE Y, Habatmu K, Cella M, Alem A, et al
    Validation of the Amharic version of Cognitive Assessment Interview (CAI-A) in people with schizophrenia in Ethiopia.
    Schizophr Res. 2024;274:441-449.
    >> Share

  18. XU L, Yang W, Fan R, Wu Y, et al
    A novel digital intervention for improving cognitive impairment in patients with chronic schizophrenia: A randomized clinical trial.
    Schizophr Res. 2024;274:433-440.
    >> Share

  19. YAEGASHI H, Haga M, Misawa F, Mizuno Y, et al
    Intentional non-adherence to antipsychotic medication in patients with schizophrenia.
    Schizophr Res. 2024;274:427-432.
    >> Share

  20. NI P, Ma Y, Chung S
    Mitochondrial dysfunction in psychiatric disorders.
    Schizophr Res. 2024;273:62-77.
    >> Share

    October 2024
  21. ALI MP, Tiles-Sar N, Simons CJP, Osicka DA, et al
    Does stigma leave its mark? The interplay between negative effects of perceived stigma with positive effect of self-esteem on long-term social functioning in schizophrenia.
    Schizophr Res. 2024;274:417-426.
    >> Share

  22. ANDERSON JC, Seitz DP, Crockford D, Addington D, et al
    Quality indicators for schizophrenia care: A scoping review.
    Schizophr Res. 2024;274:406-416.
    >> Share

  23. BERGSON Z, Ahmed AO, Bell J, Butler PD, et al
    Visual remediation of contrast processing impairments in schizophrenia: A preliminary clinical trial.
    Schizophr Res. 2024;274:396-405.
    >> Share

  24. REZAEI K, Sanchez-Rico M, Garces-Gonzalez MS, Vandel P, et al
    Mortality among older people with late-onset and non-late-onset schizophrenia: A 5-year prospective multicenter study.
    Schizophr Res. 2024;274:393-395.
    >> Share

  25. JUCKEL G
    Reply to Dyadic interaction in schizophrenia - A promising new avenue of investigation?
    Schizophr Res. 2024;274:392.
    >> Share

  26. ABDULLAHI A, Wong TW, Ng SS
    Understanding the potential mechanisms of disease modifying effects of physical activity and exercise in people with schizophrenia.
    Schizophr Res. 2024;274:381-391.
    >> Share

  27. TIAN J, Dong S, Nomura N, Siafis S, et al
    Efficacy and tolerability of blonanserin in schizophrenia: A systematic review and meta-analysis of randomized controlled trials.
    Schizophr Res. 2024;274:360-373.
    >> Share

  28. LI S, Lu C, Liu N, Li Y, et al
    Association between auditory P300 event-related potential and suicidal thoughts and behaviors in first-episode antipsychotic-naive patients with schizophrenia.
    Schizophr Res. 2024;274:352-359.
    >> Share

  29. GENG C, Chen C
    Bidirectional Mendelian randomization to explore the causal relationships between schizophrenia and narcolepsy.
    Schizophr Res. 2024;274:345-351.
    >> Share

  30. ISMAIL Z, Meehan SR, Farovik A, Miguelez M, et al
    Assessment of patient life engagement in schizophrenia using items from the Positive and Negative Syndrome Scale.
    Schizophr Res. 2024;274:337-344.
    >> Share

  31. DEWAN M, Campbell Daniels E, Hunt JE, Bryant EA, et al
    Aberrant salience signaling in auditory processing in schizophrenia: Evidence for abnormalities in both sensory processing and emotional reactivity.
    Schizophr Res. 2024;274:329-336.
    >> Share

  32. SABBAH SG, Northoff G
    Basic self-disturbance in schizophrenia: From neuronal to mental topographic dedifferentiation.
    Schizophr Res. 2024;274:327-328.
    >> Share

  33. ULIANA DL, Martinez A, Grace AA
    THPP-1 PDE10A inhibitor reverses the cognitive deficits and hyperdopaminergic state in a neurodevelopment model of schizophrenia.
    Schizophr Res. 2024;274:315-326.
    >> Share

  34. DE BEER F, Wijnen B, Wouda L, Koops S, et al
    Antipsychotic dopamine D(2) affinity and negative symptoms in remitted first episode psychosis patients.
    Schizophr Res. 2024;274:299-306.
    >> Share

  35. ZHOU Y, Zheng Q, Tian J
    Letter to the editor regarding "The effects of mindful exercise on cognition in patients with schizophrenia: A systematic review and meta-analysis of randomized controlled trials".
    Schizophr Res. 2024;274:288-289.
    >> Share

  36. JAMBAWO SM, Owolewa R, Jambawo TT
    The effectiveness of peer support on the recovery and empowerment of people with schizophrenia: A systematic review and meta-analysis.
    Schizophr Res. 2024;274:270-279.
    >> Share

  37. FOERSTER FR, Joos E, Martin B, Coull JT, et al
    Corrigendum to "Self and time in individuals with schizophrenia: A motor component?" [Schizophr. Res. 272 (2024) 12-19 (October)].
    Schizophr Res. 2024;274:269.
    >> Share

  38. CHENG W, Zhao M, Zhang X, Zhou X, et al
    Schizophrenia and antipsychotic medications present distinct and shared gut microbial composition: A meta-analysis.
    Schizophr Res. 2024;274:257-268.
    >> Share

  39. SARANGI S, Sharma S, Nahak SK, Panda AK, et al
    Association of CACNA1C polymorphisms (rs1006737, rs4765905, rs2007044) with schizophrenia: A meta-analysis and trial sequential analysis.
    Schizophr Res. 2024;274:247-256.
    >> Share

  40. COWAN HR
    Aligning phenomenology and neuroscience of the basic and narrative self in schizophrenia.
    Schizophr Res. 2024;274:245-246.
    >> Share

  41. HAJDUK M, Park S, Pinkham AE
    Dyadic interaction in schizophrenia - A promising new avenue of investigation?
    Schizophr Res. 2024;274:243-244.
    >> Share

  42. BRANDT AS, Nucifora FC Jr, Zandi PP, Margolis RL, et al
    The timing and severity of clozapine-associated neutropenia in the US: Is the risk overstated?
    Schizophr Res. 2024;272:104-109.
    >> Share

  43. BJORNESTAD J, Tjora T, Joa I, Johannessen JO, et al
    Early and later remission from clinical high risk of psychosis. A latent class and predictor analysis.
    Schizophr Res. 2024;274:237-242.
    >> Share

    September 2024
  44. JOHNSTONE S, Hubbard AN, Schenkel A, Ashare RL, et al
    Effects of acute smoking abstinence among people with schizophrenia: A systematic review and meta-analysis of laboratory studies.
    Schizophr Res. 2024;274:220-236.
    >> Share

  45. WRIGHT AC, McKenna A, Tice JA, Rind DM, et al
    A network meta-analysis of KarXT and commonly used pharmacological interventions for schizophrenia.
    Schizophr Res. 2024;274:212-219.
    >> Share

  46. RESTELLINI R, Golay P, Jenni R, Baumann PS, et al
    Winter birth: A factor of poor functional outcome in a Swiss early psychosis cohort.
    Schizophr Res. 2024;274:206-211.
    >> Share

  47. WANG X, Wang RX, Bian C, Liu FY, et al
    Sleep quality, psychological resilience, family resilience, social support, and mental disability in patients with chronic schizophrenia: A cross-sectional study.
    Schizophr Res. 2024;274:199-205.
    >> Share

  48. POLETTI M, Raballo A
    Schizophrenia spectrum disorders in children and adolescents: Clinical, phenomenological, diagnostic, and prognostic features across subtypes.
    Schizophr Res. 2024;274:189-198.
    >> Share

  49. LEE HS, Sangimino M, Baxter T, Buck L, et al
    Self-other boundary under social threat in schizophrenia.
    Schizophr Res. 2024;274:182-188.
    >> Share

  50. LUCKHOFF H, Smit R, Del Re E, Kilian S, et al
    Associations of sexual orientation with symptom profiles in first-episode schizophrenia spectrum disorders.
    Schizophr Res. 2024;274:180-181.
    >> Share

  51. CABUK T, Sevim N, Mutlu E, Yagcioglu AEA, et al
    Corrigendum to "Natural language processing for defining linguistic features in schizophrenia: A sample from Turkish speakers" [Schizophr. Res. 266 (2024) 183-189].
    Schizophr Res. 2024;274:178-179.
    >> Share

  52. ZILBERSTEIN T, Shomron B
    The depiction of people with schizophrenia in news media: A cross-national analysis.
    Schizophr Res. 2024;274:171-177.
    >> Share

  53. PHALEN P, Jones N, Davis B, Sarpal D, et al
    Suicidality among clients in a network of coordinated specialty care (CSC) programs for first-episode psychosis: Rates, changes in rates, and their predictors.
    Schizophr Res. 2024;274:150-157.
    >> Share

  54. PELIZZA L, Leuci E, Quattrone E, Azzali S, et al
    Rates and predictors of service disengagement in first episode psychosis: Results from a 2-year follow-up study in an Italian real-world care setting.
    Schizophr Res. 2024;274:142-149.
    >> Share

  55. MOLHO W, Stiltner B, Raymond N, Kiely C, et al
    Retinal electrophysiological alterations are associated with cognition in early course psychosis.
    Schizophr Res. 2024;274:137-141.
    >> Share

  56. SNELLEKSZ M, Scarr E, Dean B
    Lower levels of kainate receptors, but not AMPA or NMDA receptors, in Brodmann's area (BA) 9, but not BA 10, from a subgroup of people with schizophrenia who have a marked deficit in cortical muscarinic M1 receptors.
    Schizophr Res. 2024;274:129-136.
    >> Share

  57. KIZILAY E, Arslan B, Verim B, Demirlek C, et al
    Automated linguistic analysis in youth at clinical high risk for psychosis.
    Schizophr Res. 2024;274:121-128.
    >> Share

  58. SU Q, Xuekelaiti Z, Ma H, Qiu Y, et al
    The associations between duration of untreated psychosis, growth factors, and neurocognition in patients with drug-naive schizophrenia.
    Schizophr Res. 2024;274:113-120.
    >> Share

  59. SHAKIR M, van Harten PN, Hoogendoorn AW, Willems AE, et al
    Switching a combination of first- and second-generation antipsychotic polypharmacy to antipsychotic monotherapy in long-term inpatients with schizophrenia and related disorders. The SwAP trial II: Results on side effects.
    Schizophr Res. 2024;274:105-112.
    >> Share

  60. GARTNER SP, Olesen TB, Jensen H, Mortensen LM, et al
    Recognition of schizophrenia and quality of treatment during the COVID-19 pandemic: A Danish nationwide study.
    Schizophr Res. 2024;274:98-104.
    >> Share

  61. WU C, She S, Gong B, Li Q, et al
    Spontaneous neural activity underlying neutral and happy speech recognition in noise and its association with psychiatric symptoms in patients with schizophrenia.
    Schizophr Res. 2024;274:90-97.
    >> Share

  62. SALVI V, Tripodi B, Cerveri G, Migliarese G, et al
    Insulin-resistance as a modifiable pathway to cognitive dysfunction in schizophrenia: A systematic review.
    Schizophr Res. 2024;274:78-89.
    >> Share

  63. LEE R, Griffiths SL, Gkoutos GV, Wood SJ, et al
    Predicting treatment resistance in positive and negative symptom domains from first episode psychosis: Development of a clinical prediction model.
    Schizophr Res. 2024;274:66-77.
    >> Share

  64. HORAN WP, Targum SD, Claxton A, Kaul I, et al
    Efficacy of KarXT on negative symptoms in acute schizophrenia: A post hoc analysis of pooled data from 3 trials.
    Schizophr Res. 2024;274:57-65.
    >> Share

  65. RAJ V, Stogios N, Agarwal SM, Cheng AJ, et al
    The neuromuscular basis of functional impairment in schizophrenia: A scoping review.
    Schizophr Res. 2024;274:46-56.
    >> Share

  66. KRAMER M, Fink F, Campo LA, Akinci E, et al
    Video analysis of interaction in schizophrenia reveals functionally relevant abnormalities.
    Schizophr Res. 2024;274:24-32.
    >> Share

  67. THOMPSON JL, Silverstein SM, Papathomas TV, Keane BP, et al
    Hallucinations and the depth-inversion illusion in schizophrenia.
    Schizophr Res. 2024;274:21-23.
    >> Share

  68. STARZER M, Hansen HG, Hjorthoj C, Albert N, et al
    Long-term quality of life and social disconnection 20 years after a first episode psychosis, results from the 20-year follow-up of the OPUS trial.
    Schizophr Res. 2024;274:33-45.
    >> Share

  69. ALESSANDRO DL, Leuci E, Quattrone E, Azzali S, et al
    Obsessive-compulsive symptoms in individuals at clinical high risk for psychosis: A 2-year longitudinal study.
    Schizophr Res. 2024;274:11-20.
    >> Share

  70. GREENWAY FT, Weal M, Palmer-Cooper EC
    Hybrid mHealth care: Patient perspectives of blended treatments for psychosis. A systematic review.
    Schizophr Res. 2024;274:1-10.
    >> Share

  71. SMUCNY J, Wood A, Davidson IN, Carter CS, et al
    Are factors that predict conversion to psychosis associated with initial transition to a high risk state? An adolescent brain cognitive development study analysis.
    Schizophr Res. 2024;272:128-132.
    >> Share

  72. TERENZI D, Silvetti M, Zoccolan G, Rumiati RI, et al
    The impact of subclinical psychotic symptoms on delay and effort discounting: Insights from behavioral, computational, and electrophysiological methods.
    Schizophr Res. 2024;271:271-280.
    >> Share

  73. HARVEY PD, Davidson M, Saoud JB, Kuchibhatla R, et al
    Prevalence of prominent and predominant negative symptoms across different criteria for negative symptom severity and minimal positive symptoms: A comparison of different criteria.
    Schizophr Res. 2024;271:246-252.
    >> Share

  74. GONZALO-DE MIGUEL A, Abascal-Peiro S, Cegla-Schvartzman FB, Martinez-Ales G, et al
    Antipsychotic use in a large community sample of patients with delusional disorder.
    Schizophr Res. 2024;271:194-199.
    >> Share

  75. SARPAL DK
    Astrocytic contributions to clozapine response: Potential support for a psychopharmacologic glial process.
    Schizophr Res. 2024;271:142-143.
    >> Share

  76. ARORA S, Suhas S, Gowda GS, Reddi VSK, et al
    DRESS syndrome, seizures, and myocarditis on low dose clozapine - A case report.
    Schizophr Res. 2024;271:391-393.
    >> Share

    August 2024
  77. REAVIS EA, Wynn JK, Green MF
    Pre-stimulus EEG phase coherence predicts visual target detection failures in schizophrenia: A pilot study.
    Schizophr Res. 2024;272:112-119.
    >> Share

  78. ELKIS H, Melzer-Ribeiro DL, Napolitano IC
    Response to Markota et al. "Clinical heterogeneity and ECT in patients with clozapine resistant schizophrenia" SCHRES-D-24-00481.
    Schizophr Res. 2024;272:110-111.
    >> Share

  79. LIZANO P, Karmacharya R
    Harnessing stem cell-based approaches for clinically meaningful discoveries in schizophrenia.
    Schizophr Res. 2024 Aug 29:S0920-9964(24)00377.
    >> Share

  80. SONG SH, Hayirli TC, Shore O, Coconcea C, et al
    Atypical presentation of schizophrenia with ablution avoidance: A case report.
    Schizophr Res. 2024;272:96-97.
    >> Share

  81. MLAKAR V, Akkouh I, Halff EF, Srivastava DP, et al
    Telomere biology and its maintenance in schizophrenia spectrum disorders: Exploring links to cognition.
    Schizophr Res. 2024;272:89-95.
    >> Share

  82. COTTER SJ, Smith CL, Gao CX, Khanna R, et al
    What impact did the COVID-19 pandemic have on psychosis and the delivery of early intervention psychosis services?
    Schizophr Res. 2024;272:79-88.
    >> Share

  83. MARKOTA M, Croarkin PE, Coombes BJ, Gentry MT, et al
    Clinical heterogeneity and ECT in patients with clozapine resistant schizophrenia.
    Schizophr Res. 2024;272:77-78.
    >> Share

  84. SHIRINBAKHSHMASOLEH M, Aboulatta L, Leong C, Riel H, et al
    The impact of COVID-19 public health measures on the utilization of antipsychotics in schizophrenia in Manitoba - A population-based study.
    Schizophr Res. 2024;272:69-76.
    >> Share

  85. TARGUM SD, Ge T, Asgharnejad M, Reksoprodjo P, et al
    Use of video-recordings of site-based interviews for quality assurance in a study of subjects with schizophrenia and persistent negative symptoms.
    Schizophr Res. 2024;272:61-68.
    >> Share

  86. JIMENEZ AM, Green MF
    Disturbance at the self-other boundary in schizophrenia: Linking phenomenology to clinical neuroscience.
    Schizophr Res. 2024;272:51-60.
    >> Share

  87. LIU Z, Sun YH, Ren Y, Perez JM, et al
    Upregulated solute-carrier family genes in the hippocampus of schizophrenia can be rescued by antipsychotic medications.
    Schizophr Res. 2024;272:39-50.
    >> Share

  88. REDLICH BOSSY M, Muller DR, Jabat M, Burrer A, et al
    Relationship between psychopathological symptoms and dimensions in inpatients with schizophrenia: A network analysis.
    Schizophr Res. 2024;272:36-38.
    >> Share

  89. POLETTI M, Raballo A
    Ontogenesis of self-disorders in the schizophrenia spectrum: A phenomenological neuro-developmental model.
    Schizophr Res. 2024;272:26-35.
    >> Share

  90. GU B, Rose J, Kurtz MM
    Cognitive training for schizophrenia: Do race and ethnicity matter?
    Schizophr Res. 2024;272:20-25.
    >> Share

  91. FOERSTER FR, Joos E, Martin B, Coull JT, et al
    Self and time in individuals with schizophrenia: A motor component?
    Schizophr Res. 2024;272:12-19.
    >> Share

  92. LOCHMANN VAN BENNEKOM MWH, IntHout J, Gijsman HJ, Akdede BBK, et al
    Efficacy and tolerability of antipsychotic polypharmacy for schizophrenia spectrum disorders. A systematic review and meta-analysis of individual patient data.
    Schizophr Res. 2024;272:1-11.
    >> Share

  93. MESSINIS A, Panteli E, Paraskevopoulou A, Zymarikopoulou AK, et al
    Altered lipidomics biosignatures in schizophrenia: A systematic review.
    Schizophr Res. 2024;271:380-390.
    >> Share

  94. HE Q, Zhu P, Liu X, Huo C, et al
    Association of new-onset diabetes mellitus in adults with schizophrenia treated with clozapine versus patients treated with olanzapine, risperidone, or quetiapine: A systematic review and meta-analysis.
    Schizophr Res. 2024;271:371-379.
    >> Share

  95. PIRAS M, Popovic I, Ranjbar S, Grosu C, et al
    Aripiprazole dose associations with metabolic adverse effect: Results from a longitudinal study.
    Schizophr Res. 2024;270:403-409.
    >> Share

  96. KOHLER-FORSBERG O, Hojlund M, Rohde C, Kemp AF, et al
    Efficacy and acceptability of interventions to reduce antipsychotic polypharmacy: A systematic review and meta-analysis of randomized clinical trials.
    Schizophr Res. 2024;270:135-143.
    >> Share

    July 2024
  97. VAN DYNE A, Wu TC, Adamowicz DH, Lee EE, et al
    Longitudinal relationships between BMI and hs-CRP among people with schizophrenia.
    Schizophr Res. 2024;271:337-344.
    >> Share

  98. PROKOPEZ CR, Cesarini JI, Corral RM, Sere L, et al
    Renaming schizophrenia in Argentina: Could a change of name resolve the stigma? Results from a national survey.
    Schizophr Res. 2024;271:334-336.
    >> Share

  99. EACK SM
    Defeatist beliefs about performance are important treatment targets for negative symptoms in the early course of schizophrenia.
    Schizophr Res. 2024;271:332-333.
    >> Share

  100. KENNEDY L, Ku BS, Addington J, Amir CM, et al
    Occasional cannabis use is associated with higher premorbid functioning and IQ in youth at clinical high-risk (CHR) for psychosis: Parallel findings to psychosis cohorts.
    Schizophr Res. 2024;271:319-331.
    >> Share

  101. CHEN CC, Howie J, Ebrahimi M, Teymouri K, et al
    Analysis of the complement component C4 gene with schizophrenia subphenotypes.
    Schizophr Res. 2024;271:309-318.
    >> Share

  102. SALVADE A, Golay P, Abrahamyan L, Bonnarel V, et al
    Gender differences in first episode psychosis: Some arguments to develop gender specific treatment strategies.
    Schizophr Res. 2024;271:300-308.
    >> Share

  103. WANG Y, Ouyang L, Fan L, Zheng W, et al
    Functional and structural abnormalities of thalamus in individuals at early stage of schizophrenia.
    Schizophr Res. 2024;271:292-299.
    >> Share

  104. SICOTTE R, D'Andrea G, Dumais A, Crocker AG, et al
    Aggressive behaviors in first-episode psychosis: Distinction between the premorbid phase and the onset of psychosis.
    Schizophr Res. 2024;271:283-291.
    >> Share

  105. MILLGATE E, Smart SE, Pardinas AF, Kravariti E, et al
    Corrigendum to "Cognitive performance at first episode of psychosis and the relationship with future treatment resistance: Evidence from an international prospective cohort study" [Schizophr. Res. volume 225 (May 2023) 173-181].
    Schizophr Res. 2024;270:495-496.
    >> Share

  106. ASAI T, Ikegame T, Satomura Y, Kumagai E, et al
    Lower plasma betaine levels in men at clinical high risk for psychosis: Findings from a metabolomics investigation.
    Schizophr Res. 2024;271:281-282.
    >> Share

  107. STEPHENS RL, Leavitt I, Cornea E, Jarskog LF, et al
    Early cognitive development and psychopathology in children at familial high risk for schizophrenia.
    Schizophr Res. 2024;271:262-270.
    >> Share

  108. ABEL DB, Vohs JL, Salyers MP, Wu W, et al
    Social anhedonia in the daily lives of people with schizophrenia: Examination of anticipated and consummatory pleasure.
    Schizophr Res. 2024;271:253-261.
    >> Share

  109. CHEN CR, Lee YW, Chen TT, Hsu CW, et al
    The effects of mindful exercise on cognition in patients with schizophrenia: A systematic review and meta-analysis of randomized controlled trials.
    Schizophr Res. 2024;271:237-245.
    >> Share

  110. CORADDUZZA D, di Lorenzo B, Sedda S, Nivoli AM, et al
    Investigating bilirubin concentrations in schizophrenia: A systematic review and meta-analysis.
    Schizophr Res. 2024;271:228-236.
    >> Share

  111. SOLEIMANI MF, Ayubi E, Khosronezhad S, Hasler G, et al
    Human endogenous retroviruses type W (HERV-) activation and schizophrenia: A meta-analysis.
    Schizophr Res. 2024;271:220-227.
    >> Share

  112. COSTA DFB, Rossignoli P, Pontarolli DRS, Junior PC, et al
    Increased COVID-19 mortality in patients with schizophrenia: A retrospective study in Brazil.
    Schizophr Res. 2024;271:200-205.
    >> Share

  113. KADIVAR A, Ilapakurti M, Dobkins K, Cadenhead KS, et al
    Visual contrast sensitivity in clinical high risk and first episode psychosis.
    Schizophr Res. 2024;271:186-193.
    >> Share

  114. WINKLER K, Lincoln TM, Wiesjahn M, Jung E, et al
    How does loneliness interact with positive, negative and depressive symptoms of psychosis? New insights from a longitudinal therapy process study.
    Schizophr Res. 2024;271:179-185.
    >> Share

  115. RYCHAGOV N, Del Re EC, Zeng V, Oykhman E, et al
    Gyrification across psychotic disorders: A bipolar-schizophrenia network of intermediate phenotypes study.
    Schizophr Res. 2024;271:169-178.
    >> Share

  116. KENNEDY KP, Zito MF, Marder SR
    Does relapse cause illness progression in first-episode psychosis? A review.
    Schizophr Res. 2024;271:161-168.
    >> Share

  117. CHINTOH A, Liu L, Braun A, Akseer S, et al
    Sex differences in clinical presentation in youth at high risk for psychosis who transition to psychosis.
    Schizophr Res. 2024;271:153-160.
    >> Share

  118. KOSTER M, van der Pluijm M, van de Giessen E, Schrantee A, et al
    The association of tobacco smoking and metabolite levels in the anterior cingulate cortex of first-episode psychosis patients: A case-control and 6-month follow-up (1)H-MRS study.
    Schizophr Res. 2024;271:144-152.
    >> Share

  119. AL-CHALABI N, Nader G, Fischer C, Graff A, et al
    Effect of DNA methylation and AUDIT-C polygenic scores on alcohol use disorder comorbidity in psychoses: No evidence of epigenetic basis of polygenic risk.
    Schizophr Res. 2024;271:138-141.
    >> Share

  120. CARRION RE, Ku BS, Dorvil S, Auther AM, et al
    Neurocognition in adolescents and young adults at clinical high risk for psychosis: Predictive stability for social and role functioning.
    Schizophr Res. 2024;271:129-137.
    >> Share

  121. LI R, Cao M, Fu D, Wei W, et al
    Deciphering language disturbances in schizophrenia: A study using fine-tuned language models.
    Schizophr Res. 2024;271:120-128.
    >> Share

  122. FEOLA B, Flook EA, Seo DJ, Fox V, et al
    Altered brain and physiological stress responses in early psychosis.
    Schizophr Res. 2024;271:112-119.
    >> Share

  123. KREIS I, Lagerberg TV, Wold KF, Asbo G, et al
    Behind the heterogeneity in the long-term course of first-episode psychosis: Different psychotic symptom trajectories are associated with different patterns of cannabis and stimulant use.
    Schizophr Res. 2024;271:91-99.
    >> Share

  124. LISBOA JRF, Costa O, Pakes GH, Colodete DAE, et al
    Perineuronal net density in schizophrenia: A systematic review of postmortem brain studies.
    Schizophr Res. 2024;271:100-109.
    >> Share

  125. LAK M, Jafarpour A, Shahrbaf MA, Lak M, et al
    The effect of physical exercise on cognitive function in schizophrenia patients: A GRADE assessed systematic review and meta-analysis of controlled clinical trials.
    Schizophr Res. 2024;271:81-90.
    >> Share

  126. MACHIRAJU SN, Wyss J, Light G, Braff DL, et al
    Novel N100 area reliably captures aberrant sensory processing and is associated with neurocognition in early psychosis.
    Schizophr Res. 2024;271:71-80.
    >> Share

  127. BIONDI M, Marino M, Mantini D, Spironelli C, et al
    Unveiling altered connectivity between cognitive networks and cerebellum in schizophrenia.
    Schizophr Res. 2024;271:47-58.
    >> Share

  128. VARATHAN A, Senthooran S, Jeyananthan P
    Role of different omics data in the diagnosis of schizophrenia disorder: A machine learning study.
    Schizophr Res. 2024;271:38-46.
    >> Share

  129. DROSOS P, Johnsen E, Bartz-Johannessen CA, Larsen TK, et al
    Remission in schizophrenia spectrum disorders: A randomized trial of amisulpride, aripiprazole and olanzapine.
    Schizophr Res. 2024;271:9-18.
    >> Share

  130. LATRECHE I, Slatnia S, Kazar O, Harous S, et al
    Identification and diagnosis of schizophrenia based on multichannel EEG and CNN deep learning model.
    Schizophr Res. 2024;271:28-35.
    >> Share

  131. DWYER GE, Johnsen E, Hugdahl K
    NMDAR dysfunction and the regulation of dopaminergic transmission in schizophrenia.
    Schizophr Res. 2024;271:19-27.
    >> Share

  132. CORBERA S, Wexler BE, Bell MD, Pittman B, et al
    Disentangling negative and positive symptoms in schizophrenia and autism spectrum disorder.
    Schizophr Res. 2024;271:1-8.
    >> Share

  133. ZAMPERONI G, Tan EJ, Sumner PJ, Rossell SL, et al
    Exploring the conceptualisation, measurement, clinical utility and treatment of formal thought disorder in psychosis: A Delphi study.
    Schizophr Res. 2024;270:486-493.
    >> Share

  134. LIU L, Ren D, Li K, Ji L, et al
    Unraveling schizophrenia's genetic complexity through advanced causal inference and chromatin 3D conformation.
    Schizophr Res. 2024;270:476-485.
    >> Share

  135. BARNBY JM, Haslbeck JMB, Rosen C, Sharma R, et al
    Modelling the longitudinal dynamics of paranoia in psychosis: A temporal network analysis over 20 years.
    Schizophr Res. 2024;270:465-475.
    >> Share

  136. LUI SSY, Lam EHY, Wang LL, Leung PBM, et al
    Negative symptoms in treatment-resistant schizophrenia and its relationship with functioning.
    Schizophr Res. 2024;270:459-464.
    >> Share

  137. THIBAULT M, Romain AJ, Tessier C, Theagene JMJ, et al
    Feasibility and Acceptability of a Physical Activity Group Program Using telerehabilitation during the COVID-19 Pandemic in Multiple early Intervention for Psychosis Services.
    Schizophr Res. 2024;270:451-458.
    >> Share

  138. WOLD KF, Ottesen A, Flaaten CB, Kreis I, et al
    Childhood trauma and treatment resistance in first-episode psychosis: Investigating the role of premorbid adjustment and duration of untreated psychosis.
    Schizophr Res. 2024;270:441-450.
    >> Share

  139. MIHURA JL, Boyette LL, Gorner KJ, Kleiger JH, et al
    Improving dependability in science: A critique on the psychometric qualities of the HiTOP psychosis superspectrum.
    Schizophr Res. 2024;270:433-440.
    >> Share

  140. LIN D, Fu Z, Liu J, Perrone-Bizzozero N, et al
    Association between the oral microbiome and brain resting state connectivity in schizophrenia.
    Schizophr Res. 2024;270:392-402.
    >> Share

  141. GALUBA V, Cordes J, Feyerabend S, Riesbeck M, et al
    Identifying differential predictors for treatment response to amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia: Results of the COMBINE-study.
    Schizophr Res. 2024;270:383-391.
    >> Share

  142. MORRIS A, Reed T, McBride G, Chen J, et al
    Dietary interventions to improve metabolic health in schizophrenia: A systematic literature review of systematic reviews.
    Schizophr Res. 2024;270:372-382.
    >> Share

  143. MORFINI F, Bauer CCC, Zhang J, Whitfield-Gabrieli S, et al
    Targeting the superior temporal gyrus with real-time fMRI neurofeedback: A pilot study of the indirect effects on self-referential processes in schizophrenia.
    Schizophr Res. 2024;270:358-365.
    >> Share

  144. DING Y, Hou W, Wang C, Sha S, et al
    Longitudinal changes in cognitive function in early psychosis: a meta-analysis with the MATRICS consensus cognitive battery (MCCB).
    Schizophr Res. 2024;270:349-357.
    >> Share

  145. HEUSCHEN CBBCM, Bolhuis K, Zantvoord JB, Bockting CL, et al
    Self-reported suicidal ideation among individuals with first episode psychosis and healthy controls: Findings from the international multicentre EU-GEI study.
    Schizophr Res. 2024;270:339-348.
    >> Share

  146. LIU Y, Wu H, Liu B, Chen S, et al
    Multi-omics analysis reveals the impact of gut microbiota on antipsychotic-induced weight gain in schizophrenia.
    Schizophr Res. 2024;270:325-338.
    >> Share

  147. LIN PY, Chen YH, Chang YJ, Chen JW, et al
    Deep learning for schizophrenia classification based on natural language processing-A pilot study.
    Schizophr Res. 2024;270:323-324.
    >> Share

  148. CORRIPIO I, Fraguas D, Garcia-Portilla MP, Olivares JM, et al
    Functioning in schizophrenia: Recommendations of an expert panel.
    Schizophr Res. 2024;270:317-322.
    >> Share

  149. MANA L, Schwartz-Palleja M, Vila-Vidal M, Deco G, et al
    Overview on cognitive impairment in psychotic disorders: From impaired microcircuits to dysconnectivity.
    Schizophr Res. 2024;269:132-143.
    >> Share

  150. ELKIS H, Melzer-Ribeiro DL, Napolitano IC, Correll CU, et al
    The danger of averages in the context of heterogeneity: Response to the letter to the editor of SCZ RES- role of ECT in patients with CRS-Markota et al. 2024.
    Schizophr Res. 2024;269:120-122.
    >> Share

    June 2024
  151. JEONG JH, Kim SW, Yu JC, Won SH, et al
    Clinical, cognitive, and functional characteristics of recent-onset psychosis with autistic features: A 2-year longitudinal study.
    Schizophr Res. 2024;270:304-316.
    >> Share

  152. SOURANDER A, Upadhyaya S, Surcel HM, Hinkka-Yli-Salomaki S, et al
    Maternal vitamin D levels during pregnancy and offspring schizophrenia.
    Schizophr Res. 2024;270:289-294.
    >> Share

  153. HU W, Ran X, Wu Z, Zhu H, et al
    Short-term antipsychotic treatment reduces functional connectivity of the striatum in first-episode drug-naive early-onset schizophrenia.
    Schizophr Res. 2024;270:281-288.
    >> Share

  154. HAMERS IMH, Brand BA, Begemann MJH, Weickert CS, et al
    The association of prolactin and gonadal hormones with cognition and symptoms in men with schizophrenia spectrum disorder: Divergent effects of testosterone and estrogen.
    Schizophr Res. 2024;270:273-280.
    >> Share

  155. IGLESIAS-MARTINEZ-ALMEIDA M, Campos-Rios A, Freiria-Martinez L, Rivera-Baltanas T, et al
    Characterization and modulation of voltage-gated potassium channels in human lymphocytes in schizophrenia.
    Schizophr Res. 2024;270:260-272.
    >> Share

  156. KURTULMUS A, Yildiz FBP
    The potential role of gamma-secretase complex in schizophrenia: Bridging neurodevelopmental and neurodegenerative hypotheses.
    Schizophr Res. 2024;270:258-259.
    >> Share

  157. MURTHY V, Hanson E, DeMartinis N, Asgharnejad M, et al
    INTERACT: a randomized phase 2 study of the DAAO inhibitor luvadaxistat in adults with schizophrenia.
    Schizophr Res. 2024;270:249-257.
    >> Share

  158. JACOBSEN SL, Kohler-Forsberg O, Rohde C
    Are patients with schizophrenia treated less with second-line glucose-lowering drugs for type 2 diabetes?
    Schizophr Res. 2024;270:231-234.
    >> Share

  159. NOGUEIRA GN, Andrade AGM, Guimaraes APC, Gomes SP, et al
    Exploring substance use in first episode psychoses, what can we do more?
    Schizophr Res. 2024;270:229-230.
    >> Share

  160. SKIBA RM, Chinchani AM, Menon M, Lepage M, et al
    Overlap between individual differences in cognition and symptoms of schizophrenia.
    Schizophr Res. 2024;270:220-228.
    >> Share

  161. FILIP TF, Hellemann GS, Ventura J, Subotnik KL, et al
    Defeatist performance beliefs in individuals with recent-onset schizophrenia: Relationships with cognition and negative symptoms.
    Schizophr Res. 2024;270:212-219.
    >> Share

  162. HE H, Long J, Song X, Li Q, et al
    A connectome-wide association study of altered functional connectivity in schizophrenia based on resting-state fMRI.
    Schizophr Res. 2024;270:202-211.
    >> Share

  163. PARNAS J, Sandsten KE
    The phenomenological nature of schizophrenia and disorder of selfhood.
    Schizophr Res. 2024;270:197-201.
    >> Share

  164. TAN EJ, Rossell SL
    Exploring associations between trait symptoms and speech patterns in schizophrenia spectrum disorders: A mediation analysis.
    Schizophr Res. 2024;270:188-190.
    >> Share

  165. WANG C, Zhang Y, Chong JS, Zhang W, et al
    Altered functional connectivity subserving expressed emotion environments in schizophrenia: An fNIRS study.
    Schizophr Res. 2024;270:178-187.
    >> Share

  166. MOHN C, Ueland T, Haatveit B, Saether LS, et al
    Neurocognitive function and delusion severity in schizophrenia spectrum disorders.
    Schizophr Res. 2024;270:172-177.
    >> Share

  167. ZHANG R, Lei X, Ren J, Zhang C, et al
    The roles of extracellular vesicle-derived microRNAs in schizophrenia: A scoping review.
    Schizophr Res. 2024;270:162-164.
    >> Share

  168. TORRES-CARMONA E, Nakajima S, Iwata Y, Ueno F, et al
    Clozapine treatment and astrocyte activity in treatment resistant schizophrenia: A proton magnetic resonance spectroscopy study.
    Schizophr Res. 2024;270:152-161.
    >> Share

  169. BROBAKKEN MF, Nygard M, Vedul-Kjelsas E, Harvey PD, et al
    Everyday function in schizophrenia: The impact of aerobic endurance and skeletal muscle strength.
    Schizophr Res. 2024;270:144-151.
    >> Share

  170. DUNMON D, Schooler NR, Severe JB, Buckley PF, et al
    Insomnia and cardiovascular disease risk in schizophrenia.
    Schizophr Res. 2024;270:132-134.
    >> Share

  171. NASRALLAH HA
    Is self-disturbance in schizophrenia due to inter- and intra-hemispheric white matter dysconnectivity?
    Schizophr Res. 2024;270:129-131.
    >> Share

  172. SAKAKIBARA E, Satomura Y, Matsuoka J, Koike S, et al
    Abnormal resting-state hyperconnectivity in schizophrenia: A whole-head near-infrared spectroscopy study.
    Schizophr Res. 2024;270:121-128.
    >> Share

  173. NIBBIO G, Pinton IC, Barlati S, Stanga V, et al
    Predictors of psychosocial functioning in people diagnosed with schizophrenia spectrum disorders that committed violent offences and in those that did not: Results of the Recoviwel study.
    Schizophr Res. 2024;270:112-120.
    >> Share

  174. CHEN X, Huang H, Pu Z, Shi Y, et al
    Increased risk of atypical antipsychotics-induced metabolic syndrome associated with MIF CATT >5/6 among females with chronic schizophrenia.
    Schizophr Res. 2024;270:94-101.
    >> Share

  175. PANY S, Rawat K, Swami MK
    Sleep patterns in treated and untreated patients of schizophrenia.
    Schizophr Res. 2024;270:111.
    >> Share

  176. SHEINBAUM T, Gizdic A, Kwapil TR, Barrantes-Vidal N, et al
    A longitudinal study of the impact of childhood adversity dimensions on social and psychological factors and symptoms of psychosis, depression, and anxiety.
    Schizophr Res. 2024;270:102-110.
    >> Share

  177. SHEN C, Tong X, Ran J, Sun S, et al
    Associations between residential environments and late-onset schizophrenia in UK Biobank: Interaction with genetic risk factor.
    Schizophr Res. 2024;270:85-93.
    >> Share

  178. MOROSAN L, de Almeida ER, van der Tuin S, van den Berg D, et al
    The impact of daily social support on the associations between daily negative events and daily suspiciousness across different clinical stages of psychosis.
    Schizophr Res. 2024;270:76-84.
    >> Share

  179. DEFAYETTE AB, Silverstein SM, Pisani AR
    Social network structure as a biopsychosocial suicide prevention target for young people at clinical high-risk for psychosis.
    Schizophr Res. 2024;270:63-67.
    >> Share

  180. SANDSTEN KE, Jensen MT, Saebye D, Null K, et al
    Altered cardiac autonomic functioning associates with self-disorders in schizophrenia.
    Schizophr Res. 2024;270:57-62.
    >> Share

  181. CECERSKA-HERYC E, Polikowska A, Serwin N, Michalczyk A, et al
    The importance of oxidative biomarkers in diagnosis, treatment, and monitoring schizophrenia patients.
    Schizophr Res. 2024;270:44-56.
    >> Share

  182. MUKAI Y, Lupinacci R, Marder S, Snow-Adami L, et al
    Effects of PDE10A inhibitor MK-8189 in people with an acute episode of schizophrenia: A randomized proof-of-concept clinical trial.
    Schizophr Res. 2024;270:37-43.
    >> Share

  183. ABDOLIZADEH A, Hosseini Kupaei M, Kambari Y, Amaev A, et al
    The effect of second-generation antipsychotics on anxiety/depression in patients with schizophrenia: A systematic review and meta-analysis.
    Schizophr Res. 2024;270:11-36.
    >> Share

  184. DE LEON J
    Promoting safer and wider worldwide use of clozapine.
    Schizophr Res. 2024;268:1-6.
    >> Share

  185. NIITSU T, Yasui-Furukori N, Inada K, Kanazawa T, et al
    Current practice for clozapine-induced leukopenia in Japanese psychiatric hospitals: A nationwide survey.
    Schizophr Res. 2024;268:82-87.
    >> Share

  186. BAPTISTA T, Motuca M, Serrano A, Perez Lo Presti A, et al
    An expert review of clozapine in Latin American countries: Use, monitoring, and pharmacovigilance.
    Schizophr Res. 2024;268:60-65.
    >> Share

  187. KUZO N, Blyzniuk B, Chumakov E, Seifritz E, et al
    Clozapine research standards in former USSR states: A systematic review of quality issues with recommendations for future harmonization with modern research standards.
    Schizophr Res. 2024;268:48-52.
    >> Share

  188. MEYER JM
    Making sense of norclozapine levels: 3 clinical axioms.
    Schizophr Res. 2024;268:289-292.
    >> Share

  189. VERDOUX H, Quiles C, de Leon J
    Optimizing antidepressant and clozapine co-prescription in clinical practice: A systematic review and expert recommendations.
    Schizophr Res. 2024;268:243-251.
    >> Share

  190. ZOLEZZI M, Eltorki Y
    A brief history and challenges of clozapine utilization in the Arab world.
    Schizophr Res. 2024;268:21-24.
    >> Share

  191. YANG Z, Takeuchi H, Yee JY, See YM, et al
    Once-daily versus divided dosing regimens of clozapine: A cross-sectional study in Singapore.
    Schizophr Res. 2024;268:66-73.
    >> Share

  192. MUNOZ-MANCHADO LI, Perez-Revuelta JI, Banerjee A, Galindo-Guarin L, et al
    Influence of time to clozapine prescription on the clinical outcome.
    Schizophr Res. 2024;268:189-192.
    >> Share

  193. SAGUD M, Breznoscakova D, Celofiga A, Chihai J, et al
    An expert review of clozapine in Eastern European countries: Use, regulations and pharmacovigilance.
    Schizophr Res. 2024;268:53-59.
    >> Share

  194. SANKARANARAYANAN A, Kazi S, Andrade C
    Prevalence and predictors of QTc prolongation in patients seen in a clozapine clinic in a real-world setting in Australia.
    Schizophr Res. 2024;268:145-149.
    >> Share

  195. SCHULTE PFJ, Veerman SRT, Bakker B, Bogers JPAM, et al
    Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring: Can the regulations be relaxed?
    Schizophr Res. 2024;268:74-81.
    >> Share

  196. KIRILOCHEV O, Chumakov E, Kuzo N, Schoretsanitis G, et al
    A scoping review of literature on clozapine from former USSR states published in Russian language.
    Schizophr Res. 2024;268:38-47.
    >> Share

  197. CARSWELL O, Wilton LR, Nicholls K, Thomas V, et al
    A 12-month audit of clozapine associated myocarditis in a South Australian Local Health Network: The importance of screening and personalised titration.
    Schizophr Res. 2024;268:88-93.
    >> Share

  198. DE LEON J, Wang L, Simpson GM
    The introduction of clozapine at the Nathan Kline Institute in New York and its long-term consequences.
    Schizophr Res. 2024;268:14-20.
    >> Share

  199. LEUNG JG, Allen ND, Markota M
    A case series of clozapine titrations affected by inflammatory processes.
    Schizophr Res. 2024;268:94-97.
    >> Share

  200. KELLY DL, Glassman M, Wonodi I, Vyas G, et al
    Clozapine and neutrophil response in patients of African descent: A six-month, multinational, prospective, open-label clinical trial.
    Schizophr Res. 2024;268:312-322.
    >> Share

  201. CLARK SR, Wilton LR, Dawson JL, Chiew K, et al
    Dotting the I's and crossing the T's: A South Australian perspective on variability in troponin thresholds for myocarditis risk in clozapine treatment.
    Schizophr Res. 2024;268:114-117.
    >> Share

  202. RUAN CJ, Olmos I, Ricciardi C, Schoretsanitis G, et al
    Exploring low clozapine C/D ratios, inverted clozapine-norclozapine ratios and undetectable concentrations as measures of non-adherence in clozapine patients: A literature review and a case series of 17 patients from 3 studies.
    Schizophr Res. 2024;268:293-301.
    >> Share

  203. LIN SK, Lane HY
    A brief history of clozapine use in Taiwan.
    Schizophr Res. 2024;268:34-37.
    >> Share

  204. GROVER S, Naskar C
    Patient and caregivers perspective about clozapine: A systematic review.
    Schizophr Res. 2024;268:223-232.
    >> Share

  205. KIKUCHI Y, Komatsu H, Otsuka Y, Ito F, et al
    Slower clozapine titration than the official Japanese protocol led to fewer inflammatory adverse effects: A retrospective chart review of seven hospitals.
    Schizophr Res. 2024;268:98-106.
    >> Share

  206. SCHORETSANITIS G, Anil Yagcioglu AE, Ruan CJ, Eap CB, et al
    Clozapine ultrarapid metabolism during weak induction probably exists but requires careful diagnosis. A literature review, five new cases and a proposed definition.
    Schizophr Res. 2024;268:302-307.
    >> Share

  207. RUAN CJ, Wang CY, Zang YN, Liu CG, et al
    A brief history of clozapine in China with a look forward.
    Schizophr Res. 2024;268:25-28.
    >> Share

  208. VERDOUX H, Quiles C, de Leon J
    Risks and benefits of clozapine and lithium co-prescribing: A systematic review and expert recommendations.
    Schizophr Res. 2024;268:233-242.
    >> Share

    May 2024
  209. BARRUEL D, Hilbey J, Charlet J, Chaumette B, et al
    Predicting treatment resistance in schizophrenia patients: Machine learning highlights the role of early pathophysiologic features.
    Schizophr Res. 2024;270:1-10.
    >> Share

  210. SABBAH SG, Northoff G
    Global neural self-disturbance in schizophrenia: A systematic fMRI review.
    Schizophr Res. 2024;269:163-173.
    >> Share

  211. GALLESE V, Ardizzi M, Ferroni F
    Schizophrenia and the bodily self.
    Schizophr Res. 2024;269:152-162.
    >> Share

  212. VARAMBALLY S, Holla B, Venkatasubramanian G, Mullapudi T, et al
    Clinical effects of a yoga-based intervention for patients with schizophrenia - A six-month randomized controlled trial.
    Schizophr Res. 2024;269:144-151.
    >> Share

  213. MARKOTA M, Croarkin PE, Gentry MT, Leung JG, et al
    Role of electroconvulsive therapy in patients with clozapine-refractory schizophrenia.
    Schizophr Res. 2024;269:130-131.
    >> Share

  214. REN H, Li J, Zhou J, Chen X, et al
    Grey matter volume reduction in the frontotemporal cortex associated with persistent verbal auditory hallucinations in Chinese patients with chronic schizophrenia: Insights from a 3 T magnetic resonance imaging study.
    Schizophr Res. 2024;269:123-129.
    >> Share

  215. GABBERT T, Scheunemann J, Balzan RP, Doehring N, et al
    The contributions of risk-taking and impulsivity to jumping to conclusions in the psychosis spectrum.
    Schizophr Res. 2024;269:116-119.
    >> Share

  216. VILLA J, Campbell DG, Parrish EM, Jeon ME, et al
    Associations between fearlessness about death and suicidal ideation in individuals with psychosis.
    Schizophr Res. 2024;269:96-102.
    >> Share

  217. ADELINO MPM, Nunes MV, Nunes MFQ, Quarantini LC, et al
    Efficacy of sodium nitroprusside in the treatment of drug-naive subjects in first episode psychosis - An open label study.
    Schizophr Res. 2024;269:114-115.
    >> Share

  218. TORRES-CARMONA E, Ueno F, Iwata Y, Nakajima S, et al
    Elevated intrinsic cortical curvature in treatment-resistant schizophrenia: Evidence of structural deformation in functional connectivity areas and comparison with alternate indices of structure.
    Schizophr Res. 2024;269:103-113.
    >> Share

  219. BOSE A, Agarwal SM, Nawani H, Shivakumar V, et al
    Effect of add-on tDCS therapy for auditory hallucinations on frequency and duration deviant mismatch negativity in schizophrenia.
    Schizophr Res. 2024;269:93-95.
    >> Share

  220. AVERSA S, Ghanem J, Grunfeld G, Lemonde AC, et al
    Sociodemographic and clinical correlates of hallucinations in patients entering an early intervention program for first episode psychosis.
    Schizophr Res. 2024;269:86-92.
    >> Share

  221. ALLIENDE LM, Strauss GP, Yang LH, Mittal VA, et al
    Perceptions of stigma in youth at clinical high risk for psychosis and depressive symptomatology.
    Schizophr Res. 2024;269:79-85.
    >> Share

  222. KIM E, Redwood S, Liu F, Roche DJO, et al
    Pilot study indicates that a gluten-free diet lowers oxidative stress for gluten-sensitive persons with schizophrenia.
    Schizophr Res. 2024;269:71-78.
    >> Share

  223. CHIAPPELLI J, Savransky A, Ma Y, Gao S, et al
    Impact of lifetime stressor exposure on neuroenergetics in schizophrenia spectrum disorders.
    Schizophr Res. 2024;269:58-63.
    >> Share

  224. JOSE BJ, Antonio GA, Reveca GF
    Cortisol response in individuals with genetic risk of schizophrenia. Some considerations.
    Schizophr Res. 2024;269:56-57.
    >> Share

  225. FENG S, Huang Y, Li H, Zhou S, et al
    Dynamic effective connectivity in the cerebellar dorsal dentate nucleus and the cerebrum, cognitive impairment, and clinical correlates in patients with schizophrenia.
    Schizophr Res. 2024 May 9:S0920-9964(24)00184.
    >> Share

  226. ZHU Q, Jiang G, Zheng Y, Fu Z, et al
    The effect of cognitive impairment based on Mini-Mental State Examination (MMSE) on suicidal tendency in patients with schizophrenia: A large cross-sectional study.
    Schizophr Res. 2024;269:48-55.
    >> Share

  227. LI N, Li Y, Yu T, Gou M, et al
    Immunosenescence-related T cell phenotypes and white matter in schizophrenia patients with tardive dyskinesia.
    Schizophr Res. 2024;269:36-47.
    >> Share

  228. WANG Y, Xu Y, Wu P, Zhou Y, et al
    Exploring the interplay between core and mood symptoms in schizophrenia: A network analysis.
    Schizophr Res. 2024;269:28-35.
    >> Share

  229. SHIMADA T, Morimoto T, Nagayama H, Nakamura N, et al
    Effect of individualized occupational therapy on cognition among patients with schizophrenia: A randomized controlled trial.
    Schizophr Res. 2024;269:18-27.
    >> Share

  230. ZHANG C, Liang J, Yan H, Li X, et al
    Fractional amplitude of low-frequency fluctuations in sensory-motor networks and limbic system as a potential predictor of treatment response in patients with schizophrenia.
    Schizophr Res. 2024 May 3:S0920-9964(24)00173.
    >> Share

  231. DAUB J, Brandt GA, Volkmer S, Northoff G, et al
    Arthur Schopenhauer: An underappreciated philosopher in psychiatry and his applied epistemology of body and self- experience.
    Schizophr Res. 2024;267:487-496.
    >> Share

  232. LYNE J, Piacenza F, Radovic J, O'Donoghue B, et al
    The effectiveness of adjunctive cariprazine for treatment of negative symptoms: A systematic review of randomised controlled trials.
    Schizophr Res. 2024;267:213-215.
    >> Share

  233. TIRUPATI S, Arachchi MK
    Reply to "Obesity as a potential confounder of clozapine-induced myocarditis in the Hunter Region of Australia".
    Schizophr Res. 2024;267:191-192.
    >> Share

  234. VAN DER HEIDE DH, Bogers JPAM, Schulte PRFJ
    Recovery from leukopenia after discontinuation of clozapine does not exclude lymphoma.
    Schizophr Res. 2024;267:72-74.
    >> Share

  235. KIKUCHI Y, Komatsu H, Tomita H
    Obesity as a potential confounder of clozapine-induced myocarditis in the Hunter region of Australia.
    Schizophr Res. 2024;267:42-43.
    >> Share

    April 2024
  236. SASS L, Feyaerts J
    Schizophrenia, the very idea: On self-disorder, hyperreflexivity, and the diagnostic concept.
    Schizophr Res. 2024 Apr 30:S0920-9964(24)00122.
    >> Share

  237. ALBEELY AM, Williams OOF, Blight CR, Theriault RK, et al
    Sex differences in neuronal oscillatory activity and memory in the methylazoxymethanol acetate model of schizophrenia.
    Schizophr Res. 2024;267:451-461.
    >> Share

  238. LI H, Huang Y, Liang L, Li H, et al
    The relationship between the gut microbiota and oxidative stress in the cognitive function of schizophrenia: A pilot study in China.
    Schizophr Res. 2024;267:444-450.
    >> Share

  239. LE BARS T, Bulteau S, Bonnot O, Gollier-Briant F, et al
    Home-based transcranial direct current stimulation in schizophrenia: Systematic literature review, a teenager case report with cost-utility analysis.
    Schizophr Res. 2024;267:441-443.
    >> Share

  240. GOGOS A, Sbisa A, van den Buuse M
    Disruption of NMDA receptor-mediated regulation of PPI in the maternal immune activation model of schizophrenia is restored by 17beta-estradiol and raloxifene.
    Schizophr Res. 2024;267:432-440.
    >> Share

  241. AL-CHALABI N, Nader G, Gerretsen P, Fischer C, et al
    Assessing past suicidal behaviour in schizophrenia spectrum disorders using the Columbia-Suicide Severity Rating Scale and the Beck Scale for Suicide Ideation: Analysis across the life-span.
    Schizophr Res. 2024;267:415-421.
    >> Share

  242. MOURA BM, Madeira L, Bakker PR, van Harten P, et al
    The association between alterations in motor and cognitive dimensions of schizophrenia-spectrum disorders: A systematic review.
    Schizophr Res. 2024;267:398-414.
    >> Share

  243. HOLT DJ
    Personal space as a model neurobehavioral system for investigating schizophrenia.
    Schizophr Res. 2024;267:396-397.
    >> Share

  244. TOROUS J, Smith KA, Hardy A, Vinnikova A, et al
    Digital health interventions for schizophrenia: Setting standards for mental health.
    Schizophr Res. 2024;267:392-395.
    >> Share

  245. COHEN M, Roe D, Savir T, Baumel A, et al
    Blended care in psychosis - A systematic review.
    Schizophr Res. 2024;267:381-391.
    >> Share

  246. TAKAHASHI T, Katagiri N, Higuchi Y, Nishiyama S, et al
    Nomenclature for psychosis risk in Japan: Survey results from high-risk individuals, caregivers, and mental health professionals.
    Schizophr Res. 2024;267:373-380.
    >> Share

  247. CELLA M, Parri L, Wang K, Quinn R, et al
    Evaluating remote delivery of cognitive remediation in people with psychosis.
    Schizophr Res. 2024;267:367-372.
    >> Share

  248. MOREIRA-ALMEIDA A, Costa MA, Gattaz WF
    Spiritist anomalous experience is not associated with psychosis.
    Schizophr Res. 2024;267:356-358.
    >> Share

  249. LANDOLT A, Muller M, Ilg Y, Schulz PJ, et al
    Linguistic and (micro)cultural differences in the global debate about re-naming 'schizophrenia': A mixed-methods survey from Switzerland.
    Schizophr Res. 2024;267:341-348.
    >> Share

  250. ROCCA P, Brasso C, Montemagni C, Del Favero E, et al
    The relationship between the resting state functional connectivity and social cognition in schizophrenia: Results from the Italian Network for Research on Psychoses.
    Schizophr Res. 2024;267:330-340.
    >> Share

  251. SHEITMAN A, Bello I, Montague E, Scodes J, et al
    Observed Trajectories of Cannabis Use and Concurrent Longitudinal Outcomes in Youth and Young Adults Receiving Coordinated Specialty Care for Early Psychosis.
    Schizophr Res. 2024;267:313-321.
    >> Share

  252. GOUSE BM, Oblath R, Gibbs JS, Reagan EG, et al
    COVID-19 pandemic and emergency department visits for psychosis: Visit volume, restraint use, medication use, psychiatric hospitalization, and length of stay.
    Schizophr Res. 2024;267:301-307.
    >> Share

  253. DIAO H, Ma J, Jia Y, Jia H, et al
    Abnormalities in motor adaptation to different types of perturbations in schizophreniaperturbations in schizophrenia.
    Schizophr Res. 2024;267:291-300.
    >> Share

  254. CATTARINUSSI G, Di Giorgio A, Sambataro F
    Cerebellar dysconnectivity in schizophrenia and bipolar disorder is associated with cognitive and clinical variables.
    Schizophr Res. 2024 Apr 6:S0920-9964(24)00139.
    >> Share

  255. HO G, Pratt DN, Bridgwater MA, Schiffman J, et al
    Factors impacting intent to seek treatment within youth at clinical high risk for psychosis.
    Schizophr Res. 2024;267:273-281.
    >> Share

  256. KANG MJY, Eratne D, Wannan C, Santillo AF, et al
    Plasma neurofilament light chain is not elevated in people with first-episode psychosis or those at ultra-high risk for psychosis.
    Schizophr Res. 2024;267:269-272.
    >> Share

  257. SKLAR AL, Matinrazm S, Esseku A, Lopez-Caballero F, et al
    Intensity-dependent modulation of the early auditory gamma-band response in first-episode schizophrenia and its association with disease symptoms.
    Schizophr Res. 2024;267:261-268.
    >> Share

  258. MULLIGAN LD, Bojanic L, Hunt IM, Baird A, et al
    Substance use and self-poisoning in schizophrenia: 11-year findings from a national clinical survey of suicide in mental health patients in England.
    Schizophr Res. 2024;267:254-260.
    >> Share

  259. KISELY S, Arnautovska U, Siskind D, Warren N, et al
    Admissions for psychosis following agency-notified child maltreatment at 40-year-follow-up: Results from the Childhood Adversity and Lifetime Morbidity (CALM) cohort.
    Schizophr Res. 2024;267:247-253.
    >> Share

  260. OPLER M, Negash S, Tatsumi K, Liu C, et al
    Use of a novel study insight analytics (SIA) methodology to improve PANSS data quality and signal detection in a global clinical trial in schizophrenia.
    Schizophr Res. 2024;267:239-246.
    >> Share

  261. CEDERLOF E, Holm M, Taipale H, Tiihonen J, et al
    Antipsychotic medications and sleep problems in patients with schizophrenia.
    Schizophr Res. 2024;267:230-238.
    >> Share

  262. VARDEN GJERDE K, Bartz-Johannessen C, Steen VM, Andreassen OA, et al
    Cellular adhesion molecules in drug-naive and previously medicated patients with schizophrenia-spectrum disorders.
    Schizophr Res. 2024;267:223-229.
    >> Share

  263. BISMARK AW, Mikhael T, Mitchell K, Holden J, et al
    Pupillary responses as a biomarker of cognitive effort and the impact of task difficulty on reward processing in schizophrenia.
    Schizophr Res. 2024;267:216-222.
    >> Share

  264. FRANCO-RUBIO L, Puente-Martinez A, Ubillos-Landa S
    Factors associated with recovery during schizophrenia and related disorders: A review of meta-analysis.
    Schizophr Res. 2024;267:201-212.
    >> Share

  265. LI Y, Qiu D, Wu Q, Ni A, et al
    Affiliate stigma and its association with family burden among family members of people living with schizophrenia in China.
    Schizophr Res. 2024;267:193-200.
    >> Share

  266. FUJITA K, Mori Y, Kakumae Y, Takeuchi N, et al
    Pre-emptive ice pack cryotherapy for reducing pain caused by long-acting deltoid injectable antipsychotic treatment: A single-center open-label study.
    Schizophr Res. 2024;266:19-23.
    >> Share

    March 2024
  267. COHEN-LAROQUE J, Grangier I, Perez N, Kirschner M, et al
    Positive and negative symptoms in methamphetamine-induced psychosis compared to schizophrenia: A systematic review and meta-analysis.
    Schizophr Res. 2024;267:182-190.
    >> Share

  268. DODD K, Legget KT, Cornier MA, Novick AM, et al
    Relationship between functional connectivity and weight-gain risk of antipsychotics in schizophrenia.
    Schizophr Res. 2024;267:173-181.
    >> Share

  269. GAO YN, Wang R, Gu G, Chung R, et al
    Inpatient antipsychotic medication switching and rehospitalization risk among patients with schizophrenia-spectrum disorders.
    Schizophr Res. 2024;267:165-172.
    >> Share

  270. YU B, Sun Z, Li S, Chien IC, et al
    Social isolation and cognitive function in patients with schizophrenia: A two years follow-up study.
    Schizophr Res. 2024;267:150-155.
    >> Share

  271. BENNETT ME, Medoff D, Cowan T, Fang L, et al
    Tobacco smoking and nicotine vaping in persons with first episode psychosis.
    Schizophr Res. 2024;267:141-149.
    >> Share

  272. PELIZZA L, Leuci E, Leucci AC, Quattrone E, et al
    Diagnostic shift in first episode psychosis: Results from the 2-year follow-up of the "Parma Early Psychosis" program.
    Schizophr Res. 2024;267:99-106.
    >> Share

  273. MEHTA DD, Siddiqui S, Ward HB, Steele VR, et al
    Functional and structural effects of repetitive transcranial magnetic stimulation (rTMS) for the treatment of auditory verbal hallucinations in schizophrenia: A systematic review.
    Schizophr Res. 2024;267:86-98.
    >> Share

  274. LHO SK, Kim T, Moon SY, Kim M, et al
    Alteration in left frontoparietal connectivity correlates with impaired cognitive reappraisal in early psychosis.
    Schizophr Res. 2024;267:130-137.
    >> Share

  275. ZHOU R, Ye M, OuYang X, Zhang S, et al
    Insomnia and aggression in stable schizophrenic patients: The mediating role of quality of life.
    Schizophr Res. 2024;267:122-129.
    >> Share

  276. ELAM HB, Perez SM, Donegan JJ, Eassa NE, et al
    Knockdown of Lhx6 during embryonic development results in neurophysiological alterations and behavioral deficits analogous to schizophrenia in adult rats.
    Schizophr Res. 2024;267:113-121.
    >> Share

  277. EL HAJ M, Raffard S, Besche-Richard C
    Decoding schizophrenia: ChatGPT's role in clinical and neuropsychological assessment.
    Schizophr Res. 2024;267:84-85.
    >> Share

  278. NAIR N, Xavier S, Rabouin D, Mohan G, et al
    Patient-reported outcome measures in early psychosis: A cross-cultural, longitudinal examination of the self-reported health and self-reported mental health measures in Chennai, India and Montreal, Canada.
    Schizophr Res. 2024;267:75-83.
    >> Share

  279. ARSLAN B, Kizilay E, Verim B, Demirlek C, et al
    Automated linguistic analysis in speech samples of Turkish-speaking patients with schizophrenia-spectrum disorders.
    Schizophr Res. 2024;267:65-71.
    >> Share

  280. OZER D, Dissiz M
    The effect of online group based acceptance and commitment therapy on psychotic symptoms and functioning levels of individuals with early psychosis.
    Schizophr Res. 2024;267:55-64.
    >> Share

  281. MELVIN E, Green M, Keiller E, Parmar C, et al
    A systematic review of dramatherapy interventions used to support adults with psychosis.
    Schizophr Res. 2024;267:44-54.
    >> Share

  282. TZARTOS J, Karagiorgou K, Pechlivanidou M, Tzartos S, et al
    Absence of neuronal nicotinic acetylcholine receptor antibodies in sera and CSF from schizophrenia patients.
    Schizophr Res. 2024;267:39-41.
    >> Share

  283. KETCHAM E, Schooler NR, Severe JB, Buckley PF, et al
    Longitudinal study of insomnia, suicidal ideation, and psychopathology in schizophrenia.
    Schizophr Res. 2024;267:34-38.
    >> Share

  284. JOLLY AJ, Parmar A, Ghadigaonkar DS, Andrade C, et al
    Reflections on a study of electroconvulsive therapy for clozapine-refractory schizophrenia.
    Schizophr Res. 2024;267:32-33.
    >> Share

  285. LLORCA-BOFI V, Madero S, Amoretti S, Cuesta MJ, et al
    Inflammatory blood cells and ratios at remission for psychosis relapse prediction: A three-year follow-up of a cohort of first episodes of schizophrenia.
    Schizophr Res. 2024;267:24-31.
    >> Share

  286. DOLLFUS S, Letourneur F, Metivier L, Moulier V, et al
    Self-assessment scale of auditory verbal hallucinations (SAVH): A novel tool for patients with schizophrenia.
    Schizophr Res. 2024;267:19-23.
    >> Share

  287. DYKINS MM, Keedy SK, Sweeney JA, Hill SK, et al
    Characterizing cognitive heterogeneity in first-episode psychosis.
    Schizophr Res. 2024;267:16-18.
    >> Share

  288. MCLEAN RT, Buist E, St Clair D, Wei J, et al
    Autoantibodies against acetylcholine receptors are increased in archived serum samples from patients with schizophrenia.
    Schizophr Res. 2024;267:8-13.
    >> Share

  289. LI S, Liu W, Huang Z, Lin H, et al
    Sex-specific associations between sex hormones and clinical symptoms in late-life schizophrenia.
    Schizophr Res. 2024;267:1-7.
    >> Share

  290. LE TP, Ventura J, Subotnik KL, Nuechterlein KH, et al
    Intrinsic motivation predicts cognitive and functional gains during coordinated specialty care for first-episode schizophrenia.
    Schizophr Res. 2024;266:249-255.
    >> Share

  291. SLOT MIE, van Hell HH, Rossum IW, Dazzan P, et al
    A naturalistic cohort study of first-episode schizophrenia spectrum disorder: A description of the early phase of illness in the PSYSCAN cohort.
    Schizophr Res. 2024;266:237-248.
    >> Share

  292. KING B, Kempton MJ, Broberg BV, Merritt K, et al
    A letter to the editor: The effects of alcohol use on brain glutamate in first episode psychosis.
    Schizophr Res. 2024;266:234-236.
    >> Share

  293. STEPHANE M, Dzemidzic M, Yoon G
    Altered corollary discharge in the auditory cortex could reflect louder inner voice experience in patients with verbal hallucinations, a pilot fMRI study.
    Schizophr Res. 2024;265:14-19.
    >> Share

  294. LOPEZ-SILVA P, Harrow M, Jobe TH, Tufano M, et al
    'Are these my thoughts?': A 20-year prospective study of thought insertion, thought withdrawal, thought broadcasting, and their relationship to auditory verbal hallucinations.
    Schizophr Res. 2024;265:46-57.
    >> Share

    February 2024
  295. GARCIA-RIZO C, Crespo-Facorro B, Oliveira C, Gomez-Revuelta M, et al
    Anthropometry in antipsychotic-naive first-episode psychosis patients: An exploratory approach to the role of environmental early life events in two independent samples.
    Schizophr Res. 2024;266:216-226.
    >> Share

  296. ZAHER F, Diallo M, Achim AM, Joober R, et al
    Speech markers to predict and prevent recurrent episodes of psychosis: A narrative overview and emerging opportunities.
    Schizophr Res. 2024;266:205-215.
    >> Share

  297. ISAYEVA U, Manchia M, Collu R, Primavera D, et al
    Symptomatic remission and recovery in major psychosis: Is there a role for BDNF? A secondary analysis of the LABSP cohort data.
    Schizophr Res. 2024;266:197-204.
    >> Share

  298. SAVILL M, Loewy RL, Niendam TA, Porteus AJ, et al
    The diagnostic accuracy of screening for psychosis spectrum disorders in behavioral health clinics integrated into primary care.
    Schizophr Res. 2024;266:190-196.
    >> Share

  299. CABUK T, Sevim N, Mutlu E, Yagcioglu AEA, et al
    Natural language processing for defining linguistic features in schizophrenia: A sample from Turkish speakers.
    Schizophr Res. 2024;266:183-189.
    >> Share

  300. ZHAO W, Cannon TD
    Moral learning and positive schizotypy: Social cognitive mechanisms in psychosis- proneness.
    Schizophr Res. 2024;266:156-164.
    >> Share

  301. BAKER SC, Messer SJ, Girgis RR, Horga G, et al
    Prior overweighting relates to delusional ideation in individuals at clinical high-risk for psychosis.
    Schizophr Res. 2024;266:153-155.
    >> Share

  302. TIBIRICA L, Kohn J, Patapoff M, Williams AP, et al
    Acculturation and clinical symptoms of schizophrenia among Latine adults in the United States.
    Schizophr Res. 2024;266:145-152.
    >> Share

  303. PENG Z, Li Q, Liu X, Zhang H, et al
    A new schizophrenia screening instrument based on evaluating the patient's writing.
    Schizophr Res. 2024;266:127-135.
    >> Share

  304. MAKIPELTO V, Tuulio-Henriksson A, Hakulinen C, Niemela S, et al
    Association of antidepressant and benzodiazepine use, and anticholinergic burden with cognitive performance in schizophrenia.
    Schizophr Res. 2024;266:118-126.
    >> Share

  305. BALLERINI M, Magnani F, Amorosi S, Dell'Anna C, et al
    Anomalous Self-Experiences are predictive of social dysfunction in people with schizophrenia.
    Schizophr Res. 2024;266:116-117.
    >> Share

  306. TORREGROSSA LJ, Liu J, Armstrong K, Heckers S, et al
    Interplay between childhood trauma, bodily self-disturbances, and clinical phenomena in schizophrenia spectrum disorders: A network analysis.
    Schizophr Res. 2024;266:107-115.
    >> Share

  307. MILEY K, Bronstein MV, Ma S, Lee H, et al
    Trajectories and predictors of response to social cognition training in people with schizophrenia: A proof-of-concept machine learning study.
    Schizophr Res. 2024;266:92-99.
    >> Share

  308. IMAM I, Johnson KA, Saluja A, Mesholam-Gately RI, et al
    Advancing equity & access for psychosis care in Massachusetts: Proceedings from the 2023 Mass-STEP Conference.
    Schizophr Res. 2024;266:85-87.
    >> Share

  309. GURUSAMY J, Gandhi S, Damodharan D, Palaniappan M, et al
    Effect of lifestyle modification intervention (LMI) on metabolic syndrome in schizophrenia in a residential mental health care setting-A mixed method study.
    Schizophr Res. 2024;266:75-84.
    >> Share

  310. ZAKI JK, Lago SG, Spadaro B, Rustogi N, et al
    Exploring peripheral biomarkers of response to simvastatin supplementation in schizophrenia.
    Schizophr Res. 2024;266:66-74.
    >> Share

  311. BORA E, Eyuboglu MS, Cesim E, Demir M, et al
    Neurocognition and social cognition in youth and young adults at ultra-high-risk for psychosis and bipolar disorder.
    Schizophr Res. 2024;266:58-65.
    >> Share

  312. GARCIA-LEON MA, Fuentes-Claramonte P, Soler-Vidal J, Ramiro-Sousa N, et al
    Cortical volume abnormalities in schizophrenia: Correlations with symptoms and cognitive impairment.
    Schizophr Res. 2024;266:50-57.
    >> Share

  313. EKIN M, Akdal G, Bora E
    Antisaccade error rates in first-episode psychosis, ultra-high risk for psychosis and unaffected relatives of schizophrenia: A systematic review and meta-analysis.
    Schizophr Res. 2024;266:41-49.
    >> Share

  314. MAAS IL, Bohlken MM, Gangadin SS, Rosema BS, et al
    Personal recovery in first-episode psychosis: Beyond clinical and functional recovery.
    Schizophr Res. 2024;266:32-40.
    >> Share

  315. WARREN N, O'Gorman C, Horgan I, Weeratunga M, et al
    Inflammatory cerebrospinal fluid markers in schizophrenia spectrum disorders: A systematic review and meta-analysis of 69 studies with 5710 participants.
    Schizophr Res. 2024;266:24-31.
    >> Share

  316. CHANEN AM, Kerslake R, Berube FA, Nicol K, et al
    Psychopathology and psychosocial functioning among young people with first-episode psychosis and/or first-presentation borderline personality disorder.
    Schizophr Res. 2024;266:12-18.
    >> Share

  317. KRAUS J, Cavojska N, Harvanova S, Hajduk M, et al
    Interpersonal distance in schizophrenia: A systematic review.
    Schizophr Res. 2024;266:1-11.
    >> Share

  318. MCILWAINE SV, Mughal S, Ferrari M, Rosengard R, et al
    Pre-onset subthreshold psychotic symptoms are associated with differential treatment delays before a first episode of psychosis: Initial evidence and implications.
    Schizophr Res. 2024;264:549-556.
    >> Share

  319. JEYAPALAN J, Sassi P, Mittendorfer Rutz E, Tiihonen J, et al
    Characteristics of incident substance-induced psychosis compared to first-episode psychotic disorders: A nationwide register-linkage study from Sweden.
    Schizophr Res. 2024;264:526-533.
    >> Share

  320. PERALTA V, de Jalon EG, Moreno-Izco L, Peralta D, et al
    The effect of anticholinergic burden of psychiatric medications on major outcome domains of psychotic disorders: A 21-year prospective cohort study.
    Schizophr Res. 2024;264:386-393.
    >> Share

    January 2024
  321. WANG Y, Ding R, Luo Y, He P, et al
    Does college education reduce the risk of schizophrenia? Evidence from a college enrollment expansion policy in China.
    Schizophr Res. 2024;264:519-525.
    >> Share

  322. TORDAI C, Hathy E, Gyergyak H, Vincze K, et al
    Probing the biological consequences of a previously undescribed de novo mutation of ZMYND11 in a schizophrenia patient by CRISPR genome editing and induced pluripotent stem cell based in vitro disease-modeling.
    Schizophr Res. 2024 Jan 29:S0920-9964(24)00024.
    >> Share

  323. KANE JM, Schoretsanitis G, Rubio JM, Correll CU, et al
    Clozapine in treatment-resistant schizophrenia: Reflections from the Hallmark US clinical trial and beyond.
    Schizophr Res. 2024 Jan 29:S0920-9964(24)00035.
    >> Share

  324. FADEN J, Citrome L
    A systematic review of clozapine for aggression and violence in patients with schizophrenia or schizoaffective disorder.
    Schizophr Res. 2024 Jan 29:S0920-9964(23)00420.
    >> Share

  325. LOZANO-GOUPIL J, Marin L, Aubin L, Decombe A, et al
    Impaired perception of a partner's synchronizing behavior reduces positive attitude toward humanoid robot in schizophrenia patients.
    Schizophr Res. 2024;264:511-518.
    >> Share

  326. MACDOUGALL AG, Wiener JC, Puka K, Price E, et al
    Effectiveness of a mindfulness-based intervention for persons with early psychosis: A multi-site randomized controlled trial.
    Schizophr Res. 2024;264:502-510.
    >> Share

  327. MURPHY SM, Flores AT, Wojtalik JA, Keshavan MS, et al
    Symptom contributors to quality of life in schizophrenia: Exploratory factor and network analyses.
    Schizophr Res. 2024;264:494-501.
    >> Share

  328. ESCANDON K
    Toward non-stigmatizing media and language in mental health: Addressing the social stigma of schizophrenia.
    Schizophr Res. 2024;264:491-493.
    >> Share

  329. ZEDAN SA, Zahid A, Best MW
    Examining the effects of diagnostic awareness, positive symptoms, and negative symptoms on stigmatizing attitudes and social exclusion towards schizophrenia.
    Schizophr Res. 2024;264:482-490.
    >> Share

  330. BHARGAV H, Keshavan M
    Why and how might yoga differ from other mind-body approaches in schizophrenia?
    Schizophr Res. 2024;264:479-481.
    >> Share

  331. VAN DER PLUIJM M, Alting M, Schrantee A, Edden RAE, et al
    Glutamate and GABA levels in the anterior cingulate cortex in treatment resistant first episode psychosis patients.
    Schizophr Res. 2024;264:471-478.
    >> Share

  332. LIU H, Tang E, Guan C, Li J, et al
    Not socially blind: Unimpaired perception of social interaction in schizophrenia.
    Schizophr Res. 2024;264:448-450.
    >> Share

  333. GRADY S, Twomey C, Cullen C, Gaynor K, et al
    Does affect mediate the relationship between interpersonal trauma and psychosis? A systematic review and meta-analysis.
    Schizophr Res. 2024;264:435-447.
    >> Share

  334. D'ARCEY JN, Zhao H, Wang W, Voineskos AN, et al
    An SMS text messaging intervention to improve clinical engagement in early psychosis: A pilot randomized-controlled trial.
    Schizophr Res. 2024;264:416-423.
    >> Share

  335. CHEN MY, Wang YY, Si TL, Liu YF, et al
    Poor sleep quality in schizophrenia patients: A systematic review and meta-analyses of epidemiological and case-control studies.
    Schizophr Res. 2024;264:407-415.
    >> Share

  336. CAI Y, Zhu ZH, Qi Q, Yin XY, et al
    The negative association of serum complement 3 and 4 levels with visuospatial/constructional function in first-episode patients with schizophrenia.
    Schizophr Res. 2024;264:404-406.
    >> Share

  337. SHANKAR A, Tripathi A
    Comments on "The effect on relapse rate and psychiatric symptomatology: Switching a combination of first- and second-generation antipsychotic polypharmacy to antipsychotic monotherapy in long-term inpatients with schizophrenia and related disorders. A
    Schizophr Res. 2024;264:402-403.
    >> Share

  338. NG BHM, Yu BCL, Leung JSY
    Investigation on the association between perceived family expressed emotion, self-stigma, and subjective quality of life in people with early psychosis in Hong Kong: A cross-sectional approach.
    Schizophr Res. 2024;264:394-401.
    >> Share

  339. GHIEH R, Krezolek M, Gaweda L
    Self-monitoring deficits in schizophrenia: A cross-sectional study of the underlying cognitive mechanisms.
    Schizophr Res. 2024;264:378-385.
    >> Share

  340. LAWRENCE RE, Appelbaum PS
    Ethics in placebo-controlled, acute treatment trials in schizophrenia: Two rival ethical frameworks.
    Schizophr Res. 2024;264:372-377.
    >> Share

  341. BOWERSOX NW, Smith CM, Austin K, Bradford DW, et al
    Mortality and suicidality in veterans health administration patients with newly-identified early episode psychosis.
    Schizophr Res. 2024;264:362-369.
    >> Share

  342. SONDERGAARD A, Gregersen M, Wilms M, Brandt JM, et al
    Exploring the relationship between attributional style measured in virtual reality and bullying among children at familial high risk of schizophrenia or bipolar disorder compared with controls.
    Schizophr Res. 2024;264:354-361.
    >> Share

  343. THAKKAR KN, Silverstein SM, Fattal J, Bao J, et al
    Stronger tilt aftereffects in individuals diagnosed with schizophrenia spectrum disorders but not bipolar disorder.
    Schizophr Res. 2024;264:345-353.
    >> Share

  344. PENTZ AB, O'Connel KS, van Jole O, Timpe CMF, et al
    Mismatch negativity and polygenic risk scores for schizophrenia and bipolar disorder.
    Schizophr Res. 2024;264:314-326.
    >> Share

  345. IBRAHIM K, Iturmendi-Sabater I, Vasishth M, Barron DS, et al
    Neural circuit disruptions of eye gaze processing in autism spectrum disorder and schizophrenia: An activation likelihood estimation meta-analysis.
    Schizophr Res. 2024;264:298-313.
    >> Share

  346. WANG P, Jiang Y, Biswal BB
    Aberrant interhemispheric structural and functional connectivity within whole brain in schizophrenia.
    Schizophr Res. 2024;264:336-344.
    >> Share

  347. OKADA H, Morimoto T, Ikeda N
    Exploratory; study on driving ability of people with schizophrenia: Relationships among cognitive function, symptoms, and brain activity.
    Schizophr Res. 2024;264:290-297.
    >> Share

  348. XIONG J, Ding Y, Wu X, Zhan J, et al
    Association between serum insulin-like growth factor 1 levels and the improvements of cognitive impairments in a subgroup of schizophrenia: Preliminary findings.
    Schizophr Res. 2024;264:282-289.
    >> Share

  349. DEAM MM, Gupta T, Bridgwater MA, Haas GL, et al
    Associations between interpersonal trauma and social impairments in adolescents with and without a family history of psychosis.
    Schizophr Res. 2024;264:280-281.
    >> Share

  350. CHEN YL, Chen PY, Pan CH, Chen PH, et al
    Prevalence and 3-year incidence of physical illnesses after schizophrenia diagnosis: Comparison with general population.
    Schizophr Res. 2024;264:272-279.
    >> Share

  351. DONMEZLER S, Sonmez D, Yilbas B, Ozturk HI, et al
    Thalamic nuclei volume differences in schizophrenia patients and healthy controls using probabilistic mapping: A comparative analysis.
    Schizophr Res. 2024;264:266-271.
    >> Share

  352. SU Y, Pan X, Li H, Zhang G, et al
    Effects of mind-body therapies on schizophrenia: A systematic review and network meta-analysis.
    Schizophr Res. 2024;264:236-247.
    >> Share

  353. MILLER M, Braun A, Cadenhead KS, Cornblatt BA, et al
    Self-perceptions and depression in youth at risk of psychosis.
    Schizophr Res. 2024;264:231-232.
    >> Share

  354. CHANG Y, Wang X, Liao J, Chen S, et al
    Temporal hyper-connectivity and frontal hypo-connectivity within gamma band in schizophrenia: A resting state EEG study.
    Schizophr Res. 2024;264:220-230.
    >> Share

  355. LEGRAND A, Moyal M, Deschamps C, Louveau C, et al
    Catatonia and genetic variant in GABA receptor: A case report involving GABRB2.
    Schizophr Res. 2024;263:191-193.
    >> Share

  356. KARL S, Sartorius A, Aksay SS
    Catatonia and ECT across the lifespan.
    Schizophr Res. 2024;263:246-251.
    >> Share

  357. HIRJAK D, Brandt GA, Fritze S, Kubera KM, et al
    Distribution and frequency of clinical criteria and rating scales for diagnosis and assessment of catatonia in different study types.
    Schizophr Res. 2024;263:93-98.
    >> Share

  358. WADDINGTON JL
    From operational diagnostic to dimensional-continuum concepts of psychotic and non-psychotic illness: Embracing catatonia across psychopathology and intrinsic movement disorder in neural network dysfunction.
    Schizophr Res. 2024;263:99-108.
    >> Share

  359. SAINI A, Begum N, Matti J, Ghanem DA, et al
    Clozapine as a treatment for catatonia: A systematic review.
    Schizophr Res. 2024;263:275-281.
    >> Share

    December 2023
  360. KLAASSEN AL, Michel C, Stuble M, Kaess M, et al
    Reduced anterior callosal white matter in risk for psychosis associated with processing speed as a fundamental cognitive impairment.
    Schizophr Res. 2023;264:211-219.
    >> Share

  361. RASMUSSEN AR
    Anomalies of imagination and development of psychosis: A phenomenological account.
    Schizophr Res. 2023;264:204-210.
    >> Share

  362. SABE M, Kohler R, Perez N, Sauvain-Sabe M, et al
    Mindfulness-based interventions for patients with schizophrenia spectrum disorders: A systematic review of the literature.
    Schizophr Res. 2023;264:191-203.
    >> Share

  363. DOLLFUS S, Letourneur F, Metivier L, Moulier V, et al
    A digital tool for self-assessment of auditory verbal hallucinations in schizophrenia.
    Schizophr Res. 2023;264:188-190.
    >> Share

  364. MYERS EJ, Abel DB, Mickens JL, Russell MT, et al
    Meta-analysis of the relationship between metacognition and disorganized symptoms in psychosis.
    Schizophr Res. 2023;264:178-187.
    >> Share

  365. MELZER-RIBEIRO DL, Napolitano IC, Leite SA, Alencar de Souza JA, et al
    Randomized, double-blind, sham-controlled trial to evaluate the efficacy and tolerability of electroconvulsive therapy in patients with clozapine-resistant schizophrenia.
    Schizophr Res. 2023 Dec 26:S0920-9964(23)00421.
    >> Share

  366. BAHLINGER K, Lincoln TM, Clamor A
    Do deficits in subjective stress recovery predict subsequent stress sensitivity and symptoms in schizophrenia spectrum disorders?
    Schizophr Res. 2023;264:170-177.
    >> Share

  367. ZINELLU A, Mangoni AA
    The pathophysiological role of circulating adhesion molecules in schizophrenia: A systematic review and meta-analysis.
    Schizophr Res. 2023;264:157-169.
    >> Share

  368. BARBALAT G, Marechal L, Plasse J, Chereau-Boudet I, et al
    Functioning, clinical severity, education and sex moderate the inverse relationship between insight and quality of life in patients with schizophrenia.
    Schizophr Res. 2023;264:149-156.
    >> Share

  369. TROISI A, Brune M
    The ethological method for studying facial behavior in schizophrenia.
    Schizophr Res. 2023;264:147-148.
    >> Share

  370. HYATT A, Mullin B, Hasler V, Madore D, et al
    Predictors of relapse and engagement in care one year after ending services in an urban safety net coordinated specialty care program for first episode psychosis.
    Schizophr Res. 2023;264:140-146.
    >> Share

  371. JI Y, Pearlson G, Bustillo J, Kochunov P, et al
    Identifying psychosis subtypes use individualized covariance structural differential networks and multi-site clustering.
    Schizophr Res. 2023;264:130-139.
    >> Share

  372. HUANG TY, Chen LC, Li XP, Li WH, et al
    Elevated triglycerides and low triiodothyronine: Key risk factors for coronary artery calcification in patients with schizophrenia.
    Schizophr Res. 2023;264:113-121.
    >> Share

  373. DONDE C, Coulon N, Turbe H, Andre M, et al
    Clinical and cognitive characteristics of subjects with schizophrenia and childhood attention-deficit/hyperactivity disorder: Results from the multicentric FACE-SZ cross-sectional dataset.
    Schizophr Res. 2023;264:105-112.
    >> Share

  374. MORERA D, Miller BJ
    Meta-analysis of a family history of diabetes in schizophrenia.
    Schizophr Res. 2023;264:90-94.
    >> Share

  375. GUAN X, Chen Y, Wang X, Xiu M, et al
    Total antioxidant capacity, obesity and clinical correlates in first-episode and drug-naive patients with schizophrenia.
    Schizophr Res. 2023;264:81-86.
    >> Share

  376. SAPIENZA J, Agostoni G, Dall'Acqua S, Sut S, et al
    The kynurenine pathway in treatment-resistant schizophrenia at the crossroads between pathophysiology and pharmacotherapy.
    Schizophr Res. 2023;264:71-80.
    >> Share

  377. BOIKO DI, Chopra H, Bilal M, Kydon PV, et al
    Schizophrenia and disruption of circadian rhythms: An overview of genetic, metabolic and clinical signs.
    Schizophr Res. 2023;264:58-70.
    >> Share

  378. LIEBRAND M, Katsarakis A, Josi J, Diezig S, et al
    EEG microstate D as psychosis-specific correlate in adolescents and young adults with clinical high risk for psychosis and first-episode psychosis.
    Schizophr Res. 2023;264:49-57.
    >> Share

  379. CADENHEAD KS, Mirzakhanian H, Achim C, Reyes-Madrigal F, et al
    Peripheral and central biomarkers associated with inflammation in antipsychotic naive first episode psychosis: Pilot studies.
    Schizophr Res. 2023;264:39-48.
    >> Share

  380. LIU S, Zhang L, Fan X, Wang G, et al
    Lactate levels in the brain and blood of schizophrenia patients: A systematic review and meta-analysis.
    Schizophr Res. 2023;264:29-38.
    >> Share

  381. TANDON R, Nasrallah H, Akbarian S, Carpenter WT Jr, et al
    The schizophrenia syndrome, circa 2024: What we know and how that informs its nature.
    Schizophr Res. 2023;264:1-28.
    >> Share

  382. GARCIA-MARTI G, Escarti MJ, Nacher J, Perez-Rando M, et al
    Progressive loss of cortical gray matter in first episode psychosis patients with auditory hallucinations.
    Schizophr Res. 2023 Dec 2:S0920-9964(23)00423.
    >> Share

  383. LE TP, Green MF, Wynn JK, Iglesias JE, et al
    Effort-based decision-making as a determinant of supported employment outcomes in psychotic disorders.
    Schizophr Res. 2023;262:149-155.
    >> Share

  384. VIROLLE J, Redon M, Montastruc F, Taib S, et al
    What clinical analysis of antipsychotic-induced catatonia and neuroleptic malignant syndrome tells us about the links between these two syndromes: A systematic review.
    Schizophr Res. 2023;262:184-200.
    >> Share

    November 2023
  385. YU S, Qu Y, Du Z, Ou M, et al
    The expression of immune related genes and potential regulatory mechanisms in schizophrenia.
    Schizophr Res. 2023 Nov 21:S0920-9964(23)00419.
    >> Share

  386. SCHAUG JP, Storebo OJ, Pedersen MB, Haahr UH, et al
    How first-episode psychosis patients' subjective beliefs about their childhood trauma's causal effect provide support for potential schizophrenia subtypes.
    Schizophr Res. 2023;262:175-183.
    >> Share

  387. FU X, Baranova A, Cao H, Liu Y, et al
    miR-9-5p deficiency contributes to schizophrenia.
    Schizophr Res. 2023;262:168-174.
    >> Share

  388. TANG W, Zhou LJ, Zhang WQ, Jia YJ, et al
    Adverse perinatal pregnancy outcomes in women with schizophrenia: A systematic review and meta-analysis.
    Schizophr Res. 2023;262:156-167.
    >> Share

  389. DEL RE EC, Keshavan MS
    Childhood trauma and psychosis-Searching for causes and mechanisms.
    Schizophr Res. 2023;262:146-148.
    >> Share

  390. VAN HOOIJDONK CFM, van der Pluijm M, de Vries BM, Cysouw M, et al
    The association between clinical, sociodemographic, familial, and environmental factors and treatment resistance in schizophrenia: A machine-learning-based approach.
    Schizophr Res. 2023;262:132-141.
    >> Share

  391. MOE AM, Kilicoglu MFV, Angers K, Huang K, et al
    Coordinated specialty care for first-episode psychosis: Effects on social motivation and social pleasure.
    Schizophr Res. 2023;262:130-131.
    >> Share

  392. EL KIRAT H, Khattabi A, Khalis M, Belrhiti Z, et al
    Effects of physical activity and nutrient supplementation on symptoms and well-being of schizophrenia patients: An umbrella review.
    Schizophr Res. 2023;262:112-120.
    >> Share

  393. TIEN YT, Wang LJ, Lee Y, Lin PY, et al
    Comparative predictive efficacy of atherogenic indices on metabolic syndrome in patients with schizophrenia.
    Schizophr Res. 2023;262:95-101.
    >> Share

  394. BURKE T, Holleran L, Mothersill D, Lyons J, et al
    Bilateral anterior corona radiata microstructure organisation relates to impaired social cognition in schizophrenia.
    Schizophr Res. 2023;262:87-94.
    >> Share

  395. XU S, Xu L
    Childhood emotional maltreatment increases the "wear-and-tear" of physiological systems, especially neuroendocrine changes in schizophrenia.
    Schizophr Res. 2023;262:84-86.
    >> Share

  396. STEENHUIS LA, Harms T, Nauta MH, Bartels-Velthuis AA, et al
    The dynamics of social activation and suspiciousness in individuals at ultra-high risk for psychosis.
    Schizophr Res. 2023;262:67-75.
    >> Share

  397. BARUTH JM, Bateman DR, Kovacs RJ, Bateman PV, et al
    Cardiac healthcare disparities and electrocardiography (ECG) differences in schizophrenia at end of life.
    Schizophr Res. 2023;262:60-66.
    >> Share

  398. OH H, Karcher NR, Schiffman J, Anglin DM, et al
    A broader conceptualization of premorbid risk in psychoses can motivate primordial prevention.
    Schizophr Res. 2023;262:53-54.
    >> Share

  399. PANIKRATOVA YR, Lebedeva IS, Akhutina TV, Tikhonov DV, et al
    Executive control of language in schizophrenia patients with history of auditory verbal hallucinations: A neuropsychological and resting-state fMRI study.
    Schizophr Res. 2023 Nov 1:S0920-9964(23)00388.
    >> Share

  400. HAHN B, Holzel ES
    Nicotine insensitivity and cue-controlled smoking behavior in people with schizophrenia.
    Schizophr Res. 2023;262:51-52.
    >> Share

  401. EACK SM, Wojtalik JA, Keshavan MS
    Anticholinergic medications in the treatment of psychoses: Pharmacological subtraction is better than addition.
    Schizophr Res. 2023;262:40-41.
    >> Share

  402. RINCON-CORTES M, Grace AA
    Sex-dependent emergence of prepubertal social dysfunction and augmented dopamine activity in a neurodevelopmental rodent model relevant for schizophrenia.
    Schizophr Res. 2023;262:32-39.
    >> Share

  403. VAZIRI N, Marques D, Greenway SC, Bousman CA, et al
    The cellular mechanism of antipsychotic-induced myocarditis: A systematic review.
    Schizophr Res. 2023;261:206-215.
    >> Share

    October 2023
  404. WU X, Ao H, Wu X, Cao Y, et al
    Sulfur-containing amino acids and risk of schizophrenia.
    Schizophr Res. 2023;262:8-17.
    >> Share

  405. CLAUSS-KOBAYASHI JME, Bonah C, Danion-Grilliat A, Scarfone M, et al
    Reshaping the diagnostic borders: Historical analysis of the diagnostic changes following the introduction of the schizophrenia concept.
    Schizophr Res. 2023;262:21-29.
    >> Share

  406. STAINTON A, Cheng N, Bryce S, Dalton A, et al
    Cognition is a treatment priority for young people with psychosis: Findings from the Your Mind, Your Choice survey.
    Schizophr Res. 2023;262:30-31.
    >> Share

  407. LAMSMA J, Harte JM, Cahn W
    Risk factors for violent behaviour before and after the onset of schizophrenia spectrum disorder: A naturalistic case-control study in the Netherlands.
    Schizophr Res. 2023;262:1-7.
    >> Share

  408. ROGERS E, Gresswell M, Durrant S
    The relationship between sleep and suicidality in schizophrenia spectrum and other psychotic disorders: A systematic review.
    Schizophr Res. 2023;261:291-303.
    >> Share

  409. HUO L, Qu D, Pei C, Wu W, et al
    Alexithymia in chronic schizophrenia and its mediating effect between cognitive deficits and negative symptoms.
    Schizophr Res. 2023;261:275-280.
    >> Share

  410. WILSON M, Harris M, Pereira M, Buckle J, et al
    Predictors of hospitalisation and recovery following full antipsychotic discontinuation in first episode psychosis. A naturalistic retrospective cohort study.
    Schizophr Res. 2023;261:269-274.
    >> Share

  411. FERNANDEZ-ABASCAL B, Suarez-Pinilla M, Cobo-Corrales C, Crespo-Facorro B, et al
    Lifestyle intervention based on exercise and behavioural counselling and its effect on physical and psychological health in outpatients with schizophrenia spectrum disorders. An exploratory, pragmatic randomized clinical trial.
    Schizophr Res. 2023;261:256-268.
    >> Share

  412. POORGANJI M, Goeke K, Zomorrodi R, Voineskos D, et al
    The use of theta burst stimulation in patients with schizophrenia - A systematic review.
    Schizophr Res. 2023;261:245-255.
    >> Share

  413. BESTERMAN AD
    A genetics-guided approach to the clinical management of schizophrenia.
    Schizophr Res. 2023 Oct 7:S0920-9964(23)00353.
    >> Share

  414. STONE WS, Phillips MR, Yang LH, Kegeles LS, et al
    Is schizophrenia neurodevelopmental, neurodegenerative or something else: A reply to Murray et al. (2022).
    Schizophr Res. 2023;261:234-235.
    >> Share

  415. OLOGUNDUDU OM, Palaniyappan L, Cipriano LE, Wijnen BFM, et al
    Risk stratification for treating people at ultra-high risk for psychosis: A cost-effectiveness analysis.
    Schizophr Res. 2023;261:225-233.
    >> Share

  416. LUTHER L, Westbrook A, Ayawvi G, Ruiz I, et al
    The role of defeatist performance beliefs on cognitive effort-cost decision-making in schizophrenia.
    Schizophr Res. 2023;261:216-224.
    >> Share

  417. CHEUK NKW, Tse W, Tsui HKH, Ma CF, et al
    A systematic review and meta-analysis of the effect of clozapine on cognitive functions in patients with treatment-resistant schizophrenia.
    Schizophr Res. 2023 Oct 1:S0920-9964(23)00338.
    >> Share

    September 2023
  418. KERKOVA B, Knizkova K, Vecerova M, Sustova P, et al
    Inflammation and cognitive performance in first-episode schizophrenia spectrum disorders: The moderating effects of childhood trauma.
    Schizophr Res. 2023;261:185-193.
    >> Share

  419. PESA J, Liu Z, Fu AZ, Campbell AK, et al
    Racial disparities in utilization of first-generation versus second-generation long-acting injectable antipsychotics in Medicaid beneficiaries with schizophrenia.
    Schizophr Res. 2023;261:170-177.
    >> Share

  420. HUANG LY, Parker DA, Ethridge LE, Hamm JP, et al
    Double dissociation between P300 components and task switch error type in healthy but not psychosis participants.
    Schizophr Res. 2023;261:161-169.
    >> Share

  421. STEPHAN NM, van Sprang ED, Wiebenga JXM, Dickhoff J, et al
    Risk factors for suicidality across psychosis vulnerability spectrum.
    Schizophr Res. 2023;261:152-160.
    >> Share

  422. KANG N, Kim SH, Kim J, Kim S, et al
    Association between initial clozapine titration and pneumonia risk among patients with schizophrenia in a Korean tertiary hospital.
    Schizophr Res. 2023 Sep 26:S0920-9964(23)00340.
    >> Share

  423. OU M, Du Z, Jiang Y, Zhou Q, et al
    Causal relationship between schizophrenia and sex hormone binding globulin: A Mendelian randomization study.
    Schizophr Res. 2023 Sep 19:S0920-9964(23)00341.
    >> Share

  424. GURCAN G, Senol SH, Yagcioglu AEA, Ertugrul A, et al
    Effect of clozapine on suicidality in patients with schizophrenia at a university hospital in Turkey.
    Schizophr Res. 2023 Sep 19:S0920-9964(23)00297.
    >> Share

  425. LI X, Lafit G, van Aubel E, Vaessen T, et al
    Emotion regulation in daily life in early psychosis: The role of contextual appraisals.
    Schizophr Res. 2023;261:130-138.
    >> Share

  426. CHEN Q, Li X, Weng K, Zhang Y, et al
    Inflammatory mediators and the effect of electroconvulsive therapy in patients with schizophrenia.
    Schizophr Res. 2023;261:125-127.
    >> Share

  427. DAMIANI S, Zarbo C, Stolarski M, Zamparini M, et al
    Time will tell: Associations between unbalanced time perspectives and symptom severity in individuals with schizophrenia spectrum disorders.
    Schizophr Res. 2023;261:116-124.
    >> Share

  428. HEGDE S, Keshavan MS
    The brain on the beat: How music may heal schizophrenia.
    Schizophr Res. 2023;261:113-115.
    >> Share

  429. ZHANG L, James SH, Strauss GP
    Environmental resource reductions predict greater severity of negative symptoms in schizophrenia.
    Schizophr Res. 2023;261:94-99.
    >> Share

  430. PENTZ AB, Timpe CMF, Normann EM, Slapo NB, et al
    Mismatch negativity in schizophrenia spectrum and bipolar disorders: Group and sex differences and associations with symptom severity.
    Schizophr Res. 2023;261:80-93.
    >> Share

  431. GAUDIANO BA, Ellenberg S, Johnson JE, Mueser KT, et al
    Effectiveness of acceptance and commitment therapy for inpatients with psychosis: Implementation feasibility and acceptability from a pilot randomized controlled trial.
    Schizophr Res. 2023;261:72-79.
    >> Share

  432. QI W, Wen Z, Chen J, Capichioni G, et al
    Aberrant resting-state functional connectivity of the globus pallidus interna in first-episode schizophrenia.
    Schizophr Res. 2023;261:100-106.
    >> Share

  433. SAUER A, Grent-'t-Jong T, Zeev-Wolf M, Singer W, et al
    Spectral and phase-coherence correlates of impaired auditory mismatch negativity (MMN) in schizophrenia: A MEG study.
    Schizophr Res. 2023;261:60-71.
    >> Share

  434. GOVANI V, Shastry AM, Iosifescu DV, Govil P, et al
    Augmentation of learning in schizophrenia by d-serine and auditory remediation is related to auditory and frontally-generated biomarkers: A randomized, double-blind, placebo-controlled study.
    Schizophr Res. 2023;260:205-208.
    >> Share

  435. SORIA BRETONES C, Roncero Parra C, Cascon J, Borja AL, et al
    Automatic identification of schizophrenia employing EEG records analyzed with deep learning algorithms.
    Schizophr Res. 2023;261:36-46.
    >> Share

  436. MATSUI K, Kuriyama K, Yoshiike T, Kawamura A, et al
    Relapse of schizophrenia associated with comorbid delayed sleep-wake phase disorder but not with evening chronotype.
    Schizophr Res. 2023;261:34-35.
    >> Share

  437. PANCHAL Y, Gannon JM, Tatar JM, Balasubramani GK, et al
    COVID-19 vaccination among patients with schizophrenia prescribed clozapine.
    Schizophr Res. 2023;261:31-33.
    >> Share

  438. FERRARA M, Guloksuz S, Hazan H, Li F, et al
    The effect of duration of untreated psychosis (DUP) on the risk for hospitalization after admission to a first episode service.
    Schizophr Res. 2023;260:198-204.
    >> Share

  439. GOLAY P, Abrahamyan Empson L, Mebdouhi N, Conus P, et al
    A better understanding of the impact of childhood trauma on depression in early psychosis: A differential item functioning approach.
    Schizophr Res. 2023;261:18-23.
    >> Share

  440. PATEL R, Chan KMY, Palmer EOC, Valko M, et al
    Associations of comorbid substance use disorders with clinical outcomes in schizophrenia using electronic health record data.
    Schizophr Res. 2023;260:191-197.
    >> Share

  441. SCHOTTLE D, Wiedemann K, Correll CU, Janetzky W, et al
    Response prediction in treatment of patients with schizophrenia after switching from oral aripiprazole to aripiprazole once-monthly.
    Schizophr Res. 2023;260:183-190.
    >> Share

  442. GANGADIN SS, Germann M, de Witte LD, Gelderman KA, et al
    Complement component 4A protein levels are negatively related to frontal volumes in patients with schizophrenia spectrum disorders.
    Schizophr Res. 2023;261:6-14.
    >> Share

  443. HINKLEY LBN, Haas SS, Cheung SW, Nagarajan SS, et al
    Reduced neural connectivity in the caudate anterior head predicts hallucination severity in schizophrenia.
    Schizophr Res. 2023;261:1-5.
    >> Share

  444. POLETTI M, Raballo A
    Subjective self-experiences at the mirror in patients with schizophrenia.
    Schizophr Res. 2023;260:180-182.
    >> Share

  445. WANG T, Codling D, Bhugra D, Msosa Y, et al
    Unraveling ethnic disparities in antipsychotic prescribing among patients with psychosis: A retrospective cohort study based on electronic clinical records.
    Schizophr Res. 2023;260:168-179.
    >> Share

  446. ROBINSON N, Ploner A, Muller-Eberstein R, Lichtenstein P, et al
    Migration and risk of schizophrenia and bipolar disorder: A Swedish national study.
    Schizophr Res. 2023;260:160-167.
    >> Share

  447. GRANRUD OE, Rodriguez Z, Cowan T, Masucci MD, et al
    Alogia and pressured speech do not fall on a continuum of speech production using objective speech technologies.
    Schizophr Res. 2023;259:121-126.
    >> Share

    August 2023
  448. HONIGFELD G
    Clozapine in treatment-resistant schizophrenia: Who designed that famous US clinical trial?
    Schizophr Res. 2023 Aug 31:S0920-9964(23)00287.
    >> Share

  449. GRIFFITHS K, Smart SE, Barker GJ, Deakin B, et al
    Treatment resistance NMDA receptor pathway polygenic score is associated with brain glutamate in schizophrenia.
    Schizophr Res. 2023;260:152-159.
    >> Share

  450. CLEMENTZ BA, Chattopadhyay I, Trotti RL, Parker DA, et al
    Clinical characterization and differentiation of B-SNIP psychosis Biotypes: Algorithmic Diagnostics for Efficient Prescription of Treatments (ADEPT)-1.
    Schizophr Res. 2023;260:143-151.
    >> Share

  451. GOFF DC, Santacatterina M, Capichioni G, Ando F, et al
    Levetiracetam effects on hippocampal blood flow and symptoms in medication-free individuals with nonaffective first episode psychosis (letter).
    Schizophr Res. 2023;260:140-142.
    >> Share

  452. MUESER KT, Sussman RF, DeTore NR, Eberlin ES, et al
    The impact of early intervention for first episode psychosis on cognitive functioning.
    Schizophr Res. 2023;260:132-139.
    >> Share

  453. SMYTH E, Steel C, Ellett L
    The prevalence of non-affective psychosis in refugee populations: A systematic review.
    Schizophr Res. 2023;260:99-112.
    >> Share

  454. TORGALSBOEN AK, Mohn C, Laroi F, Fu S, et al
    A ten-year longitudinal repeated assessment study of cognitive improvement in patients with first-episode schizophrenia and healthy controls: The Oslo Schizophrenia Recovery (OSR) study.
    Schizophr Res. 2023;260:92-98.
    >> Share

  455. KANG N, Kim SH, Kim J, Kim S, et al
    Association between initial pattern of clozapine titration, concentration-to-dose ratio, and incidence of fever in patients with schizophrenia spectrum disorders in a Korean tertiary hospital.
    Schizophr Res. 2023 Aug 24:S0920-9964(23)00259.
    >> Share

  456. SELVAGGI P, Fazio L, Toro VD, Mucci A, et al
    Effect of anticholinergic burden on brain activity during Working Memory and real-world functioning in patients with schizophrenia.
    Schizophr Res. 2023;260:76-84.
    >> Share

  457. NYGARD M, Brobakken MF, Lydersen S, Guzey IC, et al
    Strength training integrated in long term collaborative care of patients with schizophrenia.
    Schizophr Res. 2023;260:67-75.
    >> Share

  458. ABEL DB, Minor KS
    Social pleasure in daily life: A meta-analysis of experience sampling studies in schizophrenia.
    Schizophr Res. 2023;260:56-64.
    >> Share

  459. REN W, Han M, Zhang Z
    Duration estimation abnormalities in unaffected first-degree relatives and individuals of schizophrenia.
    Schizophr Res. 2023;260:39-40.
    >> Share

  460. CECCHI GA, Corcoran CM
    Exploring language and cognition in schizophrenia: Insights from computational analysis.
    Schizophr Res. 2023 Aug 6:S0920-9964(23)00256.
    >> Share

  461. TAKAHASHI T, Sasabayashi D, Takayanagi Y, Furuichi A, et al
    Gross anatomical variations of the insular cortex in first-episode schizophrenia.
    Schizophr Res. 2023;260:23-29.
    >> Share

  462. VOCKEL J, Thiemann U, Weisbrod M, Schroder J, et al
    Movement initiation and preparation in subjects with schizophrenia - The amplitude of the readiness potential as a biological marker for negative symptom severity.
    Schizophr Res. 2023;260:3-11.
    >> Share

  463. CAO T, Zhang S, Chen Q, Zeng C, et al
    Long non-coding RNAs in schizophrenia: Genetic variations, treatment markers and potential targeted signaling pathways.
    Schizophr Res. 2023;260:12-22.
    >> Share

  464. WILLIAMS TF, Pratt DN, Pinkham AE, Mittal VA, et al
    Advances in online data gathering and personalized advertisement complicate assessment of some symptoms.
    Schizophr Res. 2023;258:69-70.
    >> Share

    July 2023
  465. GANNON L, Pearson N, Tsiglopoulos J, Mifsud N, et al
    Longitudinal study of the prevalence of sleep disorders in first episode psychosis and its clinical correlates.
    Schizophr Res. 2023;258:81-83.
    >> Share

  466. ZHANG Z, Lin H, Feng Z, Xie H, et al
    Impaired calcium channel function and pronounced hippocampal atrophy in a schizophrenia patient with cognitive impairment carrying Presenilin-2 Ser130Leu mutation: A case report and literature review.
    Schizophr Res. 2023;258:78-80.
    >> Share

  467. MARDER SR, Umbricht D
    Negative symptoms in schizophrenia: Newly emerging measurements, pathways, and treatments.
    Schizophr Res. 2023;258:71-77.
    >> Share

  468. MORO L, Orri M, Sicotte R, Thibaudeau E, et al
    Sociodemographic and clinical risk factors associated with suicidal ideation and attempt during a 2-year early intervention program for first-episode psychosis.
    Schizophr Res. 2023;258:61-68.
    >> Share

  469. LEWANDOWSKI KE, Ongur D, Cohen BM
    Recall of treatment information by patients in a first episode psychosis outpatient clinic.
    Schizophr Res. 2023;258:58-60.
    >> Share

  470. ZAVLIS O, Elahi A, Alba C, Valiente CM, et al
    Increased network connectivity among paranoid beliefs characterizes the clinical end of the schizophrenia-spectrum: A Conversian systems perspective.
    Schizophr Res. 2023;258:55-57.
    >> Share

  471. CHEN WY, Chen PH, Pan CH, Su SS, et al
    Clozapine and its protective effect on all-cause, natural, and suicide mortality in patients with schizophrenia: A nationwide cohort study in Taiwan.
    Schizophr Res. 2023 Jul 19:S0920-9964(23)00240.
    >> Share

  472. SANCHEZ-IGLESIAS I, Grana DF
    Use and abuse of causal language in non-experimental studies on cannabis use and the development of psychosis.
    Schizophr Res. 2023;258:53-54.
    >> Share

  473. LOCH AA, Gondim JM, Argolo FC, Lopes-Rocha AC, et al
    Detecting at-risk mental states for psychosis (ARMS) using machine learning ensembles and facial features.
    Schizophr Res. 2023;258:45-52.
    >> Share

  474. HASAN SM, Huq MS, Chowdury AZ, Baajour S, et al
    Learning without contingencies: A loss of synergy between memory and reward circuits in schizophrenia.
    Schizophr Res. 2023;258:21-35.
    >> Share

    June 2023
  475. PEREZ SM, Elam HB, McCoy AM, Boley AM, et al
    Congenital blindness does not protect against a schizophrenia-related phenotype in rodents.
    Schizophr Res. 2023;258:1-8.
    >> Share

  476. SALISBURY DF, Seebold D, Longenecker JM, Coffman BA, et al
    White matter tracts differentially associated with auditory hallucinations in first-episode psychosis: A correlational tractography diffusion spectrum imaging study.
    Schizophr Res. 2023 Jun 14:S0920-9964(23)00208.
    >> Share

  477. YIN Y, Li S, Tong J, Huang J, et al
    Short-term antipsychotic treatment response in early-onset, typical-onset, and late-onset first episode schizophrenia.
    Schizophr Res. 2023;257:58-63.
    >> Share

  478. MUSTAFA S, Malla A, Mohan G, Padmavati R, et al
    Subjective quality of life among first-episode psychosis patients in Chennai, India and Montreal, Canada.
    Schizophr Res. 2023;257:41-49.
    >> Share

  479. ORHAN F, Goiny M, Becklen M, Mathe L, et al
    CSF dopamine is elevated in first-episode psychosis and associates to symptom severity and cognitive performance.
    Schizophr Res. 2023;257:34-40.
    >> Share

  480. RAUGH IM, Luther L, Bartolomeo LA, Gupta T, et al
    Negative Symptom Inventory-Self-Report (NSI-SR): Initial development and validation.
    Schizophr Res. 2023;256:79-87.
    >> Share

  481. ABALO-RODRIGUEZ I, Santos-Mayo A, Moratti S
    Pavlovian conditioning-induced hallucinations reduce MMN amplitudes for duration but not frequency deviants.
    Schizophr Res. 2023;256:63-71.
    >> Share

  482. VAN DE MEENT I, Maat A, Boute M, van Dellen E, et al
    The Laban/Bartenieff Movement System in gait-analysis reveals upper-lower body movement dysconnectivity in psychotic disorders.
    Schizophr Res. 2023;256:47-49.
    >> Share

    May 2023
  483. KRUCKOW L, Basit S, Nordentoft M, Banner J, et al
    The influence of comorbid disease on premature death due to natural and unnatural causes in persons with schizophrenia.
    Schizophr Res. 2023;257:27-33.
    >> Share

  484. LIN CH, Lane HY
    Sodium benzoate: A novel multi-target pharmaceutical approach to rescue clozapine-resistant schizophrenia.
    Schizophr Res. 2023 May 23:S0920-9964(23)00171.
    >> Share

  485. SERPA M, Doshi J, Joaquim HPG, Vieira ELM, et al
    Inflammatory cytokines and white matter microstructure in the acute phase of first-episode psychosis: A longitudinal study.
    Schizophr Res. 2023;257:5-18.
    >> Share

  486. RICHARDS SE, Sumner PJ, Tan EJ, Meyer D, et al
    A detailed examination of pitch discrimination deficits associated with auditory verbal hallucinations in schizophrenia.
    Schizophr Res. 2023;257:19-24.
    >> Share

  487. SAPERSTEIN AM, Meyler S, Golub JS, Medalia A, et al
    Correlates of hearing loss among adults with schizophrenia.
    Schizophr Res. 2023;257:1-4.
    >> Share

  488. KORMAN N, Stanton R, Vecchio A, Chapman J, et al
    The effect of exercise on global, social, daily living and occupational functioning in people living with schizophrenia: A systematic review and meta-analysis.
    Schizophr Res. 2023;256:98-111.
    >> Share

  489. PRASAD KM, Muldoon B, Theis N, Iyengar S, et al
    Multipronged investigation of morphometry and connectivity of hippocampal network in relation to risk for psychosis using ultrahigh field MRI.
    Schizophr Res. 2023;256:88-97.
    >> Share

  490. OKRUSZEK L, Piejka A, Chrustowicz M, Krawczyk M, et al
    Social cognitive bias increases loneliness both directly and by decreasing social connection in patients with schizophrenia.
    Schizophr Res. 2023;256:72-78.
    >> Share

  491. DANIELS EC, Eaton WW, Cihakova D, Talor MV, et al
    The relationship of peripheral inflammation with antibodies to gliadin (AGA IgG) in persons with schizophrenia.
    Schizophr Res. 2023;256:50-51.
    >> Share

  492. ALTMAN RAE, Tan EJ, Rossell SL
    Access to cognitive remediation in Australia for people with schizophrenia.
    Schizophr Res. 2023;256:44-46.
    >> Share

  493. SURTI TS, Ranganathan M, Johannesen JK, Gueorguieva R, et al
    Randomized controlled trial of the glycine transporter 1 inhibitor PF-03463275 to enhance cognitive training and neuroplasticity in schizophrenia.
    Schizophr Res. 2023;256:36-43.
    >> Share

  494. BENITO RA, Gatusky MH, Panoussi MW, McCall KL, et al
    Thirteen-fold variation between states in clozapine prescriptions to United States Medicaid patients.
    Schizophr Res. 2023;255:79-81.
    >> Share

  495. ZHANG L, Lizano P, Xu Y, Rubin LH, et al
    Peripheral inflammation is associated with impairments of inhibitory behavioral control and visual sensorimotor function in psychotic disorders.
    Schizophr Res. 2023;255:69-78.
    >> Share

  496. RAMSEY A, Govind T, Lam JA, Palmer BW, et al
    Self-compassion, but not compassion toward others, is associated with better physical health: A cross-sectional study.
    Schizophr Res. 2023;255:17-23.
    >> Share

    April 2023
  497. LUNDIN NB, Cowan HR, Singh DK, Moe AM, et al
    Lower cohesion and altered first-person pronoun usage in the spoken life narratives of individuals with schizophrenia.
    Schizophr Res. 2023 Apr 29:S0920-9964(23)00143.
    >> Share

  498. MORCH-JOHNSEN L, Jorgensen KN, Barth C, Nerland S, et al
    Thalamic nuclei volumes in schizophrenia and bipolar spectrum disorders - Associations with diagnosis and clinical characteristics.
    Schizophr Res. 2023;256:26-35.
    >> Share

  499. BRASSO C, Bellino S, Bozzatello P, Del Favero E, et al
    Inter-relationships among psychopathology, cognition, and real-life functioning in early and late phase schizophrenia: A network analysis approach.
    Schizophr Res. 2023;256:8-16.
    >> Share

  500. MARTINEZ-ALES G, Bello I, Basaraba C, Van der Ven E, et al
    Incidence, prevalence, and trajectories of suicidal ideation among clients enrolled in early intervention services for first episode psychosis in New York State.
    Schizophr Res. 2023;256:17-25.
    >> Share

  501. ZHAO J, Chen DY, Li XB, Xi YJ, et al
    EMDR versus waiting list in individuals at clinical high risk for psychosis with post-traumatic stress symptoms: A randomized controlled trial.
    Schizophr Res. 2023;256:1-7.
    >> Share

  502. DEAN B, Haroutunian V, Scarr E
    Lower levels of cortical [(3)H]pirenzepine binding to postmortem tissue defines a sub-group of older people with schizophrenia with less severe cognitive deficits.
    Schizophr Res. 2023;255:274-282.
    >> Share

  503. MULLER K, Schuster F, Rodolico A, Siafis S, et al
    How should patient decision aids for schizophrenia treatment be designed? - A scoping review.
    Schizophr Res. 2023;255:261-273.
    >> Share

  504. ZHANG G, Ye X, Wang X, Lin Y, et al
    Serum total cholesterol levels associated with immediate memory performance in patients with chronic schizophrenia.
    Schizophr Res. 2023;255:256-260.
    >> Share

  505. FOUCHER JR, Hirjak D, Walther S, Dormegny-Jeanjean LC, et al
    From one to many: Hypertonia in schizophrenia spectrum psychosis an integrative review and adversarial collaboration report.
    Schizophr Res. 2023 Apr 12:S0920-9964(23)00125.
    >> Share

  506. BASAVARAJU R, France J, Sigmon HC, Girgis RR, et al
    Increased parietal and occipital lobe gyrification predicts conversion to syndromal psychosis in a clinical high-risk cohort.
    Schizophr Res. 2023;255:246-255.
    >> Share

  507. HAGLER MA, Ferrara M, Yoviene Sykes LA, Li F, et al
    Sampling from different populations: Sociodemographic, clinical, and functional differences between samples of first episode psychosis individuals and clinical high-risk individuals who progressed to psychosis.
    Schizophr Res. 2023;255:239-245.
    >> Share

  508. PARNAS J, Yttri JE, Urfer-Parnas A
    Phenomenology of auditory verbal hallucination in schizophrenia: An erroneous perception or something else?
    Schizophr Res. 2023 Apr 4:S0920-9964(23)00139.
    >> Share

  509. KUBERA KM, Rashidi M, Schmitgen MM, Barth A, et al
    Functional network interactions in patients with schizophrenia with persistent auditory verbal hallucinations: A multimodal MRI fusion approach using three-way pICA.
    Schizophr Res. 2023 Apr 4:S0920-9964(23)00094.
    >> Share

  510. WANG C, Tishler TA, Oughourlian T, Nuechterlein KH, et al
    Prospective, randomized, multicenter clinical trial evaluating longitudinal changes in brain function and microstructure in first-episode schizophrenia patients treated with long-acting injectable paliperidone palmitate versus oral antipsychotics.
    Schizophr Res. 2023;255:222-232.
    >> Share

  511. SHI JY, Cao YM, Luo HY, Liu S, et al
    Effect of a group-based acceptance and commitment therapy (ACT) intervention on self-esteem and psychological flexibility in patients with schizophrenia in remission.
    Schizophr Res. 2023;255:213-221.
    >> Share

    March 2023
  512. GLEESON JFM, Koval P, Zyphur M, Lederman R, et al
    A randomized controlled trial of moderated online social therapy for family carers of first-episode psychosis patients in a specialist treatment setting.
    Schizophr Res. 2023;255:203-212.
    >> Share

  513. TISHLER TA, Ellingson BM, Salvadore G, Baker P, et al
    Effect of treatment with paliperidone palmitate versus oral antipsychotics on frontal lobe intracortical myelin volume in participants with recent-onset schizophrenia: Magnetic resonance imaging results from the DREaM study.
    Schizophr Res. 2023;255:195-202.
    >> Share

  514. MILLGATE E, Smart SE, Pardinas AF, Kravariti E, et al
    Cognitive performance at first episode of psychosis and the relationship with future treatment resistance: Evidence from an international prospective cohort study.
    Schizophr Res. 2023;255:173-181.
    >> Share

  515. ALMSTRUP FB, Nordentoft M, Jensen MA, Kristiansen J, et al
    Associations between saliva alpha-amylase, heart rate variability, saliva cortisol and cognitive performance in individuals at ultra high-risk for psychosis.
    Schizophr Res. 2023;255:165-172.
    >> Share

  516. NORDHOLM D, Jensen MA, Kristiansen J, Glenthoj LB, et al
    A longitudinal study on physiological stress in individuals at ultra high-risk of psychosis.
    Schizophr Res. 2023;254:218-226.
    >> Share

  517. VAESSEN T, Reininghaus U, van Aubel E, Beijer-Klippel A, et al
    Neural correlates of daily-life affective stress reactivity in early psychosis: A study combining functional MRI and experience sampling methodology.
    Schizophr Res. 2023;255:93-101.
    >> Share

  518. HOGOBOOM A, Rouch M, Lauerman D, Pauselli L, et al
    Initial evidence of vowel space reduction in a subset of individuals with schizophrenia.
    Schizophr Res. 2023;255:158-164.
    >> Share

  519. KULAGA SS, Wehring HJ, Demyanovoich HJ, Rubin L, et al
    The hormonal effects of childhood trauma in adult women with and without schizophrenia.
    Schizophr Res. 2023;255:155-157.
    >> Share

  520. KRUIPER C, Sommer IEC, Koster M, Bakker PR, et al
    Clonidine augmentation in patients with schizophrenia: A double-blind, randomized placebo-controlled trial.
    Schizophr Res. 2023;255:148-154.
    >> Share

  521. ZHANG W, Wang D, Zhou H, Chen D, et al
    Sex difference in association between tardive dyskinesia and cognitive deficits in patients with chronic schizophrenia.
    Schizophr Res. 2023;255:140-147.
    >> Share

  522. IYO M, Akiyoshi H, Sekine D, Shibasaki Y, et al
    An exploratory database study of factors influencing the continuation of brexpiprazole treatment (prescription) in patients with schizophrenia using information from psychiatric electronic medical records processed with natural language processing.
    Schizophr Res. 2023;255:122-131.
    >> Share

  523. HUA JPY, Cummings J, Roach BJ, Fryer SL, et al
    Rich-club connectivity and structural connectome organization in youth at clinical high-risk for psychosis and individuals with early illness schizophrenia.
    Schizophr Res. 2023;255:110-121.
    >> Share

  524. DEL RE EC, Yassin W, Zeng V, Keedy S, et al
    Characterization of childhood trauma, hippocampal mediation and Cannabis use in a large dataset of psychosis and non-psychosis individuals.
    Schizophr Res. 2023;255:102-109.
    >> Share

  525. SAMPEDRO A, Ibarretxe-Bilbao N, Pena J, Cabrera-Zubizarreta A, et al
    Analyzing structural and functional brain changes related to an integrative cognitive remediation program for schizophrenia: A randomized controlled trial.
    Schizophr Res. 2023;255:82-92.
    >> Share

  526. PRASAD K, Rubin J, Iyengar S, Cape J, et al
    Global network disorganization underlying psychosis high risk states.
    Schizophr Res. 2023;255:67-68.
    >> Share

  527. LI Z, Qing Y, Cui G, Li M, et al
    Shotgun metagenomics reveals abnormal short-chain fatty acid-producing bacteria and glucose and lipid metabolism of the gut microbiota in patients with schizophrenia.
    Schizophr Res. 2023;255:59-66.
    >> Share

  528. BUCHANAN A, Stefanovics E, Rosenheck R
    Victimization in schizophrenia and its relation to violence.
    Schizophr Res. 2023;255:52-58.
    >> Share

  529. MARTINHO FP, Magalhaes D, Felicio R, Ferreira TF, et al
    Obsessive-compulsive symptoms in first episode psychosis and risk states: Systematic review with meta-analysis.
    Schizophr Res. 2023;255:41-51.
    >> Share

  530. VAN ECK RM, van Velden J, Vellinga A, van der Krieke L, et al
    Personal recovery suits us all: A study in patients with non-affective psychosis, unaffected siblings and healthy controls.
    Schizophr Res. 2023;255:24-32.
    >> Share

  531. DOBBS MF, McGowan A, Selloni A, Bilgrami Z, et al
    Linguistic correlates of suicidal ideation in youth at clinical high-risk for psychosis.
    Schizophr Res. 2023 Mar 16:S0920-9964(23)00108.
    >> Share

  532. PFARR JK, Meller T, Evermann U, Sahakyan L, et al
    Trait schizotypy and the psychosis prodrome: Current standard assessment of extended psychosis spectrum phenotypes.
    Schizophr Res. 2023;254:208-217.
    >> Share

  533. RABINOWITZ J, Staner C, Saoud J, Weiser M, et al
    Long-term effects of Roluperidone on negative symptoms of schizophrenia.
    Schizophr Res. 2023;255:9-13.
    >> Share

  534. PRATT SI, Ferron JC, Wolfe R, Xie H, et al
    Healthy choices, healthy changes: A randomized trial of incentives to promote healthy eating and exercise in people with schizophrenia and other serious mental illnesses.
    Schizophr Res. 2023;255:1-8.
    >> Share

  535. SANTARRIAGA S, Gerlovin K, Layadi Y, Karmacharya R, et al
    Human stem cell-based models to study synaptic dysfunction and cognition in schizophrenia: A narrative review.
    Schizophr Res. 2023 Mar 14:S0920-9964(23)00084.
    >> Share

  536. TANTCHIK W, Green MJ, Quide Y, Erk S, et al
    Investigating the neural correlates of affective mentalizing and their association with general intelligence in patients with schizophrenia.
    Schizophr Res. 2023;254:190-198.
    >> Share

  537. CECCHI M, Adachi M, Basile A, Buhl DL, et al
    Validation of a suite of ERP and QEEG biomarkers in a pre-competitive, industry-led study in subjects with schizophrenia and healthy volunteers.
    Schizophr Res. 2023;254:178-189.
    >> Share

  538. TAKEUCHI H, Lee J, Fervaha G, Agid O, et al
    Second version of Brief Evaluation of Psychosis Symptom Domains (BE-PSD-V2.0).
    Schizophr Res. 2023;254:176-177.
    >> Share

  539. HOPTMAN MJ, Tural U, Arnold MS, Collins KA, et al
    Suicidal ideation and behavior in schizophrenia: The role of negative urgency and psychiatric symptoms.
    Schizophr Res. 2023;254:173-175.
    >> Share

  540. MURILLO-GARCIA N, Ortiz-Garcia de la Foz V, Miguel-Corredera M, Vazquez-Bourgon J, et al
    Intelligence quotient changes over 10 years: Diversity of cognitive profiles in first episode of psychosis and healthy controls.
    Schizophr Res. 2023;254:163-172.
    >> Share

  541. SIAO WH, Chang FY, Chen YC
    Memantine treats psychosis and agitation associated with Moderna COVID-19 vaccine.
    Schizophr Res. 2023;255:14-16.
    >> Share

  542. LIANG S, Cao B, Deng W, Kong X, et al
    Functional dysconnectivity of anterior cingulate subregions in schizophrenia and psychotic and nonpsychotic bipolar disorder.
    Schizophr Res. 2023;254:155-162.
    >> Share

  543. DEMIRLEK C, Bora E
    Sleep-dependent memory consolidation in schizophrenia: A systematic review and meta-analysis.
    Schizophr Res. 2023;254:146-154.
    >> Share

  544. TANDON R
    Computational psychiatry and the psychopathology of psychosis: Promising leads and blind alleys.
    Schizophr Res. 2023;254:143-145.
    >> Share

  545. DETORE NR, Balogun-Mwangi O, Mueser KT, McGurk SR, et al
    Comparison of Black and White participants with severe mental illness in response to cognitive remediation as an augmentation of vocational rehabilitation.
    Schizophr Res. 2023;253:60-67.
    >> Share

    February 2023
  546. VAN DEE V, Schnack HG, Cahn W
    Systematic review and meta-analysis on predictors of prognosis in patients with schizophrenia spectrum disorders: An overview of current evidence and a call for prospective research and open access to datasets.
    Schizophr Res. 2023;254:133-142.
    >> Share

  547. MICHAELS TI, Carrion RE, Addington J, Bearden CE, et al
    Ethnoracial discrimination and the development of suspiciousness symptoms in individuals at clinical high-risk for psychosis.
    Schizophr Res. 2023;254:125-132.
    >> Share

  548. KUMAZAKI H, Muramatsu T, Yoshikawa Y, Matsumoto Y, et al
    Android robot was beneficial for communication rehabilitation in a patient with schizophrenia comorbid with autism spectrum disorders.
    Schizophr Res. 2023;254:116-117.
    >> Share

  549. DE MICHELI A, Provenzani U, Solmi M, Van Pabst AVL, et al
    Prevalence of tobacco smoking in people at clinical high-risk for psychosis: Systematic review and meta-analysis.
    Schizophr Res. 2023;254:109-115.
    >> Share

  550. STEVENS KL, Teich CD, Longenecker JM, Sponheim SR, et al
    Relational memory function in schizophrenia: Electrophysiological evidence for early perceptual and late associative abnormalities.
    Schizophr Res. 2023;254:99-108.
    >> Share

  551. KARBALAEE M, Jameie M, Amanollahi M, TaghaviZanjani F, et al
    Efficacy and safety of adjunctive therapy with fingolimod in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial.
    Schizophr Res. 2023;254:92-98.
    >> Share

  552. MAO Z, Bo Q, Sun Y, Li W, et al
    Prepulse inhibition and attentional modulation in individuals with attenuated psychotic syndrome and at genetically high risk of schizophrenia.
    Schizophr Res. 2023;254:90-91.
    >> Share

  553. SHOHAM N, Lewis G, Hayes JF, Silverstein SM, et al
    Association between visual impairment and psychosis: A longitudinal study and nested case-control study of adults.
    Schizophr Res. 2023;254:81-89.
    >> Share

  554. CABUK T, Mutlu E, Toulopoulou T
    Thought and language disorder as a possible endophenotype in schizophrenia: Evidence from patients and their unaffected siblings.
    Schizophr Res. 2023;254:78-80.
    >> Share

  555. DONDE C, Pouchon A, Polosan M
    Recovery effect: Cigarette smoking acts on the neural dynamics of early auditory processing in schizophrenia.
    Schizophr Res. 2023;254:76-77.
    >> Share

  556. RAMAIN J, Conus P, Golay P
    Interactions between mood and paranoid symptoms affect suicidality in first-episode affective psychoses.
    Schizophr Res. 2023;254:62-67.
    >> Share

  557. COOPER SM, Fusar-Poli P, Uhlhaas PJ
    Characteristics and clinical correlates of risk symptoms in individuals at clinical high-risk for psychosis: A systematic review and meta-analysis.
    Schizophr Res. 2023;254:54-61.
    >> Share

  558. CASTRO MN, Bocaccio H, De Pino G, Sanchez SM, et al
    Abnormal brain network community structure related to psychological stress in schizophrenia.
    Schizophr Res. 2023;254:42-53.
    >> Share

  559. TAKAHASHI Y, Fujii S, Osakabe Y, Hoshino H, et al
    Impaired mismatch negativity reflects the inability to perceive beat interval in patients with schizophrenia.
    Schizophr Res. 2023;254:40-41.
    >> Share

  560. LIN Y, Li C, Wang X, Song Y, et al
    Channel- and category-specific emotion recognition deficits and their associations with symptomatology and cognition in individuals with schizophrenia.
    Schizophr Res. 2023;254:37-39.
    >> Share

  561. SHEKHAR SK
    Schizophrenia and COVID-19: A bibliometric analysis of trends and themes.
    Schizophr Res. 2023;254:35-36.
    >> Share

  562. PANULA JM, Lindgren M, Kieseppa T, Suvisaari J, et al
    Associations between acceptance of the implausible bias, theory of mind and delusions in first-episode psychosis patients; A longitudinal study.
    Schizophr Res. 2023;254:27-34.
    >> Share

  563. TANDON R, Keshavan M, Nasrallah H
    "Reinventing schizophrenia: Updating the construct". Project update and next steps.
    Schizophr Res. 2023;252:345-347.
    >> Share

  564. KULKARNI J, Gurvich C, Gilbert H, Worsley R, et al
    The use of first and second-generation antipsychotic drugs and the potential to develop gestational diabetes mellitus among perinatal patients with psychosis.
    Schizophr Res. 2023;254:22-26.
    >> Share

  565. SCHNEIDER BC, Rahmede M, Pillny M, Karow A, et al
    In the eyes of the beholders: Subjective experiences of positive symptoms among patients with symptoms of psychosis seeking psychotherapy.
    Schizophr Res. 2023;254:14-21.
    >> Share

  566. PADEE A, Missonnier P, Prevot A, Favre G, et al
    Anticipatory deficits in psychosis during social cognition task analysed by task-based EEG dynamic functional connectivity.
    Schizophr Res. 2023;254:11-13.
    >> Share

  567. LIMA MF, Sarudiansky M, Oddo S, Giagante B, et al
    Comorbid psychosis in temporal lobe epilepsy is associated with auditory emotion recognition impairments.
    Schizophr Res. 2023;254:8-10.
    >> Share

    January 2023
  568. MANDAL MK, Habel U, Gur RC
    Facial expression-based indicators of schizophrenia: Evidence from recent research.
    Schizophr Res. 2023;252:335-344.
    >> Share

  569. WOOTTON O, Dalvie S, Susser E, Gur RC, et al
    Within-individual variability in cognitive performance in schizophrenia: A narrative review of the key literature and proposed research agenda.
    Schizophr Res. 2023;252:329-334.
    >> Share

  570. NASRALLAH HA
    Is preventing the second psychotic episode a disease-modifying strategy for schizophrenia?
    Schizophr Res. 2023;252:326-328.
    >> Share

  571. IHLER HM, Lyngstad SH, Gardsjord ES, Widing LH, et al
    The trajectory of two negative symptom dimensions in first-episode psychosis and the role of cannabis use: A 10-year follow-up study.
    Schizophr Res. 2023;252:317-325.
    >> Share

  572. OKADA Y, Inada K, Akazawa M
    Comparative effectiveness of long-acting injectable antipsychotics in patients with schizophrenia in Japan.
    Schizophr Res. 2023;252:300-308.
    >> Share

  573. GAUR V, Singh S
    Psychopathology, clinical insight and cognitive insight in patients with treatment resistant schizophrenia.
    Schizophr Res. 2023;252:294-295.
    >> Share

  574. ALBERT N, Hansen HG, Starzer M, Nordentoft M, et al
    Functioning pre- and post-treatment in schizophrenia; further investigations into lead time bias and duration of untreated psychosis.
    Schizophr Res. 2023;252:287-293.
    >> Share

  575. STEENKAMP LR, Parrish EM, Chalker SA, Badal VD, et al
    Childhood trauma and real-world social experiences in psychosis.
    Schizophr Res. 2023;252:279-286.
    >> Share

  576. CUESTA MJ, Sanchez-Torres AM, Garcia de Jalon E, Moreno-Izco L, et al
    Empirical validity of Leonhard's psychoses: A long-term follow-up study of first-episode psychosis patients.
    Schizophr Res. 2023 Jan 20:S0920-9964(22)00469.
    >> Share

  577. BENNETT ME, Brown CH, Fang LJ, Blanchard JJ, et al
    Increasing social and community participation in veterans living with schizophrenia: A treatment outcome study.
    Schizophr Res. 2023;252:262-270.
    >> Share

  578. SUN H, Lui S, Huang X, Sweeney J, et al
    Effects of randomness in the development of machine learning models in neuroimaging studies of schizophrenia.
    Schizophr Res. 2023;252:253-261.
    >> Share

  579. COURY SM, Lombroso A, Avila-Quintero VJ, Taylor JH, et al
    Systematic review and meta-analysis: Season of birth and schizophrenia risk.
    Schizophr Res. 2023;252:244-252.
    >> Share

  580. AMADOR X
    Denial of anosognosia in schizophrenia.
    Schizophr Res. 2023;252:242-243.
    >> Share

  581. BARENDSE MEA, Lara GA, Guyer AE, Swartz JR, et al
    Sex and pubertal influences on the neurodevelopmental underpinnings of schizophrenia: A case for longitudinal research on adolescents.
    Schizophr Res. 2023;252:231-241.
    >> Share

  582. MIRALLES C, Alonso Y, Algora MJ, Lopez-Sanchez L, et al
    Maladaptive personality traits in patients with recent-onset psychosis: A case-control study using the Personality Inventory for the DSM-5 (PID-5).
    Schizophr Res. 2023;252:216-224.
    >> Share

  583. MILLER BJ, McEvoy JP, McCall WV
    Meta-analysis of clozapine and insomnia in schizophrenia.
    Schizophr Res. 2023;252:208-215.
    >> Share

  584. LI SB, Liu C, Zhang JB, Wang LL, et al
    Corrigendum to "Revisiting the latent structure of negative symptoms in schizophrenia: Evidence from two second-generation clinical assessments" [Schizophr. Res. 248 (2022) 131-139].
    Schizophr Res. 2023;252:206-207.
    >> Share

  585. PATRONO E, Hruzova K, Svoboda J, Stuchlik A, et al
    The role of optogenetic stimulations of parvalbumin-positive interneurons in the prefrontal cortex and the ventral hippocampus on an acute MK-801 model of schizophrenia-like cognitive inflexibility.
    Schizophr Res. 2023;252:198-205.
    >> Share

  586. FACAL F, Costas J
    Polygenic risk scores for schizophrenia and treatment resistance: New data, systematic review and meta-analysis.
    Schizophr Res. 2023;252:189-197.
    >> Share

  587. CHAN SKW, Liao Y, Hui CLM, Wong TY, et al
    Longitudinal changes of cognitive function and its relationship with subdomains of negative symptoms in patients with adult-onset first-episode schizophrenia: A 4-year follow up study.
    Schizophr Res. 2023;252:181-188.
    >> Share

  588. SASTRE-BUADES A, Caro-Canizares I, Ochoa S, Lorente-Rovira E, et al
    Relationship between cognition and suicidal behavior in recent-onset psychosis.
    Schizophr Res. 2023;252:172-180.
    >> Share

  589. DAVID FS, Stein F, Andlauer TFM, Streit F, et al
    Genetic contributions to transdiagnostic symptom dimensions in patients with major depressive disorder, bipolar disorder, and schizophrenia spectrum disorders.
    Schizophr Res. 2023;252:161-171.
    >> Share

  590. HERRERA SN, Sarac C, Phili A, Gorman J, et al
    Psychoeducation for individuals at clinical high risk for psychosis: A scoping review.
    Schizophr Res. 2023;252:148-158.
    >> Share

  591. PALMER-COOPER EC, Wright AC, Maguire N, Montagnese M, et al
    Metacognition and psychosis-spectrum experiences: A study of objective and subjective measures.
    Schizophr Res. 2023 Jan 14:S0920-9964(22)00461.
    >> Share

  592. ALKELAI A, Greenbaum L, Shohat S, Povysil G, et al
    Genetic insights into childhood-onset schizophrenia: The yield of clinical exome sequencing.
    Schizophr Res. 2023;252:138-145.
    >> Share

  593. OGYU K, Matsushita K, Honda S, Wada M, et al
    Decrease in gamma-band auditory steady-state response in patients with treatment-resistant schizophrenia.
    Schizophr Res. 2023;252:129-137.
    >> Share

  594. OH J, Lee E, Cha EJ, Seo HJ, et al
    Community-based multi-site randomized controlled trial of behavioral activation for patients with negative symptoms of schizophrenia.
    Schizophr Res. 2023;252:118-126.
    >> Share

  595. FLORENTIN S, Reuveni I, Rosca P, Zwi-Ran SR, et al
    Schizophrenia or schizoaffective disorder? A 50-year assessment of diagnostic stability based on a national case registry.
    Schizophr Res. 2023;252:110-117.
    >> Share

  596. HOLTTINEN T, Pirkola S, Kaltiala R
    Schizophrenia among young people first admitted to psychiatric inpatient care during early and middle adolescence.
    Schizophr Res. 2023;252:103-109.
    >> Share

  597. MILLER BJ, Lemos H, Schooler NR, Goff DC, et al
    Longitudinal study of inflammation and relapse in schizophrenia.
    Schizophr Res. 2023;252:88-95.
    >> Share

  598. HOPREKSTAD GE, Kjelby E, Gjestad R, Fathian F, et al
    Depression trajectories and cytokines in schizophrenia spectrum disorders - A longitudinal observational study.
    Schizophr Res. 2023;252:77-87.
    >> Share

  599. HONDA S, Matsushita K, Noda Y, Tarumi R, et al
    Music rhythm perception and production relate to treatment response in schizophrenia.
    Schizophr Res. 2023;252:69-76.
    >> Share

  600. MISIAK B, Bielawski T, Samochowiec J, Samochowiec A, et al
    Activation of the endocannabinoid system in schizophrenia: A compensatory mechanism of subclinical inflammation?
    Schizophr Res. 2023;252:67-68.
    >> Share

  601. GOUSE BM, Kline ER
    Clinical insights: Preventing psychosis treatment disengagement.
    Schizophr Res. 2023;252:64-66.
    >> Share

  602. CHOI SY, Ha M, Choi S, Moon SY, et al
    Altered intrinsic cerebellar-cerebral functional connectivity is related to negative symptoms in patients with first-episode psychosis.
    Schizophr Res. 2023;252:56-63.
    >> Share

  603. ROUX P, Faivre N, Urbach M, Aouizerate B, et al
    Relationships between neuropsychological performance, insight, medication adherence, and social metacognition in schizophrenia.
    Schizophr Res. 2023;252:48-55.
    >> Share

  604. SIMMONITE M, Yao B, Welsh RC, Taylor SF, et al
    Increased rostral medial frontal GABA+ in early psychosis is obscured by levels of negative affect.
    Schizophr Res. 2023;252:46-47.
    >> Share

  605. TAKAHASHI T, Sasabayashi D, Wood SJ, McGorry PD, et al
    Increased prevalence of the Heschl's gyrus duplication pattern common to various first-episode psychoses.
    Schizophr Res. 2023;252:36-38.
    >> Share

  606. ULUDAG K, Wang DM, Mohamoud Y, Wu HE, et al
    Antipsychotic-based machine learning models may help prediction of tardive dyskinesia in patients with schizophrenia.
    Schizophr Res. 2023;252:33-35.
    >> Share

  607. GIL-BERROZPE GJ, Peralta V, Sanchez-Torres AM, Moreno-Izco L, et al
    Psychopathological networks in psychosis: Changes over time and clinical relevance. A long-term cohort study of first-episode psychosis.
    Schizophr Res. 2023;252:23-32.
    >> Share

  608. BUCCI P, Giordano GM, Mucci A, Rocca P, et al
    Sex and gender differences in clinical and functional indices in subjects with schizophrenia and healthy controls: Data from the baseline and 4-year follow-up studies of the Italian Network for Research on Psychoses.
    Schizophr Res. 2023;251:94-107.
    >> Share

  609. COSTA ALL, Costa DL, Pessoa VF, Caixeta FV, et al
    Systematic review of visual illusions in schizophrenia.
    Schizophr Res. 2023;252:13-22.
    >> Share

  610. LI K, Long J, Cao M, Xue R, et al
    Thyroid hormone optimize management in electroconvulsive therapy treatment of schizophrenia.
    Schizophr Res. 2023;252:10-12.
    >> Share

  611. MOSCARELLI M, Min JY, Kopelowicz A, Torous J, et al
    The scale for the assessment of the passively received experiences (PRE) in schizophrenia and digital mental health.
    Schizophr Res. 2023;251:91-93.
    >> Share

  612. DALKNER N, Moore RC, Depp CA, Ackerman RA, et al
    Negative mood states as a correlate of cognitive performance and self-assessment of cognitive performance in bipolar disorder versus schizophrenia.
    Schizophr Res. 2023;252:1-9.
    >> Share

    December 2022
  613. BAREIS N, Olfson M, Gerhard T, Rolin S, et al
    Means of suicide among adults with schizophrenia across the life span.
    Schizophr Res. 2022;251:82-90.
    >> Share

  614. SHYMKO G, Dobson L, Acacio MC, Grace T, et al
    Weight changes in people with early psychosis treated with oral or long-acting injectable aripiprazole.
    Schizophr Res. 2022;251:74-81.
    >> Share

  615. MALETTA RM, Vass V
    A 20-year review comparing the use of 'schizophrenia' and 'psychosis' in UK newspapers from 2000 to 2019: Implications for stigma reduction.
    Schizophr Res. 2022;251:66-73.
    >> Share

  616. GANGADIN SS, Mandl RCW, de Witte LD, van Haren NEM, et al
    Lower fractional anisotropy without evidence for neuro-inflammation in patients with early-phase schizophrenia spectrum disorders.
    Schizophr Res. 2022 Dec 26:S0920-9964(22)00456.
    >> Share

  617. LE TP, Ventura J, Ruiz-Yu B, McEwen SC, et al
    Treatment engagement in first-episode schizophrenia: Associations between intrinsic motivation and attendance during cognitive training and an aerobic exercise program.
    Schizophr Res. 2022;251:59-65.
    >> Share

  618. WANG D, Russel WA, Sun Y, Belanger KD, et al
    Machine learning and network analysis of the gut microbiome from patients with schizophrenia and non-psychiatric subject controls reveal behavioral risk factors and bacterial interactions.
    Schizophr Res. 2022;251:49-58.
    >> Share

  619. CUNILL R, Vives L, Pla M, Usall J, et al
    Relationship between obsessive compulsive symptomatology and severity of psychotic symptoms in schizophrenia: Meta-analysis and meta-regression analysis.
    Schizophr Res. 2022;251:37-45.
    >> Share

  620. MALASPINA D
    What social determinants can tell us about schizophrenia.
    Schizophr Res. 2022 Dec 15:S0920-9964(22)00400.
    >> Share

  621. JENKINS AK, Lewis DA, Volk DW
    Altered expression of microglial markers of phagocytosis in schizophrenia.
    Schizophr Res. 2022;251:22-29.
    >> Share

  622. MCEWEN SC, Jarrahi B, Ventura J, Subotnik KL, et al
    A combined exercise and cognitive training intervention induces fronto-cingulate cortical plasticity in first-episode psychosis patients.
    Schizophr Res. 2022;251:12-21.
    >> Share

  623. MORORO LG, Guimaraes AL, Costa AC, Genaro L, et al
    Association between motivation and engagement with changes in cognition and symptoms after digital cognitive training in schizophrenia.
    Schizophr Res. 2022;251:1-9.
    >> Share

  624. BUCK B, Munson J, Chander A, Wang W, et al
    The relationship between appraisals of auditory verbal hallucinations and real-time affect and social functioning.
    Schizophr Res. 2022;250:112-119.
    >> Share

    November 2022
  625. CHOUDHARY A, Peles D, Nayak R, Mizrahi L, et al
    Current progress in understanding schizophrenia using genomics and pluripotent stem cells: A meta-analytical overview.
    Schizophr Res. 2022 Nov 25:S0920-9964(22)00406.
    >> Share

  626. KILIAN S, Du Plessis S, Fouche JP, Luckhoff H, et al
    Differences in white matter microstructure in first-episode schizophrenia spectrum disorders vs healthy volunteers and their association with cognition.
    Schizophr Res. 2022;250:196-202.
    >> Share

  627. MARTINUZZI LJ, Strassnig MT, Depp CA, Moore RC, et al
    A closer look at avolition in schizophrenia and bipolar disorder: Persistence of different types of activities over time.
    Schizophr Res. 2022;250:188-195.
    >> Share

  628. KHAN A, Lindenmayer JP, Insel B, Seddo M, et al
    Computerized cognitive and social cognition training in schizophrenia for impulsive aggression.
    Schizophr Res. 2022 Nov 21:S0920-9964(22)00418.
    >> Share

  629. ZHAO Q, Wang WQ, Fan HZ, Li D, et al
    Vocal acoustic features may be objective biomarkers of negative symptoms in schizophrenia: A cross-sectional study.
    Schizophr Res. 2022;250:180-185.
    >> Share

  630. RASMUSSEN AR, Zandersen M, Nordgaard J, Sandsten KE, et al
    Pseudoneurotic symptoms in the schizophrenia spectrum: An empirical study.
    Schizophr Res. 2022;250:164-171.
    >> Share

  631. MOLSTROM IM, Nordgaard J, Urfer-Parnas A, Handest R, et al
    The prognosis of schizophrenia: A systematic review and meta-analysis with meta-regression of 20-year follow-up studies.
    Schizophr Res. 2022;250:152-163.
    >> Share

  632. SCHORR B, Clauss JME, de Billy CC, Dassing R, et al
    Subtyping chronic catatonia: Clinical and neuropsychological characteristics of progressive periodic catatonia and chronic system catatonias vs. non-catatonic schizophrenia.
    Schizophr Res. 2022 Nov 18:S0920-9964(22)00392.
    >> Share

  633. DJORDJEVIC M, Brink V, Wardenaar KJ, Scholte-Stalenhoef AN, et al
    Personality traits and coping strategies in recent-onset psychosis: Associations with symptom severity and psychosocial functioning.
    Schizophr Res. 2022;250:143-151.
    >> Share

  634. MILLER BJ, McEvoy JP, McCall WV, Lu XY, et al
    Lower adiponectin levels as a predictor of depressive symptoms in African-American males with schizophrenia.
    Schizophr Res. 2022;250:134-136.
    >> Share

  635. CAROFF SN, Ungvari GS, Gazdag G
    Treatment of schizophrenia with catatonic symptoms: A narrative review.
    Schizophr Res. 2022 Nov 17:S0920-9964(22)00431.
    >> Share

  636. BECKER WRIGHT ML, Ahmed AO, Barchard KA, Benning SD, et al
    Latent structure of cognitive tests is invariant in men and women with schizophrenia.
    Schizophr Res. 2022;250:127-133.
    >> Share

  637. ZHANG W, Perivoliotis D
    Promoting recovery among persons with schizophrenia using Recovery-Oriented Cognitive Therapy (CT-R).
    Schizophr Res. 2022;250:125-126.
    >> Share

  638. BROWN H, Ongur D, Smurawska L, Valcourt S, et al
    Inpatient - Outpatient transitions in first episode psychosis care.
    Schizophr Res. 2022;250:123-124.
    >> Share

  639. KIRIHARA K, Fujioka M, Suga M, Kondo S, et al
    Betaine supplementation improves positive symptoms in schizophrenia.
    Schizophr Res. 2022;250:120-122.
    >> Share

  640. COHEN BM, Singh T, Ongur D, Konstantin GE, et al
    Clinical phenotypes of five patients with psychotic disorders carrying rare schizophrenia-associated loss-of-function variants.
    Schizophr Res. 2022;250:100-103.
    >> Share

  641. NAGENDRA A, Black C, Penn DL
    Black Americans and Schizophrenia: Racism as a Driver of Inequities in Psychosis Diagnosis, Assessment, and Treatment.
    Schizophr Res. 2022 Nov 14. pii: S0920-9964(22)00390.
    >> Share

  642. CONLEY AC, Albert KM, Armstrong K, Johnson JV, et al
    A pilot study of transdermal nicotine effects on facial emotion responding in non-smoking healthy controls and individuals with schizophrenia: Feasibility and effect size estimates.
    Schizophr Res. 2022;250:89-91.
    >> Share

  643. YUAN X, Li X, Kang Y, Pang L, et al
    Gut mycobiota dysbiosis in drug-naive, first-episode schizophrenia.
    Schizophr Res. 2022;250:76-86.
    >> Share

  644. CORRELL CU, Bitter I, Hoti F, Mehtala J, et al
    Factors and their weight in reducing life expectancy in schizophrenia.
    Schizophr Res. 2022;250:67-75.
    >> Share

  645. ZHAI D, Bing J, Shan X, Luo H, et al
    Higher central set point of thyroid homeostasis in drug-naive patients affected by first episode schizophrenia.
    Schizophr Res. 2022;250:62-66.
    >> Share

  646. KAPITANY-FOVENY M
    A commentary on the interpretability of computational linguistic findings in schizophrenia research.
    Schizophr Res. 2022;250:60-61.
    >> Share

  647. FREEMAN D, Lambe S, Galal U, Yu LM, et al
    Agoraphobic avoidance in patients with psychosis: Severity and response to automated VR therapy in a secondary analysis of a randomised controlled clinical trial.
    Schizophr Res. 2022;250:50-59.
    >> Share

  648. INTSON K, Geissah S, McCullumsmith RE, Ramsey AJ, et al
    A role for endothelial NMDA receptors in the pathophysiology of schizophrenia.
    Schizophr Res. 2022;249:63-73.
    >> Share

  649. CHAUMETTE B, Sengupta SM, Lepage M, Malla A, et al
    A polymorphism in the glutamate metabotropic receptor 7 is associated with cognitive deficits in the early phases of psychosis.
    Schizophr Res. 2022;249:56-62.
    >> Share

  650. LEON-ORTIZ P, Reyes-Madrigal F, Kochunov P, Gomez-Cruz G, et al
    White matter alterations and the conversion to psychosis: A combined diffusion tensor imaging and glutamate (1)H MRS study.
    Schizophr Res. 2022;249:85-92.
    >> Share

  651. ZEPPILLO T, Schulmann A, Macciardi F, Hjelm BE, et al
    Functional impairment of cortical AMPA receptors in schizophrenia.
    Schizophr Res. 2022;249:25-37.
    >> Share

  652. QIAN N, Lipkin RM, Kaszowska A, Silipo G, et al
    Computational modeling of excitatory/inhibitory balance impairments in schizophrenia.
    Schizophr Res. 2022;249:47-55.
    >> Share

  653. ASAH S, Alganem K, McCullumsmith RE, O'Donovan SM, et al
    A bioinformatic inquiry of the EAAT2 interactome in postmortem and neuropsychiatric datasets.
    Schizophr Res. 2022;249:38-46.
    >> Share

  654. REDDY-THOOTKUR M, Kraguljac NV, Lahti AC
    The role of glutamate and GABA in cognitive dysfunction in schizophrenia and mood disorders - A systematic review of magnetic resonance spectroscopy studies.
    Schizophr Res. 2022;249:74-84.
    >> Share

  655. BENESH JL, Mueller TM, Meador-Woodruff JH
    AMPA receptor subunit localization in schizophrenia anterior cingulate cortex.
    Schizophr Res. 2022;249:16-24.
    >> Share

  656. ROBERTS RC, McCollum LA, Schoonover KE, Mabry SJ, et al
    Ultrastructural evidence for glutamatergic dysregulation in schizophrenia.
    Schizophr Res. 2022;249:4-15.
    >> Share

    October 2022
  657. KLINE ER, Thibeau H, Davis BJ, Fenley A, et al
    Motivational interviewing for loved ones: Randomized controlled trial of brief training for first episode psychosis caregivers.
    Schizophr Res. 2022;250:43-49.
    >> Share

  658. WALTHER S, Nadesalingam N, Nuoffer M, Kyrou A, et al
    Structural alterations of the motor cortex and higher order cortical areas suggest early neurodevelopmental origin of catatonia in schizophrenia.
    Schizophr Res. 2022 Oct 20. pii: S0920-9964(22)00374.
    >> Share

  659. VARNUM PV
    The what, why, and so what of psychosis.
    Schizophr Res. 2022;250:41-42.
    >> Share

  660. DEL RE EC
    Emerging themes in schizophrenia research at SIRS 2022: Inclusivity, equality and Cannabis impact on mental health.
    Schizophr Res. 2022;250:39-40.
    >> Share

  661. BARLATI S, Nibbio G, Calzavara-Pinton I, Invernizzi E, et al
    Primary and secondary negative symptoms severity and the use of psychiatric care resources in schizophrenia spectrum disorders: A 3-year follow-up longitudinal retrospective study.
    Schizophr Res. 2022;250:31-38.
    >> Share

  662. CHIEN WT, Ho LK, Gray R, Bressington D, et al
    A randomized controlled trial of a peer-facilitated self-management program for people with recent-onset psychosis.
    Schizophr Res. 2022;250:22-30.
    >> Share

  663. MOW JL, Gard DE, Mueser KT, Mote J, et al
    Smartphone-based mobility metrics capture daily social motivation and behavior in schizophrenia.
    Schizophr Res. 2022;250:13-21.
    >> Share

  664. NAGENDRA A, Orleans-Pobee M, Vincent C, Padgett J, et al
    The representation of authors of color in schizophrenia research articles published in high-impact psychiatric journals.
    Schizophr Res. 2022 Oct 7. pii: S0920-9964(22)00323.
    >> Share

  665. BRUHN D, Hwang S, Howarth A, Dube S, et al
    The burden of illness for patients with schizophrenia and primary negative symptoms: A systematic literature review.
    Schizophr Res. 2022;248:341-344.
    >> Share

  666. GAO YN, Olfson M
    National trends in metabolic risk of psychiatric inpatients in the United States during the atypical antipsychotic era.
    Schizophr Res. 2022;248:320-328.
    >> Share

  667. BENAROUS X, Lahaye H, Cottin G, Garny de la Riviere S, et al
    Trends in the use of long-acting injectable antipsychotics in children and adolescents in France between 2014 and 2018.
    Schizophr Res. 2022;248:231-232.
    >> Share

  668. KESHAVAN MS, Bishop DL, Coconcea C, Bishop JR, et al
    Clozapine, an update.
    Schizophr Res. 2022;248:168-170.
    >> Share

    September 2022
  669. CUESTA MJ, Ballesteros A, Sanchez-Torres AM, Amoretti S, et al
    Relapse of first-episode schizophrenia patients and neurocognitive impairment: The role of dopaminergic and anticholinergic burden.
    Schizophr Res. 2022;248:331-340.
    >> Share

  670. AUERBACH JG, Hans SL, Zhang Y
    Neurocognitive functioning in adult and adolescent offspring of parents with schizophrenia.
    Schizophr Res. 2022;248:300-308.
    >> Share

  671. HINOTSU K, Miyaji C, Yada Y, Kawai H, et al
    The validity of atypical psychosis diagnostic criteria to detect anti-NMDA receptor encephalitis with psychiatric symptoms.
    Schizophr Res. 2022;248:292-299.
    >> Share

  672. HOSGELEN EI, Akgul O, Akdede BB, Alptekin K, et al
    Relation between processing speed and social media use in schizophrenia patients.
    Schizophr Res. 2022;248:290-291.
    >> Share

  673. SCHILLING TM, Andelfinger V, Bossert M, Konig M, et al
    No clinically relevant effects of 12 sessions of 2 mA of anodal transcranial Direct Current Stimulation over the left DLPFC in combination with concurrent cognitive training compared to cognitive training only on executive functions in patients with s
    Schizophr Res. 2022;248:287-289.
    >> Share

  674. MONTELEONE P, Cascino G, Rossi A, Rocca P, et al
    Evolution of antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia in the real-life: A 4-year follow-up naturalistic study.
    Schizophr Res. 2022;248:279-286.
    >> Share

  675. KANE JM, Kinon BJ, Forray C, Such P, et al
    Efficacy and safety of Lu AF35700 in treatment-resistant schizophrenia: A randomized, active-controlled trial with open-label extension.
    Schizophr Res. 2022;248:271-278.
    >> Share

  676. YANG KC, Chen YY, Liu MN, Yang BH, et al
    Interactions between dopamine transporter and N-methyl-d-aspartate receptor-related amino acids on cognitive impairments in schizophrenia.
    Schizophr Res. 2022;248:263-270.
    >> Share

  677. FATTAL J, Brascamp JW, Slate RE, Lehet M, et al
    Blunted pupil light reflex is associated with negative symptoms and working memory in individuals with schizophrenia.
    Schizophr Res. 2022;248:254-262.
    >> Share

  678. KUHNEY FS, Damme KSF, Ellman LM, Schiffman J, et al
    Evaluating the Social Functioning Scale modified for use in individuals at clinical high-risk for psychosis.
    Schizophr Res. 2022;248:246-253.
    >> Share

  679. KOMULAINEN K, Elovainio M, Tormalehto S, Ruuhela R, et al
    Climatic exposures in childhood and the risk of schizophrenia from childhood to early adulthood.
    Schizophr Res. 2022;248:233-239.
    >> Share

  680. SINGH SM, Win PW, Castellani CA
    Complementary approaches involving monozygotic twins and single neuron genomics support postzygotic somatic mutations in schizophrenia.
    Schizophr Res. 2022;248:228-230.
    >> Share

  681. UNRAU J, Percie du Sert O, Joober R, Malla A, et al
    Subtyping negative symptoms in first-episode psychosis: Contrasting persistent negative symptoms with a data-driven approach.
    Schizophr Res. 2022;248:219-227.
    >> Share

  682. NORTH HF, Weissleder C, Fullerton JM, Webster MJ, et al
    Increased immune cell and altered microglia and neurogenesis transcripts in an Australian schizophrenia subgroup with elevated inflammation.
    Schizophr Res. 2022;248:208-218.
    >> Share

  683. KLINE CL, Suzuki T, Simmonite M, Taylor SF, et al
    Catatonia is associated with higher rates of negative affect amongst patients with schizophrenia and schizoaffective disorder.
    Schizophr Res. 2022 Sep 13. pii: S0920-9964(22)00334.
    >> Share

  684. TOUSKOVA TP, Bob P, Pec O, Lysaker P, et al
    Dissociative symptoms in schizophrenia spectrum disorders: Historical links and future research perspectives.
    Schizophr Res. 2022;248:206-207.
    >> Share

  685. PAINO M, Gonzalez-Menendez AM, Vallina-Fernandez O, Rus-Calafell M, et al
    A novel algorithm to detect early risk of psychosis: Results from the Prevention Program for Psychosis (P3).
    Schizophr Res. 2022;248:196-197.
    >> Share

  686. MCCULLUMSMITH RE, Rowland LM
    Postmortem, in silico, and clinical studies focused on perturbations of glutamate neurobiology in schizophrenia.
    Schizophr Res. 2022 Sep 8. pii: S0920-9964(22)00292.
    >> Share

  687. TAKEUCHI H, Sanches M, Borlido C, Remington G, et al
    Consistency of adherence to antipsychotics between two bottles in patients with schizophrenia.
    Schizophr Res. 2022;248:194-195.
    >> Share

  688. KHACHADOURIAN V, Zaks N, Lin E, Reichenberg A, et al
    Reprint of: Advanced paternal age and risk of schizophrenia in offspring - Review of epidemiological findings and potential mechanisms.
    Schizophr Res. 2022 Sep 6. pii: S0920-9964(22)00329.
    >> Share

  689. LEON-ORTIZ P, Reyes-Madrigal F, Mondragon-Maya A, Mora-Duran R, et al
    Social cognition and its association with the duration and severity of psychosis in antipsychotic-naive individuals at different stages of the schizophrenia spectrum disorders.
    Schizophr Res. 2022;248:180-182.
    >> Share

  690. ZHAO W, Zhang Q, Su Y, Chen X, et al
    Effect of schizophrenia risk gene polymorphisms on cognitive and neural plasticity.
    Schizophr Res. 2022;248:173-179.
    >> Share

  691. BOBERG M, Felding S, Jansson L, Nordgaard J, et al
    Differential diagnosis: Schizophrenia and personality disorder.
    Schizophr Res. 2022;248:171-172.
    >> Share

  692. POUSA E, Brebion G, Lopez-Carrilero R, Ruiz AI, et al
    Clinical insight in first-episode psychosis: Clinical, neurocognitive and metacognitive predictors.
    Schizophr Res. 2022;248:158-167.
    >> Share

  693. REAVIS EA, Wynn JK, Green MF
    The flickering spotlight of visual attention: Characterizing abnormal object-based attention in schizophrenia.
    Schizophr Res. 2022;248:151-157.
    >> Share

  694. WASTLER HM, Moe AM, Breitborde NJK
    Emotion regulation strategies and suicidal ideation among individuals with first-episode psychosis.
    Schizophr Res. 2022;248:149-150.
    >> Share

  695. ROSENFIELD PJ, Jiang D, Pauselli L
    Childhood adversity and psychotic disorders: Epidemiological evidence, theoretical models and clinical considerations.
    Schizophr Res. 2022;247:55-66.
    >> Share

    August 2022
  696. CHENG N, Lin A, Bowden S, Gao C, et al
    Intelligence trajectories in individuals at ultra-high risk for psychosis: An 8-year longitudinal analysis.
    Schizophr Res. 2022;248:140-148.
    >> Share

  697. LI SB, Liu C, Zhang JB, Wang LL, et al
    Revisiting the latent structure of negative symptoms in schizophrenia: Evidence from two second-generation clinical assessments.
    Schizophr Res. 2022;248:131-139.
    >> Share

  698. NKIRE N, Kingston T, Kinsella A, Russell V, et al
    Mixed-effects models reveal prediction of long-term outcome by duration of untreated psychosis (DUP) and illness (DUI) varies with quantile gradation but is invariant with time across 7 years in the Cavan-Monaghan First Episode Psychosis Study (CAMFEP
    Schizophr Res. 2022;248:124-130.
    >> Share

  699. MILLMAN ZB, Guvenek-Cokol PE, Kim HJ, Ongur D, et al
    The support, treatment, and resilience (STAR) program for youth at clinical high-risk of psychosis.
    Schizophr Res. 2022;248:122-123.
    >> Share

  700. SANTESTEBAN-ECHARRI O, Liu L, Miller M, Bearden CE, et al
    Cannabis use and attenuated positive and negative symptoms in youth at clinical high risk for psychosis.
    Schizophr Res. 2022;248:114-121.
    >> Share

  701. CHEW QH, Prakash KNB, Koh LY, Chilla G, et al
    Neuroanatomical subtypes of schizophrenia and relationship with illness duration and deficit status.
    Schizophr Res. 2022;248:107-113.
    >> Share

  702. SONNENSCHEIN SF, Mayeli A, Yushmanov VE, Blazer A, et al
    A longitudinal investigation of GABA, glutamate, and glutamine across the insula during antipsychotic treatment of first-episode schizophrenia.
    Schizophr Res. 2022;248:98-106.
    >> Share

  703. DUNCAN E, Roach BJ, Massa N, Hamilton HK, et al
    Auditory N100 amplitude deficits predict conversion to psychosis in the North American Prodrome Longitudinal Study (NAPLS-2) cohort.
    Schizophr Res. 2022;248:89-97.
    >> Share

  704. KARPOUZIAN-ROGERS T, Sweeney JA, Rubin LH, McDowell J, et al
    Reduced task-evoked pupillary response in preparation for an executive cognitive control response among individuals across the psychosis spectrum.
    Schizophr Res. 2022;248:79-88.
    >> Share

  705. SARRAF L, Lepage M, Sauve G
    The clinical and psychosocial correlates of self-stigma among people with schizophrenia spectrum disorders across cultures: A systematic review and meta-analysis.
    Schizophr Res. 2022;248:64-78.
    >> Share

  706. ALPHS L, Baker P, Brown B, Fu DJ, et al
    Evaluation of major treatment failure in patients with recent-onset schizophrenia or schizophreniform disorder: A post hoc analysis from the Disease Recovery Evaluation and Modification (DREaM) study.
    Schizophr Res. 2022;248:58-63.
    >> Share

  707. CELLA M, Tomlin P, Robotham D, Green P, et al
    Virtual Reality Therapy for the Negative Symptoms of Schizophrenia (V-NeST): A pilot randomised feasibility trial.
    Schizophr Res. 2022;248:50-57.
    >> Share

  708. STROMME MF, Bartz-Johannesen C, Kroken RA, Mehlum L, et al
    Overactive, aggressive, disruptive and agitated behavior associated with the use of psychotropic medications in schizophrenia.
    Schizophr Res. 2022;248:35-41.
    >> Share

  709. PAROLA A, Lin JM, Simonsen A, Bliksted V, et al
    Speech disturbances in schizophrenia: Assessing cross-linguistic generalizability of NLP automated measures of coherence.
    Schizophr Res. 2022 Aug 1. pii: S0920-9964(22)00274.
    >> Share

  710. LAUNDERS N, Scolamiero L, Osborn DPJ, Hayes JF, et al
    Cancer rates and mortality in people with severe mental illness: Further evidence of lack of parity.
    Schizophr Res. 2022;246:260-267.
    >> Share

  711. PAUL NB, Strauss GP, Woodyatt JJ, Paul MG, et al
    Cluster analysis of negative symptoms identifies distinct negative symptom subgroups.
    Schizophr Res. 2022;246:207-215.
    >> Share

  712. CHEUNG JP, Tubbs JD, Sham PC
    Extended gene set analysis of human neuro-psychiatric traits shows enrichment in brain-expressed human accelerated regions across development.
    Schizophr Res. 2022;246:148-155.
    >> Share

    July 2022
  713. GALLUCCI J, Tan T, Schifani C, Dickie EW, et al
    Greater individual variability in functional brain activity during working memory performance in Schizophrenia Spectrum Disorders (SSD).
    Schizophr Res. 2022;248:21-31.
    >> Share

  714. AKER S, Kahve AC
    What do psychiatrists think about renaming schizophrenia in Turkey?
    Schizophr Res. 2022;248:8-13.
    >> Share

  715. TRAN T, Spilka MJ, Ruiz I, Strauss GP, et al
    Implicit cognitive effort monitoring impairments are associated with expressive negative symptoms in schizophrenia.
    Schizophr Res. 2022;248:14-20.
    >> Share

  716. ACHIM AM, Roy MA, Fossard M
    The other side of the social interaction: Theory of mind impairments in people with schizophrenia are linked to other people's difficulties in understanding them.
    Schizophr Res. 2022 Jul 26. pii: S0920-9964(22)00273.
    >> Share

  717. GARRIDO-TORRES N, Ruiz-Veguilla M, Alameda L, Canal-Rivero M, et al
    Prevalence of metabolic syndrome and related factors in a large sample of antipsychotic naive patients with first-episode psychosis: Baseline results from the PAFIP cohort.
    Schizophr Res. 2022;246:277-285.
    >> Share

  718. COKAL D, Palominos-Flores C, Yalincetin B, Ture-Abaci O, et al
    Referential noun phrases distribute differently in Turkish speakers with schizophrenia.
    Schizophr Res. 2022 Jul 21. pii: S0920-9964(22)00259.
    >> Share

  719. ROHDE C, Hojlund M, Gasse C, Hauser AS, et al
    Psychopharmacological treatment patterns prior to a schizophrenia diagnosis: A Danish nationwide study.
    Schizophr Res. 2022;246:268-276.
    >> Share

  720. FILTS Y, Litman RE, Martinez J, Anta L, et al
    Corrigendum to "Long-term efficacy and safety of once-monthly Risperidone ISM(R) in the treatment of schizophrenia: Results from a 12-month open-label extension study" [Schizophr. Res. 239 (2022) 83-91].
    Schizophr Res. 2022;246:258-259.
    >> Share

  721. SULLIVAN SA, Kounali D, Morris R, Kessler D, et al
    Developing and internally validating a prognostic model (P Risk) to improve the prediction of psychosis in a primary care population using electronic health records: The MAPPED study.
    Schizophr Res. 2022;246:241-249.
    >> Share

  722. WALTA M, Laurikainen H, Armio RL, From T, et al
    Selection bias in clinical studies of first-episode psychosis: A follow-up study.
    Schizophr Res. 2022;246:235-240.
    >> Share

  723. TANG SX, Cong Y, Nikzad AH, Mehta A, et al
    Clinical and computational speech measures are associated with social cognition in schizophrenia spectrum disorders.
    Schizophr Res. 2022 Jul 11. pii: S0920-9964(22)00247.
    >> Share

  724. SEBASTIAN R, Song Y, Pak C
    Probing the molecular and cellular pathological mechanisms of schizophrenia using human induced pluripotent stem cell models.
    Schizophr Res. 2022 Jul 11. pii: S0920-9964(22)00263.
    >> Share

  725. MOTA NB, Ribeiro M, Malcorra BLC, Atidio JP, et al
    Happy thoughts: What computational assessment of connectedness and emotional words can inform about early stages of psychosis.
    Schizophr Res. 2022 Jul 7. pii: S0920-9964(22)00260.
    >> Share

  726. LEE J, Song S, Lee J, Kang J, et al
    Impaired migration of autologous induced neural stem cells from patients with schizophrenia and implications for genetic risk for psychosis.
    Schizophr Res. 2022;246:225-234.
    >> Share

  727. KANTOR JR, Gur RC, Calkins ME, Moore TM, et al
    Comparison of two cognitive screening measures in a longitudinal sample of youth at-risk for psychosis.
    Schizophr Res. 2022;246:216-224.
    >> Share

  728. GARCIA-RIZO C, Ortiz Garcia de la Foz V, Mayoral-van Son J, Gomez-Revuelta M, et al
    Reduced glomerular filter rate in antipsychotic-naive patients with first-episode psychosis.
    Schizophr Res. 2022;246:202-204.
    >> Share

  729. GREVE AN, Jepsen JRM, Mortensen EL, Uher R, et al
    Transmission of intelligence, working memory, and processing speed from parents to their seven-year-old offspring is function specific in families with schizophrenia or bipolar disorder.
    Schizophr Res. 2022;246:195-201.
    >> Share

  730. VER LOREN VAN THEMAAT AH, Oranje B, Larsen KM, Tomasevic L, et al
    Mismatch negativity and P3a amplitude in children with familial high risk of schizophrenia or bipolar disorder - A Danish register-based EEG study.
    Schizophr Res. 2022;246:187-194.
    >> Share

  731. ADAMS RA, Vincent P, Benrimoh D, Friston KJ, et al
    Everything is connected: Inference and attractors in delusions.
    Schizophr Res. 2022;245:5-22.
    >> Share

  732. BOUTTIER V, Duttagupta S, Deneve S, Jardri R, et al
    Circular inference predicts nonuniform overactivation and dysconnectivity in brain-wide connectomes.
    Schizophr Res. 2022;245:59-67.
    >> Share

  733. RAJJI TK, Mamo DC, Holden J, Granholm E, et al
    Corrigendum to "Cognitive-behavioral social skills training for patients with late-life schizophrenia and the moderating effect of executive dysfunction" [Schizophr. Res. 239 (2022) 160-167].
    Schizophr Res. 2022 Jul 1. pii: S0920-9964(22)00271.
    >> Share

  734. LESTRA V, Romeo B, Martelli C, Benyamina A, et al
    Could CRP be a differential biomarker of illness stages in schizophrenia? A systematic review and meta-analysis.
    Schizophr Res. 2022;246:175-186.
    >> Share

    June 2022
  735. CHRUSCIEL JH, Orso R, de Mattos BP, Fries GR, et al
    A systematic review and meta-analysis of epigenetic clocks in schizophrenia.
    Schizophr Res. 2022;246:172-174.
    >> Share

  736. BRACHER-SMITH M, Rees E, Menzies G, Walters JTR, et al
    Machine learning for prediction of schizophrenia using genetic and demographic factors in the UK biobank.
    Schizophr Res. 2022;246:156-164.
    >> Share

  737. CORONA-HERNANDEZ H, de Boer JN, Brederoo SG, Voppel AE, et al
    Assessing coherence through linguistic connectives: Analysis of speech in patients with schizophrenia-spectrum disorders.
    Schizophr Res. 2022 Jun 28. pii: S0920-9964(22)00248.
    >> Share

  738. ISAACS AN, Brooks H, Lawn S, Mohammadi L, et al
    Effectiveness of personal recovery facilitators in adults with schizophrenia and other psychoses: A systematic review of reviews and narrative synthesis.
    Schizophr Res. 2022;246:132-147.
    >> Share

  739. GOLAY P, Ramain J, Abrahamyan Empson L, Mebdouhi N, et al
    Symptom dimensions stability over time in recent onset psychosis: A prospective study.
    Schizophr Res. 2022;246:126-131.
    >> Share

  740. RIEDL L, Nagels A, Sammer G, Choudhury M, et al
    Multimodal speech-gesture training in patients with schizophrenia spectrum disorder: Effects on quality of life and neural processing.
    Schizophr Res. 2022;246:112-125.
    >> Share

  741. SCHIWY LC, Forlim CG, Fischer DJ, Kuhn S, et al
    Aberrant functional connectivity within the salience network is related to cognitive deficits and disorganization in psychosis.
    Schizophr Res. 2022;246:103-111.
    >> Share

  742. SILVA AM, Limongi R, MacKinley M, Ford SD, et al
    Syntactic complexity of spoken language in the diagnosis of schizophrenia: A probabilistic Bayes network model.
    Schizophr Res. 2022 Jun 22. pii: S0920-9964(22)00245.
    >> Share

  743. BEGUE I, Brakowski J, Seifritz E, Dagher A, et al
    Cerebellar and cortico-striatal-midbrain contributions to reward-cognition processes and apathy within the psychosis continuum.
    Schizophr Res. 2022;246:85-94.
    >> Share

  744. RAUCHER-CHENE D, Pochiet G, Lavigne KM, Heinrichs RW, et al
    Normal-range verbal memory in the first-episode of psychosis: Clinical and functional outcomes across 24 months and impact of estimated verbal memory decrement.
    Schizophr Res. 2022;246:75-84.
    >> Share

  745. NIZNIKIEWICZ MA, Brady RO, Whitfield-Gabrieli S, Keshavan MS, et al
    Dynamic intervention-based biomarkers may reduce heterogeneity and motivate targeted interventions in clinical high risk for psychosis.
    Schizophr Res. 2022;246:60-62.
    >> Share

  746. MORKVED N, Johnsen E, Kroken RA, Winje D, et al
    Impact of childhood trauma on antipsychotic effectiveness in schizophrenia spectrum disorders: A prospective, pragmatic, semi-randomized trial.
    Schizophr Res. 2022;246:49-59.
    >> Share

  747. KUO SS, Musket CW, Rupert PE, Almasy L, et al
    Age-dependent patterns of schizophrenia genetic risk affect cognition.
    Schizophr Res. 2022;246:39-48.
    >> Share

  748. POWERS AR
    Mathematical nosology: Computational approaches to understanding psychosis.
    Schizophr Res. 2022 Jun 10. pii: S0920-9964(22)00202.
    >> Share

  749. SCHOFIELD P, Thisted Horsdal H, Das-Munshi J, Thygesen M, et al
    A comparison of neighbourhood level variation and risk factors for affective versus non-affective psychosis.
    Schizophr Res. 2022 Jun 10. pii: S0920-9964(22)00192.
    >> Share

  750. CATALANO LT, Wynn JK, Green MF, Gold JM, et al
    Reduced neural activity when anticipating social versus nonsocial rewards in schizophrenia: Preliminary evidence from an ERP study.
    Schizophr Res. 2022;246:7-16.
    >> Share

  751. GALIANO RUS S, Ortiz Garcia de la Foz V, Arias-Loste MT, Iruzubieta P, et al
    Elevated risk of liver steatosis in first-episode psychosis patients: Results from a 3-year prospective study.
    Schizophr Res. 2022;246:30-38.
    >> Share

  752. LALLY J, Ajnakina O, Stubbs B, Gardner-Sood P, et al
    Vitamin D and cardiometabolic outcomes in first episode psychosis (FEP): A prospective cohort study.
    Schizophr Res. 2022;246:26-29.
    >> Share

  753. SCHOR SH, Gibbs JS, Gouse BM, Brown HE, et al
    A call to action: Increased mortality from COVID-19 among individuals with schizophrenia calls for coordinated vaccination efforts.
    Schizophr Res. 2022;246:63-64.
    >> Share

  754. ORTIZ BB, Gadelha A, Bressan RA
    Should we rethink how we introduce schizophrenia?
    Schizophr Res. 2022;244:134.
    >> Share

  755. PHELAN S, Sigala N
    The effect of treatment on insight in psychotic disorders - A systematic review and meta-analysis.
    Schizophr Res. 2022;244:126-133.
    >> Share

    May 2022
  756. SEGURA AG, Martinez-Pinteno A, Gasso P, Rodriguez N, et al
    Metabolic polygenic risk scores effect on antipsychotic-induced metabolic dysregulation: A longitudinal study in a first episode psychosis cohort.
    Schizophr Res. 2022;244:101-110.
    >> Share

  757. LIANG L, Heinrichs RW, Liddle PF, Jeon P, et al
    Cortical impoverishment in a stable subgroup of schizophrenia: Validation across various stages of psychosis.
    Schizophr Res. 2022 May 26. pii: S0920-9964(22)00188.
    >> Share

  758. PALOMAR-CIRIA N, Cegla-Schvartzman F, Bello HJ, Martinez-Ales G, et al
    Diagnostic stability of schizophrenia in clinical settings: An observational study of 198,289 patient/years.
    Schizophr Res. 2022;244:81-83.
    >> Share

  759. SETIEN-SUERO E, Ayesa-Arriola R, Pena J, Crespo-Facorro B, et al
    Longitudinal effects of cannabis use on attentional processes in patients with first episode of psychosis.
    Schizophr Res. 2022;244:71-80.
    >> Share

  760. KURTZ MM
    Kraepelin, schizophrenia and the first biological era in psychiatry.
    Schizophr Res. 2022;244:69-70.
    >> Share

  761. WILLIAMS TF, Powers AR, Ellman LM, Corlett PR, et al
    Three prominent self-report risk measures show unique and overlapping utility in characterizing those at clinical high-risk for psychosis.
    Schizophr Res. 2022;244:58-65.
    >> Share

  762. SCHIFFMAN J, Horton LE, Landa Y, Woods SW, et al
    Considerations for providing feedback to patients and families regarding clinical high-risk for psychosis status.
    Schizophr Res. 2022;244:55-57.
    >> Share

  763. SANCHEZ-TORRES AM, Peralta V, Gil-Berrozpe GJ, Mezquida G, et al
    The network structure of cognitive deficits in first episode psychosis patients.
    Schizophr Res. 2022;244:46-54.
    >> Share

  764. ALONSO-SANCHEZ MF, Limongi R, Gati J, Palaniyappan L, et al
    Language network self-inhibition and semantic similarity in first-episode schizophrenia: A computational-linguistic and effective connectivity approach.
    Schizophr Res. 2022 May 11. pii: S0920-9964(22)00160.
    >> Share

  765. CARRA G, Crocamo C, Bartoli F, Angermeyer M, et al
    Influence of positive and negative symptoms on hedonic and eudaemonic well-being in people with schizophrenia: A longitudinal analysis from the EuroSc study.
    Schizophr Res. 2022;244:21-28.
    >> Share

  766. DELISI LE
    Commentary on whether progressive brain change underlies the pathology of schizophrenia: Should this even be debated?
    Schizophr Res. 2022;244:18-20.
    >> Share

  767. CAVALIERE VS, Glassman M, DiPaula BA, Mackowick M, et al
    Anti-aggressive effects of clozapine in involuntarily committed black patients with severe mental illness.
    Schizophr Res. 2022;243:163-169.
    >> Share

  768. STEPHANE M, Dzemidzic M, Yoon G
    Altered corollary discharge in the auditory cortex could reflect louder inner voice experience in patients with verbal hallucinations, a pilot fMRI study.
    Schizophr Res. 2022;243:475-480.
    >> Share

  769. NARITA Z, Koyanagi A, Oh H, DeVylder J, et al
    Association between incarceration and psychotic experiences in a general population sample.
    Schizophr Res. 2022;243:112-117.
    >> Share

  770. CEREDA G, Boscutti A, Lazzaretti M, Enrico P, et al
    Amitriptyline for clozapine-induced hypersalivation: A case series.
    Schizophr Res. 2022;243:110-111.
    >> Share

  771. JIMENO N, Gomez-Pilar J, Poza J, Hornero R, et al
    (Attenuated) hallucinations join basic symptoms in a transdiagnostic network cluster analysis.
    Schizophr Res. 2022;243:43-54.
    >> Share

  772. RUIZ DE PELLON-SANTAMARIA A, Sarasqueta-Eizaguirre C, Basterrechea-Pena FJ
    An overall protective effect of antipsychotic drugs against COVID-19 seems implausible.
    Schizophr Res. 2022;243:486-488.
    >> Share

  773. ZHANG L, Zhang R, Han S, Womer FY, et al
    Three major psychiatric disorders share specific dynamic alterations of intrinsic brain activity.
    Schizophr Res. 2022;243:322-329.
    >> Share

  774. HJELSENG IV, Vaskinn A, Ueland T, Lunding SH, et al
    Childhood trauma is associated with poorer social functioning in severe mental disorders both during an active illness phase and in remission.
    Schizophr Res. 2022;243:241-246.
    >> Share

  775. JEREMIAN R, Bani-Fatemi A, Strauss JS, Tasmim S, et al
    Investigation of accelerated epigenetic aging in individuals suffering from schizophrenia in the context of lifetime suicide attempt.
    Schizophr Res. 2022;243:222-224.
    >> Share

  776. TASMIM S, Bani-Fatemi A, Dada OD, Wang KZ, et al
    Recent health-related stressful life events predictive of emergent suicidal ideation in schizophrenia.
    Schizophr Res. 2022;243:220-221.
    >> Share

    April 2022
  777. MALHI GS, Bell E
    Reframing schizophrenia: Altering our perceptions?
    Schizophr Res. 2022;244:8-9.
    >> Share

  778. TAKAHASHI T, Wood SJ, Yung AR, Nelson B, et al
    Pineal morphology of the clinical high-risk state for psychosis and different psychotic disorders.
    Schizophr Res. 2022;244:1-7.
    >> Share

  779. HAINING K, Grent-'t-Jong T, Chetcuti B, Gajwani R, et al
    Computerised cognitive training during early-stage psychosis improves cognitive deficits and gamma-band oscillations: A pilot study.
    Schizophr Res. 2022;243:217-219.
    >> Share

  780. GAWDE U, Hegde P, Desai K, Barai RS, et al
    Multimorbidity landscape of schizophrenia: Insights from meta-analysis of genome wide association studies.
    Schizophr Res. 2022;243:214-216.
    >> Share

  781. WEINREB S, Li F, Kurtz MM
    A meta-analysis of social cognitive deficits in schizophrenia: Does world region matter?
    Schizophr Res. 2022;243:206-213.
    >> Share

  782. MAMTANI H, Pathak H, Sakhardande KA, Gowda GS, et al
    Can peripheral brain-derived neurotrophic factor (BDNF) be a potential biomarker of suicide risk in schizophrenia?
    Schizophr Res. 2022;243:203-205.
    >> Share

  783. GUPTA T, Horton WS, Haase CM, Carol EE, et al
    Clues from caregiver emotional language usage highlight the link between putative social environment and the psychosis-risk syndrome.
    Schizophr Res. 2022 Apr 7. pii: S0920-9964(22)00151.
    >> Share

  784. AMSALEM D, Valeri L, Jankowski SE, Yang LH, et al
    Reducing public stigma toward individuals with psychosis across race and gender: A randomized controlled trial of young adults.
    Schizophr Res. 2022;243:195-202.
    >> Share

  785. SHAKIR M, Willems AE, van Harten PN, van Lutterveld R, et al
    The effect on relapse rate and psychiatric symptomatology: Switching a combination of first- and second-generation antipsychotic polypharmacy to antipsychotic monotherapy in long-term inpatients with schizophrenia and related disorders. A pragmatic ra
    Schizophr Res. 2022;243:187-194.
    >> Share

  786. MALASPINA D
    Editorial for Special Issue: From cytokines to climate and C-sections and from micronutrients to the microbiome: Neurodevelopment and the risk for psychosis.
    Schizophr Res. 2022 Apr 5. pii: S0920-9964(22)00077.
    >> Share

  787. MURRAY RM, Bora E, Modinos G, Vernon A, et al
    Schizophrenia: A developmental disorder with a risk of non-specific but avoidable decline.
    Schizophr Res. 2022;243:181-186.
    >> Share

  788. SARPAL DK, Blazer A, Wilson JD, Calabro FJ, et al
    Relationship between plasma clozapine/N-desmethylclozapine and changes in basal forebrain-dorsolateral prefrontal cortex coupling in treatment-resistant schizophrenia.
    Schizophr Res. 2022;243:170-177.
    >> Share

    March 2022
  789. STONE WS, Phillips MR, Yang LH, Kegeles LS, et al
    Neurodegenerative model of schizophrenia: Growing evidence to support a revisit.
    Schizophr Res. 2022;243:154-162.
    >> Share

  790. KHAU M, Tabbane K, Bloom D, Abadi S, et al
    Pragmatic implementation of the Clinical Global Impression Scale of Severity as a tool for measurement-based care in a first-episode psychosis program.
    Schizophr Res. 2022;243:147-153.
    >> Share

  791. TANG CH, Ramcharran D, Qiu H, Chung KH, et al
    Attaching importance to the risk of all-cause, sudden death, and cardiovascular mortality among antipsychotic-treated patients with schizophrenia.
    Schizophr Res. 2022 Mar 22. pii: S0920-9964(22)00129.
    >> Share

  792. SUHAS S, Mehta UM
    A redux of schizophrenia research in 2021.
    Schizophr Res. 2022 Mar 14. pii: S0920-9964(22)00130.
    >> Share

  793. ASKEVIS-LEHERPEUX F, Hazo JB, Agoub M, Baleige A, et al
    Accessibility of psychiatric vocabulary: An international study about schizophrenia essential features.
    Schizophr Res. 2022 Mar 13. pii: S0920-9964(22)00119.
    >> Share

  794. SHARPE V, Schoot L, Lewandowski KE, Ongur D, et al
    We both say tomato: Intact lexical alignment in schizophrenia and bipolar disorder.
    Schizophr Res. 2022;243:138-146.
    >> Share

  795. LOPEZ-DIAZ A, Ayesa-Arriola R, Garrido-Torres N, Otiz-Garcia de la Foz V, et al
    A proxy measure of premorbid adjustment in psychosis for large-scale epidemiological studies and electronic health record-based research.
    Schizophr Res. 2022 Mar 11. pii: S0920-9964(22)00112.
    >> Share

  796. PENCE AY, Pries LK, Ferrara M, Rutten BPF, et al
    Gender differences in the association between environment and psychosis.
    Schizophr Res. 2022;243:120-137.
    >> Share

  797. COSTARDI CG, Malinowski F, Fonseca L, Redondo L, et al
    COVID-19 contamination and severity among patients with schizophrenia: Results from a specialized outpatient clinic survey.
    Schizophr Res. 2022 Mar 4. pii: S0920-9964(22)00118.
    >> Share

  798. YONEZAWA K, Tani H, Nakajima S, Nagai N, et al
    AMPA receptors in schizophrenia: A systematic review of postmortem studies on receptor subunit expression and binding.
    Schizophr Res. 2022;243:98-109.
    >> Share

  799. SAKS ER
    Holding onto the center: Lived experience and the construct of schizophrenia.
    Schizophr Res. 2022 Mar 2. pii: S0920-9964(22)00094.
    >> Share

  800. ALPHS L, Brown B, Turkoz I, Baker P, et al
    The Disease Recovery Evaluation and Modification (DREaM) study: Effectiveness of paliperidone palmitate versus oral antipsychotics in patients with recent-onset schizophrenia or schizophreniform disorder.
    Schizophr Res. 2022;243:86-97.
    >> Share

  801. LUCKHOFF HK, Asmal L, Scheffler F, du Plessis S, et al
    Sex and gender associations with indicators of neurodevelopmental compromise in schizophrenia spectrum disorders.
    Schizophr Res. 2022;243:70-77.
    >> Share

  802. RANJAN T, Melcher J, Keshavan M, Smith M, et al
    Longitudinal symptom changes and association with home time in people with schizophrenia: An observational digital phenotyping study.
    Schizophr Res. 2022;243:64-69.
    >> Share

  803. MCGURK SR, Xie H, Bond GR, Mueser KT, et al
    Impact of cognitive remediation on the prediction of employment outcomes in severe mental illness.
    Schizophr Res. 2022;241:149-155.
    >> Share

  804. STEENKAMP L, Weijers J, Gerrmann J, Eurelings-Bontekoe E, et al
    The relationship between childhood abuse and severity of psychosis is mediated by loneliness: an experience sampling study.
    Schizophr Res. 2022;241:306-311.
    >> Share

    February 2022
  805. FIRST MB, Lieberman JA
    How should we diagnose schizophrenia: Don't throw the baby out with the bath water.
    Schizophr Res. 2022 Feb 28. pii: S0920-9964(22)00034.
    >> Share

  806. TANDON R, Keshavan M, Nasrallah H
    Reinventing schizophrenia. Updating the construct.
    Schizophr Res. 2022 Feb 28. pii: S0920-9964(22)00093.
    >> Share

  807. STROMEYER C 4TH
    The construct of schizophrenia as a human-specific condition.
    Schizophr Res. 2022 Feb 28. pii: S0920-9964(22)00092.
    >> Share

  808. BIOQUE M, Mezquida G, Amoretti S, Garcia-Rizo C, et al
    Clinical and treatment predictors of relapse during a three-year follow-up of a cohort of first episodes of schizophrenia.
    Schizophr Res. 2022;243:32-42.
    >> Share

  809. PHAHLADIRA L, Asmal L, Luckhoff HK, du Plessis S, et al
    The trajectories and correlates of two negative symptom subdomains in first-episode schizophrenia.
    Schizophr Res. 2022;243:17-23.
    >> Share

  810. WANG Z, Fu Y, Jiang F, Chen L, et al
    Further evidence and meta-analysis support association of a single nucleotide polymorphism rs4765905 in CACNA1C with schizophrenia.
    Schizophr Res. 2022 Feb 24. pii: S0920-9964(22)00062.
    >> Share

  811. AKOURI-SHAN L, DeLuca JS, Pitts SC, Jay SY, et al
    Internalized stigma mediates the relation between psychosis-risk symptoms and subjective quality of life in a help-seeking sample.
    Schizophr Res. 2022;241:298-305.
    >> Share

  812. RASMUSSEN AR, Parnas J
    What is obsession? Differentiating obsessive-compulsive disorder and the schizophrenia spectrum.
    Schizophr Res. 2022;243:1-8.
    >> Share

  813. HUANG BJ, Pu CC, Miao Q, Ma K, et al
    Neurocognitive trajectories and their clinical implications in first-episode schizophrenia after one year of antipsychotic treatment.
    Schizophr Res. 2022;241:292-297.
    >> Share

  814. LONG M, Stansfeld JL, Davies N, Crellin NE, et al
    A systematic review of social functioning outcome measures in schizophrenia with a focus on suitability for intervention research.
    Schizophr Res. 2022;241:275-291.
    >> Share

  815. MCGORRY PD
    Schizophrenia: Transcending old world shadows.
    Schizophr Res. 2022 Feb 18. pii: S0920-9964(22)00074.
    >> Share

  816. GORDON JA, Morris SE, Avenevoli S
    A framework for integration of dimensional and diagnostic approaches to the diagnosis of schizophrenia.
    Schizophr Res. 2022 Feb 18. pii: S0920-9964(22)00066.
    >> Share

  817. ZHANG L, Strauss GP
    Adaptive and maladaptive consequences of increased social media and internet use during the COVID-19 pandemic in schizophrenia.
    Schizophr Res. 2022 Feb 17. pii: S0920-9964(22)00085.
    >> Share

  818. SCORIELS L, Genaro LT, Keffer S, Guimaraes AL, et al
    Changes in emotion processing and social cognition with auditory versus visual neuroscience-informed cognitive training in individuals with schizophrenia.
    Schizophr Res. 2022;241:267-274.
    >> Share

  819. MCHUGO M, Rogers BP, Avery SN, Armstrong K, et al
    Increased amplitude of hippocampal low frequency fluctuations in early psychosis: A two-year follow-up study.
    Schizophr Res. 2022;241:260-266.
    >> Share

  820. WEBER S, Scott JG, Chatterton ML
    Healthcare costs and resource use associated with negative symptoms of schizophrenia: A systematic literature review.
    Schizophr Res. 2022;241:251-259.
    >> Share

  821. ZHAO Y, Guan Q, Shi J, Sun J, et al
    Impaired central set point of thyroid homeostasis during quetiapine treatment in the acute phase of schizophrenia.
    Schizophr Res. 2022;241:244-250.
    >> Share

  822. KESHAVAN MS, Yassin W, Stone WS
    Conceptualizing psychosis as an information processing disorder: Signal, bandwidth, noise, and bias.
    Schizophr Res. 2022 Feb 14. pii: S0920-9964(22)00027.
    >> Share

  823. APPAJI A, Harish V, Korann V, Devi P, et al
    Deep learning model using retinal vascular images for classifying schizophrenia.
    Schizophr Res. 2022;241:238-243.
    >> Share

  824. OOMEN PP, Gangadin SS, Begemann MJH, Visser E, et al
    The neurobiological characterization of distinct cognitive subtypes in early-phase schizophrenia-spectrum disorders.
    Schizophr Res. 2022;241:228-237.
    >> Share

  825. TANDON R, Greden JF
    Reconstructing schizophrenia: Lessons from major mood disorders.
    Schizophr Res. 2022 Feb 12. pii: S0920-9964(22)00070.
    >> Share

  826. ADANTY C, Qian J, Wang Y, Remington G, et al
    Childhood trauma exposure and personality traits in schizophrenia patients.
    Schizophr Res. 2022;241:221-227.
    >> Share

  827. MOSCARELLI M, Min JY, Kopelowicz A, Chavez O, et al
    The "PRE" scale: The assessment of the elementary passively received experiences of schizophrenia.
    Schizophr Res. 2022;241:218-220.
    >> Share

  828. GUREJE O, Ojagbemi A
    Applicability and future status of schizophrenia as a construct in Africa.
    Schizophr Res. 2022 Feb 9. pii: S0920-9964(22)00033.
    >> Share

  829. STEINER J, Dobrowolny H, Guest PC, Bernstein HG, et al
    Gender-specific elevation of plasma anthranilic acid in schizophrenia: Protection against glutamatergic hypofunction?
    Schizophr Res. 2022 Feb 9. pii: S0920-9964(22)00058.
    >> Share

  830. KOTOV R, Jonas KG, Lian W, Docherty AR, et al
    Reconceptualizing schizophrenia in the Hierarchical Taxonomy Of Psychopathology (HiTOP).
    Schizophr Res. 2022 Feb 7. pii: S0920-9964(22)00064.
    >> Share

  831. MAMAH D, Mutiso VN, Ndetei DM
    Longitudinal and cross-sectional validation of the WERCAP screen for assessing psychosis risk and conversion.
    Schizophr Res. 2022;241:201-209.
    >> Share

  832. ZHANG Y, Zhang CY, Yuan J, Zeng XZ, et al
    Epistatic interactions of NRG1 and ERBB4 on antipsychotic treatment response in first-episode schizophrenia patients.
    Schizophr Res. 2022;241:197-200.
    >> Share

  833. BASSETT D, Boyce P, Lyndon B, Mulder R, et al
    Guidelines for the management of psychosis in the context of mood disorders.
    Schizophr Res. 2022;241:187-196.
    >> Share

  834. LO KYH, Hopman HJ, Chan SC, Chau WHS, et al
    Concurrent anodal transcranial direct current stimulation (tDCS) with cognitive training to improve cognition in schizophrenia.
    Schizophr Res. 2022;241:184-186.
    >> Share

  835. FATHIAN F, Gjestad R, Kroken RA, Loberg EM, et al
    Association between C-reactive protein levels and antipsychotic treatment during 12 months follow-up period after acute psychosis.
    Schizophr Res. 2022;241:174-183.
    >> Share

  836. SMOLLER JW
    What can genetics tell us about the schizophrenia construct?
    Schizophr Res. 2022 Feb 3. pii: S0920-9964(21)00492.
    >> Share

  837. JAVITT DC, Kantrowitz JT
    The glutamate/N-methyl-d-aspartate receptor (NMDAR) model of schizophrenia at 35: On the path from syndrome to disease.
    Schizophr Res. 2022 Feb 3. pii: S0920-9964(22)00023.
    >> Share

  838. DAZZAN P
    Is our mistake trying to identify a "homogeneous" schizophrenia construct?
    Schizophr Res. 2022 Feb 3. pii: S0920-9964(22)00067.
    >> Share

  839. GIORDANO GM, Palumbo D, Mucci A, Ventura J, et al
    The Cognitive Assessment Interview (CAI): Association with neuropsychological scores and real-life functioning in a large sample of Italian subjects with schizophrenia.
    Schizophr Res. 2022;241:161-170.
    >> Share

  840. O'DONOGHUE B, Polari A, McGorry P, Nelson B, et al
    Young migrants to Australia identified as being at ultra-high risk for psychosis: Pathways to care and clinical characteristics.
    Schizophr Res. 2022;241:156-160.
    >> Share

  841. TAMMINGA CA, Pearlson G, Gershon E, Keedy S, et al
    Using psychosis biotypes and the Framingham model for parsing psychosis biology.
    Schizophr Res. 2022 Feb 2. pii: S0920-9964(22)00028.
    >> Share

  842. KAHN RS
    Retroverting schizophrenia.
    Schizophr Res. 2022 Feb 2. pii: S0920-9964(22)00050.
    >> Share

  843. HUMPHREY C, Berry K, Degnan A, Bucci S, et al
    Childhood interpersonal trauma and paranoia in psychosis: The role of disorganised attachment and negative schema.
    Schizophr Res. 2022;241:142-148.
    >> Share

  844. DIAZ E, Estric C, Schandrin A, Lopez-Castroman J, et al
    Neurocognitive functioning and impulsivity in first-episode psychosis with suicidal ideation and behavior: A systematic review.
    Schizophr Res. 2022;241:130-139.
    >> Share